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Abstract		Manipulation	of	 a	 virus’s	 capacity	 to	 circumvent	 the	 interferon	 (IFN)	 response	aids	both	 fundamental	 studies	 as	well	 as	many	practical	 applications	 including	the	design	of	live-attenuated	vaccines.	However,	these	IFN-sensitive	viruses	are	often	difficult	 to	grow	to	high	titer	 in	cells	 that	produce	and	respond	to	IFN.	 In	the	first	part	of	this	study	we	further	characterised	the	use	of	the	IFN	inhibitor,	Ruxolitinib	 (Rux)	 for	 its	 ability	 to	 block	 the	 IFN	 response	 and	 subsequently	enhance	 replication	 of	 IFN-sensitive	 viruses.	 This	 study	 has	 shown	 that	 i)	 Rux	could	 provide	 a	 more	 rapid	 and	 therefore	 more	 efficient	 alternative	 for	 the	growth	of	IFN-sensitive	viruses	than	the	current	default	option,	growth	in	Vero	cells	and	ii)	addition	of	Rux	can	increase	growth	of	multiple	viruses	in	numerous	cell-lines.	These	 results	 indicate	 that	 as	well	 as	 aiding	 fundamental	 studies	 the	addition	 of	 Rux	 could	 become	 a	 valuable	 technique	 in	 a	 number	 of	 virological	applications	 including	 live	 attenuated	 vaccine	 production	 and	 techniques	 to	isolate	newly	emerging	viruses.	In	the	second	part	of	this	study	we	developed	a	novel	method	to	isolate	IFN-sensitive	viruses	from	Paramyxoviruses,	using	PIV5	(Parainfluenza	 virus	 5)	 as	 an	 experimental	 model	 system	 to	 obtain	 selection	parameters.	 We	 successfully	 isolated	 three	 mutant	 viruses	 (rPIV5mCh-α,	rPIV5mCh-β	 and	 PIV5	 W3-γ)	 that	 each	 contain	 mutations	 within	 the	 IFN	antagonist	 V	 protein	 and	 the	 P	 protein	which	 is	 essential	 for	 RNA	 replication.	Subsequently,	 both	 rPIV5mCh-α	 and	 PIV5	 W3-γ	 were	 shown	 to	 contain	 non-functional	V	proteins	and	exhibit	IFN-sensitivity.	Ultimately,	this	study	is	the	first	step	towards	creating	a	general	method	to	isolate	various	types	of	IFN-sensitive	viruses	that	as	well	as	aiding	fundamental	studies,	may	be	further	developed	as	attenuated	vaccines	for	clinically	important	viruses	lacking	vaccines.	
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1 Introduction		
1.1 The	Interferon	(IFN)	response		
The	Interferon	(IFN)	response	 is	a	vital	defence	against	viral	 infection,	without	which	we	would	not	be	able	to	survive.	As	an	 immediate	response	to	 infection,	cells	synthesize	and	release	IFNs,	a	group	of	widely	expressed	cytokines,	which	can	 then	 communicate	 in	 an	 autocrine	 or	 paracrine	 manner	 to	 induce	 an	antiviral	 response	 that	 limits	 the	 spread	 of	 infection.	 Despite	 the	 majority	 of	viruses	having	known	mechanisms	 to	 circumvent	 the	 IFN	 response,	 it	 remains	critical	to	slow	viral	infection	to	allow	the	adaptive	immune	response	to	develop	(reviewed	in	Iwasaki	2012,	Randall	and	Goodbourn	2008,	Schneider	et	al	2014)	
1.1.1 Classes	and	subtypes	of	IFN	There	 are	 three	 classes	 of	 IFN,	 type	 I,	 II	 and	 III,	 grouped	 according	 to	 their	similarity	 in	 amino	 acid	 sequence.	The	 type	 I	 group	 consists	 of	 fourteen	 IFN-α	subtypes,	a	single	IFN-β	subtype	and	the	less	well	characterized	IFN-	ω,	ε,	τ,	δ,	κ	subtypes,	with	IFN-α	and	-β	playing	the	most	well	defined	roles	in	the	antiviral	response	(Schneider	et	al.	2014).	It	is	known	that	IFN-α/β	act	through	the	same	heterodimeric	receptor,	composed	of	interferon-alpha/beta	receptor	alpha	chain	(IFNAR1)	and	IFNAR2,	to	trigger	what	is	termed	the	IFN	signalling	pathway	(Kim	et	 al	 1997,	 Piehler	 et	 al	 2000).	 This	 receptor	 is	 thought	 to	 be	 expressed	ubiquitously	 throughout	all	 tissues	however	hematopoietic	cells	are	 thought	 to	be	the	main	producers	of	IFN-α	and	fibroblasts	of	IFN-β	(de	Weerd	et	al	2007).	Activation	 of	 this	 pathway	 then	 leads	 to	 the	 up-regulation	 of	 hundreds	 of	 IFN	
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stimulated	genes	(ISGs)	and	subsequently	forms	an	antiviral	state	within	the	cell	and	its	neighbours.		The	type	III	IFNs	comprise	IFN-	λ1,	λ2,	λ3,	which	again	are	released	in	response	to	 viral	 infection	 in	 a	 similar	 manner	 to	 type	 I	 IFNs	 (Onoguchi	 et	 al.	 2007).	However,	 unlike	 the	 type	 I	 IFNs,	 they	 exhibit	 high	 tissue	 specificity	 due	 to	 the	expression	 of	 their	 receptor,	 Interferon-lamda	 receptor	 1	 (IFNλR),	 on	 specific	cell	types	such	as	epithelial	cells	(Lazear	et	al.	2015).	 	Latterly,	a	4th	member	of	the	type	III	IFNs	has	been	discovered;	namely	λ4,	however	frameshift	mutations	render	 the	 gene	 inactive	 in	 a	 large	 proportion	 of	 the	 human	 population.	Surprisingly,	this	inactivation	has	been	shown	to	be	associated	with	an	increased	chance	of	clearance	of	Hepatitis	C	virus	(HCV)	indicating	that	its	suppression	is	somewhat	 beneficial	 despite	 it	 showing	 strong	 antiviral	 activity	 in	 vitro	(Hamming	et	al.	2013).	Type	II	IFN	contains	only	one	member,	IFN-γ,	and	unlike	the	other	types	is	secreted	by	natural	killer	cells	and	activated	T	cells	as	oppose	to	 direct	 response	 to	 viral	 infection	 (Schroder	 et	 al.	 2004;	 Billiau	 &	 Matthys	2009)		This	 study	 focuses	mainly	 on	 the	pathways	 associated	 in	 response	 to	 IFN-α/β.	Predominately,	 IFN-β	 is	 used	 as	 an	 example	 as	 this	 pathway	 is	 better	understood.	 The	 basic	 pathway	 is	 generally	 divided	 into	 two	 parts	 the	 IFN-β	induction	cascade	and	the	IFN-β	signalling	cascade,	both	of	which	are	outlined	in	the	following	sections.				 	
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1.2 IFN-β	induction		
The	 IFN-β	 induction	 cascade	 is	 mediated	 by	 the	 recognition	 of	 molecular	pathogen-associated	molecular	patterns	(PAMPS),	these	include	single	stranded	RNA	 (ssRNA),	 double	 stranded	 RNA	 (dsRNA),	 genomic	 DNA,	 or	 viral	 proteins	(reviewed	in	Iwasaki	2012).	These	PAMPS	are	recognised	by	pattern	recognition	receptors	 (PRRs)	 namely	 i)	 the	 Toll-like	 receptors	 (TLRs)	 such	 as	 TLR3,	 TLR7	and	TLR9,	ii)	the	RIG-I-like	receptors	(RLRs)	Retinoic	acid-inducible	gene	1	(RIG-I)	and	Melanoma	Differentiation-Associated	protein	5	(Mda-5)	iii)	the	nucleotide	oligomerization	domain	 (NOD)-like	 receptors	 (NLRs)	 such	 as	NACHT,	 LRR	and	OYD	domains-containing	protein	3	(NLRP3)	(Poeck	et	al.	2010),	and	the	recently	discovered	 range	 of	 cytosolic	 nucleic	 acid	 sensors	 such	 as	 cGAMP	 synthase	(cGAS)	(Sun	et	al.	2013;	Cai	et	al.	2014).	Each	group	recognises	distinct	PAMPs	such	as	dsRNA	in	endosomes,	recognised	by	TLR3,	or	ssRNA,	recognised	by	TLR7	and	 TLR9,	 thereby	 allowing	 for	 recognition	 of	 many	 types	 of	 viral	 infection	(reviewed	 in	 Broz	 and	Monack	 2013).	 	 For	 the	 purpose	 of	 this	 study	 we	 will	focus	on	the	pathways	mediated	by	the	cytoplasmic	and	endosomal	recognition	of	RNA	viruses,	which	 is	predominantly	mediated	by	RLRs	and	the	TLRs	TLR3,	TLR7	and	TLR9.	Aside	from	the	recognition	stage,	the	TLR3	and	RLR	dependent	induction	 pathways	 are	 very	 similar,	 as	 demonstrated	 in	 Figure	 1.1A.	 By	contrast,	 the	 TLR7	 and	 TLR9	 dependent	 induction	 pathway	 exhibits	 greater	differences	and	is	represented	in	Figure	1.1B.	
1.2.1.1 TLR3	and	RLR	(RIG-I	and	mda-5)-dependent	induction	cascade.			Both	 TLR3	 and	 the	 RLRs	 recognise	 substrates	 at	 different	 stages	 during	 viral	infection,	 therefore	 increasing	 the	 level	 of	 protection	 of	 the	 cell.	 In	 particular,	
Chapter	1:	Introduction		
	 4	
TLR3	 can	 recognise	 dsRNA	 in	 endosomes	 or	 extracellular	 dsRNA	 at	 the	 cell	surface	(Randall	&	Goodbourn	2008).	By	contrast,	 the	RLRs	can	only	recognise	infection	 once	 inside	 the	 cellular	 cytoplasm	 (Goubau	 et	 al	 2013).	 Specifically,	both	RIG-I	and	Mda-5	are	activated	by	dsRNA,	however,	RIG-I	is	also	activated	by	short	 blunt	 ended	dsRNA	with	 a	 5’triphosphate	 and	 is	 therefore	 indispensable	for	the	recognition	of	many	viruses	such	as	Influenza	A	(Loo	et	al.	2008;	Hornung	et	al.	2006).	Interestingly,	RIG-I	but	not	Mda-5	activation	has	been	shown	to	be	dependent	on	ubiquitination	and	is	regulated	by	the	E3	 ligases	Tripartite	motif	containing	 25	 (TRIM25),	 TRIM4	 and	Riplet,	 and	 the	Deubiquitylation	 enzymes	Ubiquitin	specific	protease	3	(USP3)	and	ubiquitin	C-terminal	hydrolase	(Heaton	et	 al.	 2016;	 Cui	 et	 al.	 2014;	 Friedman	 et	 al.	 2008;	 Yan	 et	 al.	 2014;	 Gack	 et	 al.	2007).	 Irrespectively,	 once	 activated	 each	 receptor	must	 then	 interact	with	 an	adaptor	 to	 confer	 activation	 of	 the	 induction	 pathway.	 In	 particular,	 TLR3	 and	the	RLRs	use	the	adaptors	TIR	domain-containing	adapter	inducing	interferon-β	(TRIF)	and	CARD	adapter	 inducing	 interferon-β	(CARDIF),	respectively,	both	of	which	act	as	a	scaffold	for	the	recruitment	of	a	number	of	other	factors	(Kawai	et	al.	2005;	Meylan	et	al.	2005).	Notably	it	appears	that	engagement	of	CARDIF	by	PRRs	such	as	RIG-I	results	 in	a	conformational	change	 that	recruits	 inactivated	CARDIF	and	results	in	a	large-scale	amplification	of	the	signalling	cascades	(Hou	et	al.	2011).	This	results	in	a	highly	sensitive	mechanism	to	detect	small	amounts	of	 viral	 RNA	 with	 evidence	 suggesting	 that	 less	 than	 20	 molecules	 of	5’triphosphate	 is	 sufficient	 to	 activate	 the	 RIG-I-CARDIF	 pathway	 (Zeng	 et	 al.	2010).	 From	 this	 point	 on,	 the	 signalling	 pathways	 are	 almost	 identical	 as	 the	adaptors	 can	 activate	 both	 of	 the	 so-called	 ‘arms’	 of	 the	 induction	 pathway,	namely	the	nuclear	factor-κB	(NF-κB)	‘arm’	and	the	interferon	regulatory	factor	
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(IRF)	 ‘arm’	 (Figure	 1.1A).	 The	 NF-κB	 ‘arm’	 initiates	 with	 the	 recruitment	 of	tumour	 necrosis	 factor	 receptor-associated	 factor	 6	 (TRAF6)	 and	 receptor-interacting	protein	1	(RIP1)	to	the	adaptor	(either	TRIF	or	CARDIF	depending	on	the	 initial	 receptor)(Sato	 et	 al.	 2003).	 At	 this	 stage	 the	 TRAF6-RIP1-adaptor	complex	 can	 then	 interact	 with	 a	 complex	 called	 TAK1	 that	 consists	 of	 three	subunits	namely	TAK1-binding	protein	2/3	(TAB2/3),	TAB1	and	TGF-β	activated	kinase	 1	 (TAK1)(Jiang	 et	 al	 2004,	 Meylan	 et	 al	 2004,	 Sato	 et	 al	 2003).	 This	interaction	then	promotes	the	interaction	with	a	second	complex	namely	the	IKK	complex,	 which	 also	 consists	 of	 three	 subunits:	 NF-κB	 essential	 modulator	(NEMO),	IκB	kinase-α	(IKK-α)	and	IKK-β.	Now	that	these	two	complexes	(TAK1	and	IKK)	are	in	close	proximity	the	TAK1	subunit	of	the	TAK1	complex	can	then	phosphorylate	 the	 IKK-β	 subunit	 of	 the	 IKK	 complex	 leading	 to	 its	 activation.	Here	 it	must	be	noted	that	NF-κB,	one	of	 the	molecules	that	 is	required	for	the	activation	 of	 the	 IFN-β	 promoter	 and	 thus	 IFN-β	 up-regulation,	 is	 held	 in	 an	inactive	state	within	the	cytoplasm	by	the	molecule	inhibitor	of	κB	(IκB)(Zandi	et	al.	1997;	Alexopoulou	et	al.	2001).	In	view	of	this,	the	now	active	IKK-β	subunit	can	 phosphorylate	 the	 IκB	 subunit,	 subsequently	 leading	 to	 its	 ubiquitination	and	 degradation	 (Jiang	 &	 Chen	 2012).	 This	 then	 releases	 NF-κB	 from	 its	inhibition	and	allows	 for	 its	uptake	 into	 the	nucleus	where	 it	assembles	on	the	IFN-β	 promoter	 (Jiang	 &	 Chen	 2012;	 Randall	 &	 Goodbourn	 2008).	 This	 factor	alone	however	does	not	result	 in	IFN-β	up-regulation,	because	the	activation	of	both	the	NF-κB	and	IRF	‘arms’	of	the	pathway	are	required.	In	a	similar	manner	to	 the	NF-κB	 ‘arm’,	a	number	of	 factors	are	recruited	 to	 the	adaptor	protein	 to	begin	 activation	of	 the	 ‘IRF’	 arm.	The	process	 initiates	with	 the	 recruitment	 of	the	E3	ligase	TRAF3	to	the	adaptor	(again	either	TRIF	or	CARDIF	depending	on	
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the	initial	receptor).	TRAF3	can	then	also	bind	to	a	factor	known	as	TANK,	which	in	turn	binds	to	TANK-binding	protein	1	(TBK-1)	and/or	IKKε	(Figure	1.1A)(Paz	et	al.	2011).	Primarily	TBK-1	and/or	IKKε	can	then	phosphorylate	IRF3	directly,	allowing	 it	 to	 migrate	 to	 the	 nucleus,	 however,	 in	 certain	 circumstances	 it	 is	known	that	IRF7	is	also	activated	in	a	similar	manner	(Trinchieri	2010).	In	this	case,	both	 IRFs	can	migrate	 to	 the	nucleus	 to	assemble	on	 the	 IFN-β	promoter.	Ultimately,	with	both	the	NF-κB	and	IRF	‘arms’	of	the	pathway	switched	on,	NF-κB	and	IRF3	(and	IRF7)	are	now	assembled	on	the	IFN-β	promoter.	This	in	turn	allows	 other	 factors	 to	 assemble	 on	 the	 promoter	 namely	 activating	transcription	factor	2	(ATF-2)/c-jun,	CREB-binding	protein	(CBP)/p300	and	RNA	polymerase	 II	 which	 function	 collectively	 to	 up-regulate	 the	 production	 and	secretion	of	IFN-β	(Figure	1.1A)	(Randall	&	Goodbourn	2008;	Bhoj	&	Chen	2009;	Takeuchi	et	al.	2010).		
1.2.1.2 TLR7	and	TLR9-dependent	induction	cascade	In	addition	to	the	TLR3	and	RLR	dependent	pathway,	TLR7	and	TLR9	receptors	can	 also	 trigger	 the	 induction	 of	 IFN-β.	 Notably,	 TLR7	 and	 TLR9	 recognise	different	 PAMPs	 compared	 to	 the	 previous	 method	 such	 as	 ssRNA	 and	 CpG	(unmethylated)	DNA	that	has	been	engulfed	by	endosomes,	respectively	(Heil	et	al.	 2004;	 Tabeta	 et	 al.	 2004).	 This	 property	 thereby	 increases	 the	 number	 of	ways	in	which	viral	infection	can	be	recognised,	allowing	for	greater	protection	of	 the	 cell.	 In	 a	 similar	manner	 to	 the	 TLR3	 and	 RLR-dependent	 pathway,	 the	TLR7	 and	 TLR9-dependent	 pathway	 uses	 an	 adaptor	 to	 recruit	 factors	 that	subsequently	 activate	 the	 two	NF-κB	 and	 IRF	 ‘arms’	 of	 the	 induction	pathway.	
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More	specifically,	once	TLR7	and	TLR9	are	activated	through	recognition	of	viral	PAMPs	both	can	recruit	the	adaptor	myeloid	differentiation	factor	88	(MyD88).	This	 adaptor	 can	 then	 recruit	 two	 factors	 namely	 interleukin	 1	 receptor-associated	 kinase	 4	 (IRAK4)	 and	 IRAK1	 (Kawagoe	 et	 al.	 2008).	 Subsequently,	IRAK4	 and	 IRAK1	 then	 lead	 to	 activation	 of	 the	 NF-κB	 and	 IRF	 ‘arms’	 of	 the	pathway,	 respectively.	To	 initiate	 the	activation	of	NF-κB,	 IRAK4	 interacts	with	the	 factor	 TRAF6	 (forming	 the	 MyD88-IRAK1-IRAK4-TRAF6	 complex),	 which	then	interacts	with	a	number	of	factors	namely	RIP1	and	the	TAK1	complex	(Kim	et	al	2007).	From	this	stage	onwards,	the	activation	cascade	is	exactly	the	same	as	in	the	TLR3/RLR-dependent	pathway	(Figure	1.1A	and	B).	In	brief,	the	TAK1	complex	interacts	with	the	IKK	complex	phosphorylating	the	IKK-β	subunit.	This	active	 subunit	 can	 then	 phosphorylate	 the	 IκB	 subunit	 that	 inhibits	 NF-κB	leading	to	its	ubiquitylation	and	degradation,	thus	releasing	NF-κB	to	relocate	to	the	nucleus	where	it	assembles	on	the	IFN-β	promoter	(Figure	1.1B)(Zandi	et	al.	1997;	 Alexopoulou	 et	 al.	 2001).	 Again,	 this	 alone	 does	 not	 result	 in	 IFN-β	 up-regulation,	 as	 it	 also	 requires	 the	 activation	 of	 the	 IRF	 ‘arm’	 of	 the	 pathway.	Unlike	the	previous	method	that	contained	an	IRF	‘arm’	that	activates	IRF3	(and	IRF7)	this	cascade	offers	another	route	to	IFN-β	induction	using	only	IRF7.	The	MyD88-IRAK1-IRAK4-TRAF6	complex,	described	previously,	has	been	shown	to	bind	 directly	 to	 IRF-7	 (Kawai	 et	 al.	 2004).	 IRF-7	 is	 then	 polyubiquitinated	 by	TRAF6	 in	 the	presence	of	polyubiquitinated	RIP1	 (Konno	et	 al.	 2009).	 IRF-7	 is	subsequently	phosphorylated	by	IRAK-1	allowing	the	translocation	of	the	whole	complex	 into	 the	 nucleus,	 where	 it	 binds	 to	 the	 IFN-β	 promoter	 (Figure	1.1B)(Honda	et	al.	2004;	Uematsu	et	al.	2005).	Ultimately,	activation	of	both	the	IRF	and	NF-κB	‘arms’	leads	to	the	assembly	of	the	IRF7-containing	complex	and	
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NF-κB	on	the	IFN-β	promoter,	this	along	with	a	number	of	other	co-factors	such	as	 ATF-2/c-jun,	 CBP/p300	 and	 RNA	 polymerase	 II	 leads	 to	 increased	transcription	and	secretion	of	IFN-β	(Figure	1.1B)(Randall	&	Goodbourn	2008).		
		 	
A	
B	
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Figure	1.1:	Overview	of	the	IFN-β	induction	cascade.	A)	TLR3	and	the	RLR	
(RIG-I	 and	 Mda5)-dependent	 induction	 cascade.	 Both	 TLR3	 and	 the	 RLRs	recognise	substrates	at	different	stages	during	viral	infection.	In	particular,	TLR3	can	recognise	dsRNA	in	endosomes	or	extracellular	dsRNA	at	the	cell	surface.	By	contrast,	the	RLRs	can	only	recognise	infection	once	inside	the	cell.	Specifically,	both	RIG-I	and	Mda-5	are	activated	by	dsRNA	however	RIG-I	is	also	activated	by	5’triphosphoRNA	 and	 is	 therefore	 indispensable	 for	 the	 recognition	 of	 many	viruses	 such	 as	 Influenza	 A	 (Loo	 et	 al.,	 2008,	 Hornung	 et	 al.,	 2006).	 After	recognition	of	the	infection	both	TLR3	and	the	RLRs	mediate	the	same	induction	cascade	 through	 the	 adaptors	 TRIF	 and	 CARDIF	 respectively,	 hence	 they	 are	considered	 together	 in	 A.	B)	TLR7	and	TLR9-dependent	 induction	 cascade.	TLR7	 and	 TLR9	 recognise	 ssRNA	 and	 CpG	 (unmethylated)	 DNA	 that	 has	 been	engulfed	by	endosomes,	respectively.	After	recognition	of	 the	viral	PAMPs	both	TLRs	mediate	the	same	induction	cascade	through	interaction	with	the	adaptor	MyD88,	hence	they	are	considered	together	in	B	(Randall	and	Goodbourn,	2008).	
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1.3 IFN-β	signalling		
As	 outlined	 above	 there	 are	 a	 number	 of	 methods	 by	 which	 viral	 infection	 is	recognised	however	ultimately	they	all	lead	to	the	up-regulation	of	production	of	IFN-β.	Once	produced,	this	cytokine	is	released	by	the	cell	into	the	surrounding	area,	this	importantly	signals	to	neighbouring	cells	that	it	has	been	infected	and	thus	triggers	them	to	up-regulate	the	production	of	many	protective	genes	that	are	 collectively	 known	 as	 interferon	 stimulated	 genes	 (ISGs).	 This	 so-called	‘antiviral	state’	consequently	reduces	the	spread	of	infection	to	surrounding	cells	allowing	 a	 greater	 chance	 of	 cell	 survival	 (reviewed	 in	 Ivashkiv	 and	 Donlin	2014).	The	process	by	which	this	‘antiviral	state’	is	produced	by	IFN-β	signalling	is	outlined	in	the	following	section.		
1.3.1 IFN-β	signalling	cascade		The	 IFN-β	 signalling	 cascade	 initiates	 with	 the	 activation	 of	 the	 type	 I	 IFN	receptor	by	IFN-β.	This	receptor	is	found	at	the	cell	surface	and	consists	of	two	chains	namely	IFNAR1	and	IFNAR2	(Kim	et	al	1997).	The	interaction	with	IFN-β	results	in	autophosphorylation	of	the	receptor	itself	and	subsequently	activation	of	two	janus	activated	kinases	(JAKs)	namely	tyrosine	kinase	2	(Tyk2)	and	JAK1	which	are	found	attached	to	the	cytoplasmic	domain	of	the	receptor	of	 IFNAR1	and	 IFNAR2,	 respectively	 (Figure	 2)(Velazquez	 et	 al.	 1994;	Müller	 et	 al.	 1993;	Gauzzi	et	al.	1996).	Once	activated,	these	JAKs	can	then	phosphorylate	two	signal	transducers	 and	 activators	 of	 transcription	 (STAT),	 namely,	 STAT1	 and	 STAT2	on	 tyrosine	 701	 and	 tyrosine	 690,	 respectively	 (Stark	 et	 al.	 1998).	Phosphorylated	 STAT1	 and	 STAT2	 can	 then	 interact	 and	 translocate	 to	 the	
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nucleus	where	STAT1	is	further	phosphorylated	by	cyclin-dependent	kinase	8	on	Serine	 727	 (Wen	 et	 al.	 1995;	 Uddin	 et	 al.	 2002;	 Bancerek	 et	 al.	 2013).	 This	heterodimer	 subsequently	 forms	 a	 heterotrimer	 complex	 with	 interferon	regulatory	factor	9	(IRF-9)	that	is	collectively	termed	IFN-stimulated	gene	factor	3	(ISGF3)(Fu	et	al.	1990;	Ivashkiv	&	Donlin	2014).	ISGF3	then	translocates	to	the	nucleus	 and	 binds	 to	 a	 specific	 sequence	 within	 target	 promoters,	 the	 IFN-stimulated	 response	 element	 (ISRE).	 This	 subsequently	 stimulates	 the	transcription	of	hundreds	of	ISGs,	thereby	producing	the	‘antiviral	state’	(Figure	1.2)(Schoggins	&	Rice	2011;	Stark	&	Darnell	2012).	As	well	as	regulation	by	post-translational	modification	 such	as	phosphorylation,	 STAT-	 and	 ISGF3	mediated	gene	 transcription	 is	 also	 regulated	 by	 cooperation	 with	 other	 transcription	factors	 such	 as	 IRF1,	 IRF7,	 IRF8	 and	 IRF9	 (van	 Boxel-Dezaire	 et	 al.	 2006),		chromatin	 remodelling	 which	 is	 mediated	 by	 STAT1	 and	 STAT2	 and	 IRF-mediated	 recruitment	 of	 nucleosome-remodelling	 enzymes	 and	 histone	acetyltransferases	(HATs)(Tartey	&	Takeuchi	2015),	and	through	the	interaction	of	 STATs	 with	 co-activators	 and	 co-repressors	 (Ivashkiv	 &	 Donlin	 2014;	 Au-Yeung	et	al.	2013).	Examples	of	ISGs	upregulated	by	this	pathway	include	protein	kinase	 R	 (PKR)	 and	 2'-5'-oligoadenylate	 synthetase	 (OAS),	 PKR	 prevents	initiation	 of	 transcription	 in	 the	 presence	 of	 dsRNA	and	OAS	degrades	 cellular	and	viral	RNAs	in	the	presence	of	dsRNA	(Carlos	et	al.	2007).	Another	important	example	 includes	 ISG56,	which	 has	 been	 shown	 recently	 to	 specifically	 inhibit	translation	of	mRNA	from	Rubulaviruses	such	as	PIV5	but	not	other	members	of	the	Paramyxoviridae	family	due	to	the	lack	of	methylation	at	a	particular	position	in	the	5’	guanosine	nucleoside	cap	of	viral	mRNA	(Andrejeva	et	al.	2013;	Young	et	al.	2016).	As	these	examples	show,	the	main	aim	of	the	up-regulation	of	ISGs	is	
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to	gain	a	‘head	start’	in	producing	the	proteins	that	allow	protection	against	viral	infection.	Understandably,	this	mechanism	of	defence	has	driven	viruses	to	gain	numerous	ways	in	which	to	circumvent	this	response	to	tip	the	balance	in	favour	of	viral	infection.	Crucially,	by	studying	these	interactions	we	can	gain	an	insight	into	how	to	weaken	the	virus	to	tip	the	favour	back	towards	the	host.	This	could	ultimately	 aid	 in	 the	 production	 of	 attenuated	 viruses,	which	 are	 the	 essential	component	of	numerous	vaccines.		
	
Figure	 1.2:	 Overview	 of	 the	 IFN	 signalling	 cascade.	 IFN-β	 can	 trigger	 the	activation	 of	 the	 JAK-STAT	 signalling	 pathway,	 inducing	 an	 ‘antiviral	 state’	 in	surrounding	 cells	 through	 the	 activation	 of	 many	 hundreds	 of	 Interferon	stimulated	genes	(ISGs)(Fleming	2016).	
Cytoplasm
Nucleus
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1.4 Viral	IFN	antagonism	
Viruses	have	developed	an	astonishing	variety	of	 IFN	antagonists	to	counteract	the	induction,	signalling	or	antiviral	actions	of	the	IFN	system.	Over	170	viral	IFN	antagonist	has	been	described	from	93	distinct	viruses	with	most	demonstrating	a	multifunctional	role	targeting	multiple	steps	within	the	IFN	response	(Versteeg	et	 al.	 2010;	 Haller	 et	 al.	 2006).	 Although	 each	 is	 unique,	 IFN	 antagonists	counteract	 the	 cellular	 IFN	 response	 using	 common	 strategies	 that	 include	 i)	broad-spectrum	 inhibition	 of	 cellular	 gene	 expression	 and	 ii)	 sequestration,	proteolytic	 cleavage	and	proteasome-mediated	degradation	of	key	 components	of	the	IFN	system	(Versteeg	et	al.	2010).		
1.4.1 Pleiotropic	nature	of	viral	IFN	antagonists	The	pleiotropic	nature	of	IFN	antagonists	is	dictated	by	restrictions	on	the	viral	genome.	More	specifically,	RNA	viruses	have	a	relatively	limited	genome	capacity	in	 comparison	 to	 large	 dsDNA	 viruses,	 which	 drives	 a	 high-degree	 of	multifunctionality	 of	 the	 IFN	 antagonists.	 This	 evolutionary	 pressure	 has	resulted	 in	 the	 conservation	 of	 IFN	 antagonists	 within	 related	 RNA	 viruses	whereas	 there	 is	 limited	 conservation	 in	 large	 dsDNA	 viruses	 (Versteeg	 et	 al.	2010).	 A	 prime	 example	 of	 this	 is	 the	 Non-structural,	 NS1,	 protein,	 which	 is	conserved	 among	 Influenza	 A	 and	 B,	 and	 exhibits	 a	 plethora	 of	 different	strategies	to	antagonise	the	IFN	system	(Hale	et	al.	2008).	A	second	example	of	this	 is	 the	 Non-structural	 protein,	 NSs,	 protein	 which	 is	 a	multifunctional	 IFN	antagonist	conserved	among	the	Phleboviruses	and	Orthobunyaviruses	(Elliott	&	Weber	2009).		
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1.4.2 Bunyamwera	virus	(BUN	WT)	and	the	IFN	antagonist	NSs	As	 BUN	 WT	 of	 the	 Orthobunyaviruses	 genus	 and	 the	 recombinant	 virus	BUNΔNSs	are	used	within	a	major	part	of	this	study	we	will	discuss	these	viruses	further,	 with	 particular	 focus	 on	 the	 functions	 of	 the	 IFN	 antagonist	 NSs.	Bunyamwera	virus	is	a	prototypical	virus	within	the	Bunyaviridae	 family	which	contains	pathogens	of	serious	concern	such	as	Rift	Valley	fever	virus	(RVFV)	and	Schmallenberg	 (SBV)	 (Fields	 et	 al.	 2013;	Garigliany	 et	 al.	 2012).	 It	 possesses	 a	tri-segmented	negative	sense	RNA	genome	consisting	of	 the	Large	(L),	Medium	(M)	and	Small	(S)	segments.	The	L	segment	encodes	the	viral	RNA	polymerase,	the	 M	 segment	 encodes	 a	 polyprotein	 precursor,	 which	 is	 co-translationally	cleaved	to	obtain	the	glycoproteins	Gn	and	Gc	and	a	non-structural	protein	NSm,	and	 the	 S	 segment	 encodes	 the	 N	 protein	 and	 the	 NSs	 IFN	 antagonist	 in	overlapping	 reading	 frames	 (Elliott	 and	Blakqori	 2011).	 For	BUN	WT,	NSs	 is	 a	non-essential	 small	 hydrophobic	 protein	 of	 101	 amino	 acids	 that	 is	 expressed	from	an	 internal,	+1-shifted	reading	 frame	within	 the	N	gene	of	 the	S	segment.	The	main	function	of	this	protein	is	attributed	to	globally	inhibiting	host	mRNA	transcription	 by	 blocking	RNA	polymerase	 II	 (RNAP	 II)	 through	 an	 interaction	with	 Mediator	 complex	 subunit	 8	 (MED8),	 a	 complex	 required	 for	 mRNA	production	 (Thomas	 et	 al.	 2004;	 Leonard	 et	 al.	 2006).	 Generation	 of	 a	recombinant	 virus,	 BUNΔNSs,	 which	 does	 not	 express	 NSs	 demonstrated	reduced	plaque	size	and	growth	in	IFN	competent	cells	to	approximately	10-fold	lower	 titers	 compared	 to	 the	 wild-type	 virus	 (BUN	 WT).	 Furthermore,	 when	inoculated	 intracerebrally	 into	 BALB/c	 mice,	 BUNΔNSs	 killed	 the	 mice	 in	 a	slower	time	course	than	BUN	WT	(Bridgen	et	al.	2001).	Indicating	that	although	non-essential,	 expression	of	 the	NSs	protein	aids	viral	pathogenesis	as	 the	NSs	
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deficient	virus	is	more	sensitive	to	IFN	and	therefore	attenuated	compared	to	the	wild-type	virus.	
1.5 IFN-sensitive	viruses	as	Vaccines			
With	 most,	 if	 not	 all,	 viruses	 encoding	 an	 IFN	 antagonist	 this	 opens	 up	 the	opportunity	 for	 prophylactic	 intervention	 through	 the	 development	 of	 ‘IFN-sensitive’	 viruses	 as	 live	 attenuated	virus	 vaccines. A	concept	which	has	now	been	 successfully	 verified	 for	many	 viruses	 including	 Influenza	A	 and	B,	 RVFV	and	more	 recently	 Respiratory	 syncytial	 virus	 (RSV)	 (Bird	 et	 al.	 2008;	 Jang	 &	Seong	2012;	Meng	et	al.	2014).	
Live	 attenuated	 virus	 vaccines	 contain	 a	 mutant	 strain	 of	 a	 wild-type	 virus,	whereby	 its	 ability	 to	 inhibit	 the	 hosts	 immune	 response	 has	 been	weakened.	This	impairment	can	be	associated	with	loss	of	a	viruses	IFN	antagonist	function	or	mutations	within	other	proteins	that	slow	viral	replication	such	that	it	can	be	controlled	by	the	IFN	response.	This	attenuation	does	not	prevent	host	infection	but	 rather	prevents	 the	 cause	of	 severe	disease.	As	 the	virus	 can	 still	 replicate	within	 the	 host,	 it	 can	 produce	 numerous	 antigens	 causing	 a	 wide	 range	 of	immune	responses	that	later	protect	the	host	from	subsequent	infection	from	the	wild-type	virus.		
1.5.1 Live	Attenuated	vaccine	development		
One	 of	 the	 first	 live	 attenuated	 vaccines	 to	 be	 developed	 was	 that	 against	smallpox	(variola	virus)(reviewed	in	Minor	2015).	In	the	18th	century	it	was	well	known	 among	 rural	 communities	 that	 workers	 who	 contracted	 cowpox	 were	
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subsequently	 resistant	 to	 smallpox.	 In	 1976,	 Edward	 Jenner	 experimented	 by	inoculating	 a	 young	 boy,	 James	 Phipps,	 with	 material	 from	 a	 cowpox-infected	milkmaid.	 Seven	 weeks	 later	 he	 then	 injected	 the	 boy	 with	 material	 from	 a	smallpox	 lesion	 and	 Phipps	 survived	 with	 no	 indication	 of	 infection	 (Jenner	1798).	These	initial	investigations	subsequently	led	to	compulsory	vaccination	in	the	UK	however	debate	over	the	quality	of	 the	production	of	 the	vaccine	 led	to	compulsion	 being	 dropped.	 Subsequently,	 in	 1959	 the	 World	 Health	Organisation	 developed	 criteria	 for	 the	 production	 of	 a	 safer	 vaccine	 tackling	major	problems	such	as	the	possibility	of	bacterial	contamination	of	the	vaccine	and	also	the	transfer	of	syphilis	(WHO	1959).	Unbeknown	to	many	the	original	constituent	 of	 the	 smallpox	 vaccine	 had	 mutated	 into	 what	 is	 now	 known	 as	vaccinia	 virus.	 Whether	 this	 virus	 derived	 from	 cowpox	 or	 variola	 virus	 is	unknown	however	its	effectiveness	is	unquestionable	(Elwood	1989;	Petersen	et	al.	2016).	 In	1980	smallpox	was	declared	eradicated	making	 it	one	of	 the	most	successful	human	vaccines	to	date.	Given	that	the	infectious	agent	we	now	know	as	a	virus	was	not	described	until	1898,	it	is	not	surprising	that	there	was	little	influence	of	virology	on	the	development	of	smallpox	vaccines	first	investigated	in	1798	(Minor	2015).		This	was	not	the	case	for	the	polio	vaccine.	This	vaccine	was	 obtained	 through	 a	 better	 understanding	 of	 viral	 pathogenesis	 and	 the	virology	 of	 the	 poliomyelitis.	 Albert	 Sabin	 developed	 the	 Sabin	 type	 1	 vaccine	from	the	serial	passage	of	the	wildtype	virus	through	monkey	testis	cells	(Sabin	&	Ward	1941).	The	 type	2	and	3	strains	were	 then	 isolated	 from	clinical	 cases	(Sabin	 &	 Boulger	 1973).	 Many	 years	 later,	 following	 the	 introduction	 of	 the	vaccines,	 sequence	 analysis	 of	 the	 vaccine	 strains	 then	 determined	 mutations	affecting	the	virulence	of	each	(Macadam	et	al.	1991;	Westrop	et	al.	1989).	Given	
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the	success	of	this	vaccine	in	decreasing	polio	to	an	unprecedented	level	it	is	not	surprising	that	similar	techniques	including	serial	passage	are	still	used	today	to	try	to	obtain	attenuated	viruses	for	use	as	live	attenuated	vaccines.	
1.5.2 Traditional	methods	to	obtain	attenuated	viruses		
Several	approaches	are	used	today	to	produce	live	attenuated	viruses.	One	such	technique	is	to	passage	the	virus	within	a	foreign	host.	Mutants	generated	with	increased	 virulence	 in	 the	 foreign	 host	 typically	 lose	 virulence	 in	 humans	 and	can	 therefore	 be	 analysed	 as	 a	 potential	 vaccine	 strain.	 This	method	 has	 been	shown	to	be	a	useful	method	with	RNA	viruses	as	they	have	a	particularly	high	mutation	rate.	Alternatively,	the	virus	can	be	grown	in	a	different	temperature	to	the	human	host,	this	can	cause	mutations	to	occur	which	adapt	the	virus	to	this	new	 temperature	 but	 slow	 the	 viral	 growth	 in	 human	 cells	 enough	 for	 the	adaptive	immune	response	to	fight	infection	(Baxter	2007;	Minor	2015).	A	final	approach	 is	 chemical	 mutagenesis	 which	 has	 been	 used	 to	 create	 potential	vaccines	 for	 dengue	 and	 tuberculosis	 (Blaney	 et	 al.	 2001;	 Collins	 2000).	 These	forward	 genetics	 approaches,	 firstly	 finding	 a	 mutated	 strain	 and	 then	identifying	what	is	making	that	strain	attenuated	have	been	a	successful	method	to	 identify	 numerous	 vaccines	 against	 viruses	 such	 measles	 (MeV),	 mumps	(MuV)	 and	 seasonal	 and	 pandemic	 strains	 of	 influenza	 (Fiore	 et	 al.	 2009;	Suguitan	 et	 al.	 2006;	 Bankamp	 et	 al.	 2011;	 Rubin	 et	 al.	 2008).	 However,	 this	process	 can	 be	 somewhat	 lengthy,	 as	 the	 virus	 needs	 to	 be	 passaged	multiple	times	 and	 then	 followed	 by	 pairing	 of	 genomic	 nucleotide	 changes	 with	diminished	virulence.		
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1.5.3 Rational	design	of	live	attenuated	vaccines			
Due	 to	 the	 difficulties	 associated	 with	 traditional	 empirical	 methods,	 the	development	of	vaccines	is	currently	moving	towards	rational	design.	Using	this	method	known	 IFN	antagonists	 can	be	directly	mutated	 to	attenuate	 the	virus.	This	is	typically	completed	by	mutating	the	gene	code	to	prevent	the	expression	of	the	IFN	antagonist	or	by	editing	specific	sites	to	allow	the	expression	of	a	non-functional	protein	(Rueckert	et	al.	2012).	A	prime	example	of	this	is	the	BovelaÒ	attenuated	 virus	 vaccine	 produced	 by	 mutation	 of	 the	 IFN	 antagonists	 Npro	Protease	and	ERNS	RNase	of	Bovine	Viral	Diarrhoeal	virus	(BVDV).	This	vaccine	is	now	 used	 successfully	 to	 prevent	 persistent	 infection	 of	 bovine	 with	 BVDV	(Meyers	et	al.	2007).	Recently,	codon-pair	de-optimisation	has	presented	a	novel	approach	to	the	attenuation	of	viral	IFN	antagonists.	This	method	was	first	used	to	tackle	the	issue	of	genetic	instability	of	live-attenuated	poliovirus	vaccines	by	incorporating	the	rarest	codons	in	the	human	genome	to	lower	translation	of	the	capsid	protein	resulting	in	virus	attenuation	(Mueller	et	al.	2006).	More	recently	this	 method	 has	 been	 used	 to	 attenuate	 RSV	 by	 codon	 de-optimization	 of	 the	nonessential	 IFN	antagonists	NS1	and	NS2	to	create	a	potential	 live	attenuated	vaccine	candidate	(Meng	et	al.	2014).	Importantly,	this	approach	offers	increased	safety	by	decreasing	the	likelihood	that	the	attenuated	strain	can	revert	to	regain	IFN	 antagonist	 function	 as	 well	 as	 improved	 immunogenicity.	 Despite	 the	successes	of	attenuating	a	virus	in	this	way,	this	process	is	by	no	means	simple.	Firstly,	 it	 relies	 on	 the	 notion	 that	 the	 IFN	 antagonist	 of	 the	 virus	 is	 already	known	which	is	not	always	the	case.	Secondly,	 it	 is	particularly	complicated	for	RNA	viruses	due	to	the	multifunctional	nature	of	most	IFN	antagonists,	hence	not	
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all	 rationally	 designed	 attenuations	 result	 in	 a	 viable	 live	 attenuated	 vaccine	strain.	
1.5.4 Vaccine	production		Whether	a	virus	has	been	developed	by	traditional	methods	or	by	rational	design	it	is	important	to	consider	that	the	more	attenuated	the	virus	the	more	difficult	it	will	 be	 to	 produce	 for	 clinical	 use	 (Jang	&	 Seong	 2012).	 Currently,	 the	 default	option	 for	growth	of	 IFN-sensitive	viruses	 is	 limited	 to	a	select	number	of	cell-lines	 such	 as	 Vero	 cells,	 that	 do	 not	 have	 an	 intact	 IFN	 system,	 however,	 as	viruses	 exhibit	 host	 cell	 specificity	 not	 all	 viruses	 can	 be	 grown	 in	 such	 cells	(Desmyter	et	al.	1968;	Mosca	&	Pitha	1986).	Previously	we	have	developed	cell-lines	 expressing	 IFN	 antagonists	 that	 enable	 blockage	of	 the	 IFN	 response	 and	can	subsequently	relieve	host	cell	constraints	on	the	virus,	allowing	virus	growth	(Young	et	al.	2003).	However,	development	of	these	cell-lines	is	time	consuming	and	 creates	 regulatory	problems	during	 vaccine	development,	 as	 each	 cell	 line	has	to	be	approved	for	use	during	production.			
1.5.5 Experimental	Objectives		To	 tackle	 this	 issue,	 it	 was	 hypothesised	 that	 blocking	 the	 IFN	 induction	 and	signalling	 pathways	 using	 a	 small	molecule	 inhibitor	would	 offer	 a	 simple	 and	flexible	solution	to	increase	viral	growth,	as	an	inhibitor	could	easily	supplement	the	 tissue	 culture	 medium	 of	 cell-lines	 of	 choice.	 To	 test	 this,	 eight	 inhibitors	known	 to	 target	 different	 components	 of	 the	 IFN	 response	 (TBK-1,	 IKK-b	 and	JAK1/2)	were	tested	for	their	ability	to	block	their	corresponding	pathways.	Of	these	 eight	 inhibitors,	 Ruxolitinib	 (Rux)	 the	 JAK1/2	 inhibitor	which	blocks	 the	IFN	signalling	pathway,	was	identified	as	the	most	effective	inhibitor	of	the	IFN	
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response	(Stewart	et	al.	2014).	Consequently,	the	first	objective	of	my	study	was	to	 further	 characterize	 the	 use	 of	 this	 IFN	 inhibitor,	 Rux,	 with	 respect	 to	increasing	the	growth	of	IFN-sensitive	viruses.		The	second	objective	of	my	study	then	aimed	to	speed	the	process	of	traditional	methods	 to	 identify	 attenuated	 viruses	 and	 allow	 selection	 of	 viable	 vaccine	strains	 by	 developing	 a	 method	 to	 rapidly	 isolate	 potentially	 IFN-sensitive	viruses	 from	 Paramyxoviruses,	 using	 fluorescent	 activated	 cell	 sorting	 (FACS).	Following	 isolation,	 we	 could	 then	 employ	 the	 IFN	 inhibitor	 Rux	 to	 aid	 us	 in	characterisation	of	potential	 IFN-sensitive	viruses.	As	Paramyxoviruses	 are	 the	main	 focus	 of	 this	 study,	 I	 will	 now	 outline	 the	 basic	 properties	 of	 the	
Paramyxoviridae	 family	 with	 particular	 focus	 on	 the	 prototypical	 virus	Parainfluenza	virus	type	5	(PIV5)	used	throughout	our	experimental	research.		
1.6 Paramyxoviridae	family		
The	 family	 Paramyxoviridae	 are	 responsible	 for	 a	 range	 of	 acute	 respiratory	diseases	in	both	humans	and	animals.	As	a	result,	they	are	linked	to	a	substantial	mortality	 rate	 and	 cause	 a	 significant	 economic	 burden.	 The	 family	 is	 divided	into	 the	 subfamilies	 Paramyxovirinae	 and	 Pneumovirinae	 (Table	 1.1).	 The	subfamily,	 Paramyxovirinae,	 is	 the	 largest	 group	 divided	 into	 7	 genera:	
Aquaparamyxovirus,	 Avulavirus,	 Ferlavirus,	 Henipavirus,	 Morbillivirus,	
Respirovirus	and	Rubulavirus.	 It	contains	many	clinically	important	viruses	such	as	MeV	and	MuV	virus,	which	 cause	highly	 contagious	viral	 diseases	 in	human	infants,	in	addition	to,	the	newly	emerging	viruses	Hendra	(HeV)	and	Nipah	virus	(NiV)	that	are	known	to	cause	deadly	diseases	in	both	animals	and	humans.	The	
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latter	 smaller	 subfamily,	 the	 Pneumovirinae,	 is	 divided	 into	 2	 genera	 the	
Metapneumovirus	 and	 the	Pneumovirus	 and	 it	 contains	 viruses	 such	 as	 human	RSV,	 which	 is	 the	 major	 cause	 of	 lower	 respiratory	 tract	 infection	 in	 infants	(reviewed	in	Audsley	2013,	Fields	et	al	2013).		
Table	1.1:	Paramyxoviridae	subfamily	and	genus	classification.	(adapted	from	Audsley	2013,	King	et	al	2012)	
Subfamily		 Genus		 Virus		
Paramyxovirinae	
Aquaparamyxovirus	 Atlantic	salmon	paramyxovirus	
Avulavirus	
Avian	paramyxoviruses	2-9	
Newcastle	disease	virus	
Ferlavirus	 Fer-de-Lance	paramyxovirus	
Henipavirus	
Hendra	virus	(HeV)	
Nipah	virus	(NiV)	
Morbillivirus	
Canine	distemper	virus	
Measles	virus	(MeV)	
Respirovirus	
Sendai	virus	(SeV)	
Human	 parainfluenza	 virus	 1	 and	 3	
(PIV1/3)	
Rubulavirus	
Mumps	virus	(MuV)	
Parainfluenza	virus	5	(PIV5)	
Human	 parainfluenza	 virus	 2	 and	 4	
(PIV2/4)	
Pneumovirinae	
Metapneumovirus	
Human	Metapneumovirus	
Avian	Metapneumovirus	
Pneumovirus	
Bovine	respiratory	syncytial	virus	(BRSV)	
Human	respiratory	syncytial	virus	(RSV)			 	
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1.7 Paramyxovirus	virion	structure	
Despite	 classification	 of	 paramyxoviruses	 into	 several	 genera,	 the	 basic	paramyxovirus	 virion	 structure	 is	 consistent	 across	 all	 subtypes	 (Figure	 1.3)	(reviewed	 in	Chang	and	Dutch	2012,	Fields	et	 al	2013,	El	Najjar	et	 al	2014).	 It	consists	of	pleomorphic	(spherical	or	 filamentous),	enveloped	particles	ranging	typically	 from	 150	 to	 300nm	 in	 diameter	 (Kalica	 et	 al.	 1973;	 Goldsmith	 et	 al.	2003;	 Loo	 et	 al.	 2013).	 These	 particles	 encapsidate	 a	 non-segmented,	 negative	sense,	single	stranded	RNA	that	encodes	for	the	necessary	proteins	required	for	replication	of	 the	virus.	Genomic	RNA	 is	wrapped	with	nucleoprotein	(NP),	 the	phosphoprotein	 (P)	 and	 the	 large	 (L)	 protein	 forming	 what	 is	 termed	 a	nucleocapsid	 structure,	 which	 is	 essential	 for	 RNA	 replication	 as	 well	 as	transcription	(Horikami	et	al.	1992;	Noton	&	Fearns	2015).	The	L	protein	is	the	RNA	 dependent	 RNA	 polymerase	 allowing	 transcription	 and	 replication	 of	 the	genomic	 RNA,	 aided	 by	 the	 P	 protein.	 NP	 is	 important	 for	 protecting	 the	 viral	genome	 from	 cellular	 responses	 by	 encapsidating	 the	 RNA	 during	 RNA	replication.	Together	 this	nucleocapsid	 interacts	with	 the	matrix	 (M)	protein,	a	protein	 important	 in	 virion	 assembly,	 which	 lines	 the	 virion	 envelope.	 This	envelope	contains	two	surface	glycoproteins,	a	trimeric	fusion	(F)	protein	and	a	tetrameric	 attachment	 protein-	 HN,	 H	 or	 G	 depending	 on	 the	 virus.	 The	
Aquaparamyxoviruses,	 Avulaviruses,	 Ferlaviruses,	 Respiroviruses	 and	
Rubulaviruses	 share	 a	 common	 attachment	 protein-	 Hemagglutinin–neuraminidase	 (HN)	 which	 has	 both	 Hemagglutinin	 (sialic	 acid	 binding)	 and	neuraminidase	 (sialic	 acid	 cleaving)	 activity.	 These	 viruses	 can	 therefore	 use	cellular	 surface	 sialic	 acid	 as	 their	 receptor	 (Chang	 &	 Dutch	 2012).	 The	
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Morbilliviruses	contain	only	Hemagglutinin	(H)	protein	so	can	bind	sialic	acid	but	lack	 the	 ability	 to	 cleave	 it.	 Subsequently	 it	 has	been	 shown	 that	 these	 viruses	use	 cellular	proteins	 such	as	 signalling	 lymphocyte	activation	molecule	 (SLAM;	also	 known	 as	 CD150)	 to	 gain	 entry	 to	 cells	 (Ono	 et	 al.	 2001).	 The	 remaining	families	 the	 Henipaviruses	 and	 both	 the	 Metapneumoviruses	 and	 the	
Pneumoviruses	 of	 the	 Pneumovirinae	 subfamily	 contain	 a	 G	 protein	 which	facilitates	 attachment	 to	 cellular	 proteins	 such	 as	 Ephrin	 B2/B3	 in	 the	 case	 of	HeV	and	NiV	(Negrete	et	al.	2006;	Bonaparte	et	al.	2005),	or	nucleolin	in	the	case	of	RSV	(Tayyari	et	al.	2011).	
	
Figure	1.3:	 Paramyxovirus	 virion	 structure.	 	 All	 paramyxoviruses	 contain	 a	nucleocapsid	 that	 comprises	 the	 negative	 sense	 RNA	 genome	 wrapped	 in	nucleocapsid	 protein	 (NP),	 phosphoprotein	 (P)	 and	 the	 large	 (L)	 polymerase	protein.	This	nucleocapsid	is	then	enclosed	in	a	lipid	envelope	that	is	lined	with	matrix	proteins,	which	play	an	important	role	during	virion	assembly.		The	lipid	envelope	 of	 the	 virion	 contains	 two	 surface	 glycoproteins:	 the	 attachment	proteins	(HN,	H	or	G)	and	the	fusion	protein	(F).	These	function	to	allow	binding	and	entry	to	the	host	cell	(El	Najjar	et	al	2014)	 	
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1.8 Paramyxovirus	replication	cycle	
As	 paramyxoviruses,	 like	 all	 viruses,	 are	 obligate	 parasites	 they	 must	 infect	 a	host	cell	to	replicate	and	produce	new	progeny	virions	(Figure	1.4).	This	cycle	is	initiated	by	binding	of	the	attachment	protein	(HN,	H	or	G)	to	the	receptor	on	the	host	 cell.	 The	 F	 protein	 then	 permits	 fusion	 of	 the	 envelope	 with	 the	 plasma	membrane	and	allows	release	of	the	nucleocapsid	into	the	cytoplasm	(Bose	et	al.	2013;	 Chang	 &	 Dutch	 2012).	 Once	 inside,	 transcription,	 protein	 synthesis	 and	replication	of	 the	viral	genome	can	occur	within	 the	cytoplasm	of	 the	host	cell.	Upon	entry,	 the	RNA	polymerase,	L	protein,	carried	as	part	of	 the	nucleocapsid	can	 initiate	 transcription	 of	 the	 viral	 genome	 to	 form	 individual	 mRNAs	 in	 a	transcription	gradient	that	are	subsequently	transcribed	to	proteins	(Abraham	&	Banerjee	 1976).	 The	 most	 renowned	 model	 for	 switching	 to	 RNA	 replication	then	proposes	that	when	enough	unassembled	nucleocapsid	protein	 is	present,	the	 polymerase	 can	 then	 switch	 to	 transcribe	 full-length	 positive-sense	 anti-genomic	RNA	templates	(Kolakofsky	et	al.	2004;	Noton	&	Fearns	2015).	This	can	then	be	used	as	a	template	to	synthesise	full	length	genomic	RNAs.	Notably	most	Paramyxoviruses	 obey	 the	 ‘Rule	 of	 6’,	 i.e.	 their	 genome	 length	must	 be	 exactly	divisible	by	6	to	replicate	efficiently	due	to	restrictions	on	the	wrapping	of	RNA	with	NP(Kolakofsky	et	al.	2004;	Alayyoubi	et	al.	2015).	Together	with	L,	NP	and	P,	the	progeny	RNA’s	form	nucleocapsids,	which	associate	with	the	M	protein	at	the	plasma	membrane	along	with	the	viral	glycoproteins	(HN,	H	or	G)(Ghildyal	et	al.	 2006).	Mature	virions	 can	 then	bud	 from	 the	plasma	membrane	and	exit	 to	continue	infection	(reviewed	in	Fields	et	al	2013)		
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Figure	1.4:	Paramyxovirus	replication	cycle.	Entry	 to	 the	 cell	 is	 initiated	by	binding	of	the	attachment	protein	to	the	cell	(HN,	H	or	G).	The	fusion	protein	can	then	 instigate	 fusion	 of	 the	 viral	 envelope	 to	 the	 plasma	membrane	 and	 allow	release	 of	 the	 nucleocapsid	 to	 the	 cell	 cytoplasm.	 Inside	 the	 host	 the	 viral	polymerase	 initiates	transcription	of	viral	mRNAs,	which	are	then	translated	to	proteins.	 The	 polymerase	 can	 also	 replicate	 the	 negative	 sense	 genome	 to	 a	positive	sense	antigenome,	which	can	then	be	used	as	a	 template	 to	synthesise	new	progeny	genomes.	Together	with	L,	P	and	NP,	these	newly	synthesised	RNA	genomes	form	nucleocapsids,	which	by	exploiting	M	protein	can	assemble	with	newly	synthesised	viral	glycoproteins	found	at	the	cellular	membrane	into	new	virions.	 These	 new	 virions	 then	 bud	 from	 the	 host	 and	 exit	 to	 continue	 the	spread	of	infection.	(El	Najjar	et	al	2014)	
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1.9 Additional	proteins	encoded	by	paramyxoviruses		
Interestingly,	 in	 addition	 to	 the	 aforementioned	 proteins,	 a	 number	 of	 the	
Rubulaviruses	and	Avulaviruses	and	the	entire	Pneumovirinae	subfamily	produce	a	 small	 hydrophobic	 (SH)	 protein	 that	 is	 thought	 to	 play	 a	 role	 in	 preventing	apoptosis	or	protecting	against	the	immune	response	(Li	et	al.	2013;	Wilson	et	al.	2006).	 Furthermore,	most	 paramyxoviruses	 can	 express	 a	 number	 of	 proteins	from	 the	P	 gene	 due	 to	 a	 number	 of	 overlapping	 open	 reading	 frames	 (ORFs).	The	 Morbillivirus,	 Respiroviruses,	 Henipaviruses	 and	 Avulaviruses	 transcribe	 P	mRNA	 however	 a	 process	 termed	 ‘RNA	 editing’	 can	 allow	 the	 insertion	 of	 a	 G	nucleotide	 into	 the	 transcript	 (Figure	 1.5).	 This	 insertion	 creates	 a	 frameshift	mutation	 in	 the	downstream	sequence,	which	 thereby	produces	 an	mRNA	 that	translates	 into	 a	protein	 termed	 the	V	protein.	This	protein	 therefore	 shares	 a	common	N-terminus	with	the	P	protein	but	has	a	unique	C	terminus	(Goodbourn	&	Randall	2009).	The	V	protein	is	a	cysteine	rich	protein	termed	as	an	interferon	(IFN)	antagonist	as	 it	 is	able	to	block	the	IFN	immune	response	and	allows	the	virus	to	propagate	more	easily	within	the	cell	(Andrejeva	et	al	2004,	Didcock	et	al	 1999,	 reviewed	 in	 Parks	 and	 Alexander-Miller	 2013,	 Poole	 et	 al	 2002).	 A	second	G	residue	insertion	creates	an	mRNA	that	encodes	proteins	with	different	C-termini	termed	W,	D	or	I.		Intriguingly,	it	is	the	V	protein	of	the	Rubulaviruses	such	as	PIV5	that	is	genomically	templated	and	two	G	residues	are	inserted	into	the	 mRNA	 to	 produce	 the	 P	 protein.	 Furthermore,	 the	 addition	 of	 1	 or	 4	 G	residues	 creates	 the	 I	 protein	 in	 certain	 viruses	 (reviewed	 in	 Parks	 and	Alexander-Miller	2013,	S.	M.	Thomas	et	al	1988)		
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In	 addition	 to	 RNA	 editing	 certain	 viruses	 such	 as	 the	 Morbilliviruses,	
Respiroviruses	 and	Henipaviruses	 translate	 the	 P/V/W/D	mRNAs	 by	 a	 process	termed	 ‘leaky	scanning’.	This	occurs	as	 the	P/V/C	mRNAs	contain	a	number	of	weak	start	codons	that	result	in	several	places	for	initiation	of	the	ribosome.	In	SeV,	 for	example,	 there	are	4	distinct	start	codons	which	can	generate	C’,	C,	Y1	and	 Y2	 proteins	 with	 varying	 N-termini	 but	 share	 a	 common	 C-terminus	(reviewed	 in	 Audsley	 2013,	 Goodbourn	 and	 Randall	 2009,	 Parks	 et	 al	 2011).	These	proteins	again	have	been	linked	to	functions	such	as	IFN	antagonism	and	regulation	 of	 viral	 genome	 and	 antigenome	 RNA	 synthesis	 (Irie	 et	 al.	 2008).	Inversely,	the	P	genes	of	the	Pneumovirinae	only	encode	1	protein	but	some	such	as	RSV	encode	2	extra	genes,	namely	NS1	and	NS2,	which	have	been	shown	to	act	as	IFN	antagonists	(Elliott	et	al	2007,	Goswami	et	al	2013,	Lo	et	al	2005)	.				
	
Figure	1.5:	Accessory	proteins	produced	by	RNA	editing	and	leaky	scanning	
during	 paramyxovirus	 transcription	 and	 translation	 respectively.	 Those	obtained	 by	 RNA	 editing	 are	 indicated	 in	 blue	 and	 those	 obtained	 by	 leaky	scanning	in	pink.	(Goodbourn	&	Randall	2009)	
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1.10 Parainfluenza	virus	5	(PIV5)		
For	 the	 purposes	 of	 this	 study,	 we	 shall	 now	 discuss	 the	 prototypical	paramyxovirus,	 PIV5,	 in	 more	 depth.	 Many	 fundamental	 studies	 of	paramyxoviruses	 are	 typically	 based	 on	 the	 analysis	 of	 PIV5.	 Initially	 isolated	from	rhesus	monkey	kidney	cells	the	virus	was	named	simian	virus	5	(SV5)(Hull	et	al.	1956;	Choppin	1964),	however,	since	then,	its	isolation	from	a	wide	range	of	animals	namely	canine,	porcine	and	human	have	led	to	the	proposal	that	it	be	renamed	 parainfluenza	 virus	 5	 (PIV5)	 (Chatziandreou	 et	 al.	 2004;	 Rima	 et	 al.	2014).	 Despite	 its	 isolation	 from	 a	 wide	 variety	 of	 animals,	 the	 virus	 remains	avirulent	 in	most	cases	 including	humans	and	 its	only	known	potential	 links	to	disease	are	to	kennel	cough	in	dogs	and	acute	respiratory	symptoms	in	pigs	and	calves	 (McCandlish	 et	 al.	 1978;	 Heinen	 et	 al.	 1998;	 Tong	 et	 al.	 2002).	What	 is	more	 the	 virus	 also	 grows	 rapidly	 in	 tissue	 culture.	 Undoubtedly,	 these	 assets	have	facilitated	its	study	as	the	prototypical	paramyxovirus	and	many	properties	discovered	 from	 PIV5	 studies,	 were	 later	 found	 to	 be	 common	 within	 the	
Paramyxoviridae	 family	 (Parks	 et	 al.	 2011).	 In	 addition	 to	 aiding	 fundamental	studies	of	paramyxoviruses,	PIV5	has	also	recently	gained	 interest	as	a	 tool	 for	the	 development	 of	 vaccines.	More	 specifically,	many	 of	 its	 properties	 such	 as	lack	of	pathogenicity	in	humans	and	rapidity	of	growth	have	led	to	the	proposal	that	PIV5	is	an	ideal	vaccine	vector.	For	example,	it	has	been	shown	that	PIV5	can	be	 engineered	 to	 expressed	 the	 H7	 protein	 from	 the	 fatal	 H7N9	 strain	 of	influenza	 leading	 to	 an	 effective	H7N9	vaccine	 that	 protected	mice	 from	 lethal	infection	 (Li	 et	 al.	 2015;	 Li	 et	 al.	 2013).	 Together	 these	 functions	 demonstrate	
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that	 despite	 causing	 no	 apparent	 illness	 in	 humans	 it	 is	 vital	 to	 continue	 our	studies	of	PIV5.			Currently,	 one	 of	 the	 first	 strains	 of	 PIV5	 to	 be	 isolated	 PIV5	W3	 (or	W3A)	 is	routinely	 used	 in	 our	 laboratory	 to	 study	 the	 interactions	 of	 paramyxoviruses	with	the	immune	response.	PIV5	W3	has	a	genome	of	15,246	nucleotides,	which	contains	7	genes	that	encode	for	8	known	proteins	(NP,	V,	P,	M,	F,	SH,	HN	and	L)	(Figure	1.6)(He	et	al	2002,	Parks	et	al	2011).	
	
Figure	 1.6:	 PIV5	W3	 gene	 organisation.	 PIV5	W3A	 has	 a	 genome	 of	 15,246	nucleotides	and	encodes	 for	8	proteins	 from	its	7	genes	(NP,	V,	P,	M,	F,	SH,	HN	and	L).		
1.11 PIV5	proteins		
1.11.1 Nucleoprotein	(NP)	NP	 is	 the	 first	 gene	 encoded	 from	 the	 viral	 genome	 and	 plays	 a	 vital	 role	 in	protecting	 the	 viral	 genome	 from	 degradation	 by	 encapsidating	 viral	 RNA.	 It	consists	 of	 502	 amino	 acids	 and	 sequence	 analysis	 shows	 that	 it	 contains	 a	central	motif	that	is	common	among	most	paramyxovirus	NP	sequences.	Notably,	this	motif	 has	 been	 shown	 in	 related	 viruses	 to	 be	 essential	 for	 self-assembly	with	RNA.	Recently	 it	 has	been	 shown	 that	PIV5	genomic	RNA	associates	with	~2600	copies	of	NP	to	form	the	helical	nucleocapsid	structure	and	each	PIV5	NP	binds	six	molecules	of	genomic	RNA	consistent	with	the	rule	of	six	(Alayyoubi	et	al.	 2015).	 This	 feature	 allows	 NP	 to	 encapsidate	 the	 viral	 genome	 and	
Chapter	1:	Introduction		
	 30	
antigenome,	which	provides	essential	protection	from	nuclease	degradation.	NP	also	functions	to	create	a	functional	promoter	and	is	essential	in	the	assembly	of	budding	virions	as	part	of	the	nucleocapsid	(Parks	et	al.	2011).	In	addition	to	its	interaction	with	RNA,	soluble	NP	(NP0)	has	been	found	to	associate	with	P	and	V	proteins,	 which	 may	 play	 a	 role	 in	 encapsidation	 of	 progeny	 RNA	 during	replication	 (Precious	et	al.	1995;	Randall	&	Bermingham	1996).	More	recently,	evidence	 indicates	 that	 binding	 of	 NP	 with	 V	 protein	 could	 inhibit	 RNA	replication	 meaning	 that	 V	 could	 play	 an	 important	 role	 in	 regulating	 viral	replication	during	the	initial	stages	of	infection	(Lin	et	al.	2005;	Yang	et	al.	2015).	
1.11.2 V	protein	(V)	The	V	protein	is	the	second	protein	encoded	for	by	the	viral	genome.	It	consists	of	 222	 amino	 acids	 and	 plays	 a	 multifunctional	 role	 as	 an	 IFN	 antagonist,	 an	inhibitor	 of	 viral	 RNA	 synthesis	 and	 it	 is	 also	 able	 to	 alter	 the	 cell	 cycle.	 As	described	 previously,	 the	 V	 protein	 shares	 an	 N	 terminus	 of	 164	 amino	 acids	with	the	P	protein	due	to	the	unique	process	of	RNA	editing.	Mutational	analysis	has	determined	that	this	region	contains	an	NP	binding	domain,	with	another	NP	binding	 domain	 being	 found	 at	 the	 C	 terminus.	 Each	 site	 has	 been	 shown	 to	negatively	 and	 positively	 affect	 RNA	 synthesis,	 respectively	 with	 L16	 and	 I17	identified	 as	 critical	 sites	within	 the	 NP	 binding	 domain	 for	 inhibition	 of	 viral	RNA	 synthesis	 (Yang	 et	 al.	 2015).	 The	 unique	 C	 terminus	 of	 V	 protein	 also	contains	 7	 highly	 conserved	 cysteine	 residues	 that	 can	 bind	 two	 zinc	 ions	creating	a	zinc	finger-like	structure	(Paterson	et	al.	1995;	Yang	et	al.	2015).			
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Arguably,	the	most	renowned	role	of	the	V	protein	is	its	ability	to	block	the	IFN	response	by	targeting	both	the	IFN	induction	and	signalling	cascades.	Indeed,	it	can	block	IFN	induction	via	its	interaction	with	Mda-5	and	by	sequestering	IRF3	in	 the	 cytoplasm	(Andrejeva	et	 al	2004,	Childs	et	 al	2007,	Biao	He	et	 al	2002).	More	recently	it	has	been	shown	that	the	V	protein	can	form	a	complex	between	RIG-I	and	the	Laboratory	of	genetics	and	Physiology	2	(LGP2)	protein	that	blocks	the	activation	of	RIG-I	by	RIG-I	ligands	again	blocking	activation	of	IFN	induction	(Childs	et	al	2012).		Furthermore,	the	V	protein	can	also	block	IFN	signalling	by	targeting	 STAT1	 for	 proteosomal	 degradation	 via	 its	 interaction	 with	 the	damaged	DNA	binding	protein	(DDB1)(Didcock	et	al	1999,	Precious	et	al	2005,	Precious	 et	 al	 2007).	 A	 PIV5	 virus	 lacking	 the	 cysteine	 rich	 domain	 of	 the	 V	protein	was	shown	to	be	unable	to	block	IFN	induction	or	IFN	Signalling	(He	et	al	2002).	Subsequently,	the	combination	of	Y26H,	L50P	and	L102P	mutations	were	identified	 to	 prevent	 V	 protein	 function	 against	 IFN	 signalling	 in	 the	 IFN-sensitive	virus	PIV5	CPI-,	for	the	first	time	indicating	a	role	for	the	V/P	common	N	 terminal	 domain	 in	 blocking	 IFN	 signalling	 (Chatziandreou	 et	 al.	 2002).	 In	addition	to	its	roles	in	IFN	antagonism,	the	C	terminal	region	is	also	thought	to	be	important	in	preventing	apoptosis,	as	a	recombinant	virus	lacking	the	C	terminus	induces	 a	 severe	 cytopathic	 effect	 (CPE)	 in	 tissue	 culture	 (Sun	 et	 al	 2004).	 In	addition,	the	expression	of	the	V	protein	has	been	shown	to	delay	the	cell	cycle	and	 overexpression	 of	 DDB1	 can	 partially	 restore	 this	 delay	 (Lin	 and	 Lamb	2000).	Taken	together	these	functions	highlight	the	multifunctional	role	of	the	V	protein	in	numerous	roles	within	the	virus	life	cycle	(summarised	in	Figure	1.7).		
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Figure	1.7:	Summary	of	properties	attributed	to	A)	the	V	protein	and	B)	the	
P	protein	of	PIV5	
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1.11.3 Phosphoprotein	(P)	The	third	protein,	P,	consists	of	392	amino	acids	and	it	 is	thought	that	 its	main	role	 is	 to	aid	RNA	synthesis	via	 its	non-catalytic	 interaction	with	 the	viral	RNA	polymerase	 within	 the	 nucleocapsid	 complex.	 Numerous	 models	 attempt	 to	explain	the	function	of	P	however	its	exact	role	remains	controversial.	The	most	well	supported	model	indicates	that	P	tethers	the	catalytic	L	polymerase	protein	to	 the	 genomic	 RNA	 during	 RNA	 synthesis.	 Like	 all	 other	 paramyxovirus	 P	proteins,	 the	 PIV5	 P	 protein	 is	 heavily	 phosphorylated	 however	 the	 possible	roles	for	this	remain	an	enigma	(Fuentes	et	al.	2010).	Amongst	the	P	proteins	of	the	paramyxoviruses,	the	Sendai	virus	(SeV)	and	RSV	are	the	best	studied.	Initial	studies	of	SeV	seemed	to	suggest	 that	phosphorylation	of	 the	P	protein	did	not	play	 a	 major	 role	 in	 viral	 RNA	 synthesis	 (Hu	 &	 Gupta	 2000;	 Hu	 et	 al.	 1999;	Byrappa	 et	 al.	 1996).	 Studies	 of	 the	 RSV	 P	 protein	 then	 indicated	 that	phosphorylation	 was	 dispensable	 for	 virus	 replication	 however	 more	 recent	studies	 have	 recognised	 that	 phosphorylation	 of	 the	 P	 protein	 is	 essential	 for	management	of	the	viral	protein	M2-2	and	its	ability	to	mediate	transcriptional	inhibition	 (Lu	 et	 al.	 2002;	 Asenjo	 &	 Villanueva	 2016).	 Analysis	 of	 the	 PIV5	 P	protein	 suggests	 that	 phosphorylation	 at	 different	 sites	 can	have	 both	positive	and	negative	effects	on	RNA	synthesis	 (Sun	et	al	2011a)(summarised	 in	Figure	1.7).	 One	 example	 of	 this	 shown	 to	 negatively	 regulate	 RNA	 synthesis	 is	phosphorylation	of	serine	157	together	with	serine	308	by	the	host	kinase	Polo-like	 kinase	 1	 (PLK1)	 which	 when	 mutated	 to	 prevent	 phosphorylation	 was	shown	 to	 elevate	 viral	 RNA	 synthesis	 (Sun	 et	 al	 2009,	 Timani	 et	 al	 2008).	Another	 site	 shown	 to	 positively	 affect	 RNA	 synthesis	 is	 threonine	 286	which	when	 mutated	 lead	 to	 slowed	 viral	 mRNA	 synthesis	 and	 delayed	 protein	
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expression	(Sun	et	al	2011a).	Interestingly,	sumoylation	of	the	P	protein	at	K254	is	also	 thought	 to	be	 important	 for	PIV5	growth	(Sun	et	al	2011b).	Despite	 the	debated	model	what	is	known	is	that	the	P	protein	is	essential	for	RNA	synthesis	and	it	therefore	plays	a	vital	role	in	virus	infection.		
1.11.4 Matrix	protein	(M)	Next,	 the	most	abundant	protein	 found	within	 the	PIV5	particle-	 the	M	protein	contains	 377	 amino	 acids	 and	 is	 an	 organisational	 protein	 that	 orchestrates	numerous	proteins	during	assembly	of	the	viral	particle.		During	the	replication	cycle	 the	 M	 protein	 lines	 the	 inner	 surface	 of	 the	 host	 cell	 membrane	 and	coordinates	the	interaction	of	host	proteins	such	as	caveolin-1	and	angiomotin-like	1,	viral	glycoproteins	and	cytoplasmic	nucleocapsids	(Pei	et	al.	2011).	These	interactions	lead	to	the	formation	and	subsequent	budding	of	infectious	particles	making	it	a	vital	protein	in	the	viral	life	cycle	(Parks	et	al.	2011).	
1.11.5 Fusion	protein	(F)	The	F	protein	is	a	529	amino	acid	protein	that	firstly	allows	viral	entry	to	the	cell	through	 fusion	 of	 the	 virion	 envelope	 with	 the	 host	 cell	 plasma	 membrane,	secondly	it	promotes	cell-cell	fusion	forming	what	is	known	as	syncytia	however	cell-cell	 fusion	 is	 minimal	 in	 PIV5.	 The	 protein	 is	 initially	 synthesized	 as	 a	precursor	 molecule	 Fo	 that	 is	 then	 glycosylated	 in	 the	 ER	 and	 forms	homotrimers.	 Fo	 is	 then	 cleaved	 by	 an	 unknown	 host	 protease	 to	 F1	 and	 F2	which	 results	 in	 a	 conformational	 change	 to	 a	 trimeric	 coiled	 coil	 that	permits	fusion	 (Welch	 et	 al.	 2012).	 Interestingly	 mutations	 to	 the	 fusion	 peptide	 at	positions	 3,	 7	 and	 12	 resulted	 in	 hyperfusogenic	 F	 proteins	 that	 have	 been	
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subsequently	harnessed	for	therapeutic	applications	such	as	increasing	potency	of	oncolytic	viruses	(Gainey	et	al.	2008;	Parks	et	al.	2011).		
1.11.6 Small	hydrophobic	protein	(SH)	Next,	 the	 smallest	 of	 all	 the	 proteins	 produced	 from	 the	 PIV5	 genome,	 the	 SH	protein,	 consists	 of	 only	44	 residues	many	of	which	 are	hydrophobic.	 Its	main	role	within	 the	 viral	 life	 cycle	 remains	 controversial	 with	 evidence	 suggesting	that	 it	 could	 play	 roles	 in	 preventing	 apoptosis	 by	 blocking	 TNF-α	 as	 an	 SH	knockout	virus	induced	apoptosis	in	bovine	and	mouse	cell-lines	but	not	human	A549	 or	 Hela	 cells	 (Lin	 et	 al.	 2003;	 He	 et	 al.	 2001;	Wilson	 et	 al.	 2006).	 Other	studies	suggest	 that	SH	plays	a	role	 in	counteracting	 immune	responses	but	 its	exact	role	remains	uncertain	(Parks	et	al.	2011).	Interestingly	it	has	been	shown	in	the	related	virus	RSV	that	SH	forms	small	pentameric	ion	channels	which	may	function	 in	a	similar	manner	 to	 influenza	virus	however	 there	exact	role	 is	not	certain	(Gan	et	al.	2012).	
1.11.7 Haemagglutinin-neuraminidase	protein	(HN)		Penultimately,	HN	is	found	on	the	outer	surface	of	the	virus	particle	and	consists	of	565	amino	acids.	Structurally,	it	is	a	type	II	membrane	protein	that	has	a	large	ectodomain,	a	 transmembrane	domain	and	a	small	N-terminal	cytoplasmic	 tail.	Functionally,	 it	 has	 been	 shown	 to	 be	 responsible	 for	 attachment	 of	 the	 virus	particle	to	the	host	cell	through	its	sialic	acid	binding	activity	(Bose	et	al	2011).	This	attachment	 is	 then	 thought	 to	 initiate	a	 conformational	 change	within	 the	HN	protein	exposing	 the	HN-stalk	 residues	 that	 interact	with	and	 trigger	 the	F	protein	 to	 initiate	 fusion	with	 the	 host	membrane	 (Bose	 et	 al	 2013).	 PIV5	HN	
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also	has	enzymatic	neuraminidase	activity	which	is	thought	to	function	in	aiding	release	of	the	virus	(Merz	et	al.	1981;	Welch	et	al.	2013).		
1.11.8 Large	protein	(L)	Finally,	 the	 large	 protein	 L	 comprises	 a	 huge	 2255	 amino	 acids	 and	 is	 the	essential	catalytic	subunit	of	the	viral	RNA	dependent	RNA	polymerase.	Tethered	to	the	nucleocapsid	template	via	the	P	protein	this	subunit	is	responsible	for	the	replication	and	transcription	of	viral	RNA	(Parks	et	al.	2011).	Interestingly,	it	has	been	shown	that	the	L	protein	may	have	 intrinsic	kinase	activity	that	enhances	the	 phosphorylation	 of	 RAC-alpha	 serine/threonine-protein	 kinase	 (AKT1).	Phosphorylated	 AKT1	 can	 then	 phosphorylate	 the	 viral	 P	 protein,	 which	 as	stated	previously	plays	a	vital	role	in	the	viral	life	cycle	(Luthra	et	al.	2008).	
1.12 PIV5	strains		
1.12.1 PIV5	W3	and	rPIV5mCh	In	addition	to	PIV5	W3	a	number	of	other	wild-type	and	recombinant	strains	are	routinely	 used	within	 our	 study.	 PIV5	W3	was	 originally	 isolated	 by	 Hull	 and	Minner	 in	 1957.	 Subsequently	 a	 recombinant	 strain	 of	 PIV5	 W3,	 namely	rPIV5mCh,	 has	 been	 created,	 which	 contains	 the	 gene	 expressing	 mCherry	fluorescent	 protein	 inserted	 between	 the	 HN	 and	 L	 polymerase	 of	 the	 viral	genome.	 This	 virus	 therefore	 expresses	 mCherry	 fluorescent	 protein,	 which	allows	viral	infection	to	be	tracked	easily	via	fluorescent	microscopy	techniques.		
1.12.2 PIV5	CPI+/CPI-	The	IFN-sensitive	virus,	canine	parainfluenza	CPI-	 is	also	routinely	used	within	our	study,	which	is	antigenetically	related	to	PIV5	W3.	The	parental	strain	CPI+	
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was	isolated	from	the	cerebrospinal	fluid	of	a	dog	suffering	with	incoordination	and	impaired	movement	(Evermann	et	al.	1980).	CPI-	was	later	isolated	from	the	brain	of	a	dog	during	experimental	work	on	CPI+.	Most	interestingly	it	has	been	shown	 that	 CPI-	 cannot	 block	 the	 IFN	 response	 due	 to	 three	 amino	 acid	substitutions	 in	 the	 V	 protein,	 making	 it	 an	 ideal	 control	 of	 V	 protein	functionality	(Chatziandreou	et	al.	2002).			
1.13 Research	aims			
1.13.1 Aim	 1:	 Enhancing	 virus	 replication	 of	 IFN-sensitive	 viruses	 using	 the	 IFN	
inhibitor,	Rux	The	first	aim	of	my	study	was	to	further	characterize	the	use	of	the	IFN	inhibitor,	Rux,	which	inhibits	JAK1/2	of	the	IFN	signalling	pathway,	with	respect	to	growth	of	IFN-sensitive	viruses.		
1.13.2 Aim	2:	Development	of	a	novel	method	to	rapidly	select	IFN-sensitive	viruses	
using	FACS	The	 second	 aim	 of	 this	 study	was	 to	 develop	 a	method	 to	 rapidly	 isolate	 IFN-sensitive	viruses	from	paramyxoviruses	using	FACS.	Following	isolation,	we	then	planned	 to	 employ	 the	 IFN	 inhibitor,	Rux,	 to	 characterise	 selected	mutants	 for	IFN-sensitivity.			
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2 Materials	and	Methods	
2.1 Cells,	viruses,	antibodies	and	IFN	inhibitors			
2.1.1 Mammalian	cell-lines	All	mammalian	cell-lines	used	in	this	research	are	listed	in	Table	2.1.	In	addition	to	 these	basic	 cell-lines,	 a	number	of	derivatives	of	A549	and	MRC5	cells	were	used	and	these	are	listed	in	Table	2.2.		
Table	2.1:	List	of	mammalian	cell-lines	used	in	this	study		
Cell-line	 Description	
293T	 Human	embryonic	kidney	cell-line	(provided	by	Professor	Richard	Iggo,	University	of	Bordeaux)		
A549	 Human	carcinomic	alveolar	basal	epithelial	cell-line	(obtained	from	the	European	Collection	of	Authenticated	Cell	Cultures	(ECACC))		BalB/C		 Mouse	embryonic	fibroblast	cell-line	(ECACC)	MDBK		 Madin-Darby	bovine	kidney	cell-line	(ECACC)	MDCK	 Canine	Cocker	Spaniel	kidney	epithelial	cell-line	(ECACC)	
PKIBRS2		 Biological	Institute	renale	swine	2	porcine	kidney	epithelial	cell-line	(Institute	of	Animal	Health	(House	&	House	1989))		RK.13		 Rabbit	kidney	epithelial	cell-line	(ECACC)	Vero		 African	Green	Monkey	kidney	cell-line	(ECACC)	MRC5		 Human	lung	fibroblast	cell-line	(ECACC)		 	 	
Chapter	2:	Materials	and	Methods		
	 39	
Table	2.2:	List	of	mammalian	cell-line	derivatives	used	in	this	study	
Cell-line	derivative	 Description	
A549.pr(ISRE).GFP		
A549	cell-line	that	stably	expresses	GFP	under	the	control	of	the	Interferon	stimulated	response	element	(ISRE)	element	contained	within	an	MxA	promoter.	It	also	contains	inducible	resistance	to	puromycin	as	puromycin-N-Acetyl-trasnferase	(PAC)	is	expressed	under	the	control	of	the	ISRE	element	(Stewart	et	al.	2014;	Gage	et	al.	2016)	
A549.pr(ISRE).GFP/	ISG56-/BVDV	Npro	
A549	cell-line	that	stably	expresses	GFP	and	PAC	under	the	control	of	the	ISRE	element	contained	within	an	MxA	promoter.	Secondly,	it	stably	expresses	short-hairpin	RNA	(shRNA)	to	ISG56	and	thirdly,	it	stably	expresses	the	N-terminal	protease	(Npro)	from	Bovine	Viral	Diarrhoea	Virus	(BVDV).	(See	section	2.4	for	generation	of	this	cell-line)	A549/PIV5-V	 A549	cell-line	that	stably	expresses	V	protein	from	Parainfluenza	virus	5	(Young	et	al.	2003)	
MRC5/PIV5-V		 MRC5	cell-line	that	stably	expresses	V	protein	from	Parainfluenza	virus	5	(Young	et	al.	2003)					 	
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2.1.2 Wild-type	and	recombinant	viruses	All	wildtype	and	recombinant	viruses	used	in	this	study	are	listed	in	Table	2.3	
Table	2.3:	List	of	viruses	used	in	this	study	
Virus	 Description	
ANAV	 Anopheles	A	virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)	BUN-WT	 Bunyamwera	wild-type	virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)	BUNΔNSs	 A	recombinant	Bunyamwera	virus	that	has	the	IFN	antagonist,	nonstructural	protein	(NSs),	gene	deleted	(Weber	et	al.	2002)	BWAV	 Bwamba	virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)	CVV	 Cache	Valley	Virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)	KRIV	 Kairi	Virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)	MDV	 Main	Drain	Virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)	MeV	 Measles	Edmonson	vaccine	strain	(obtained	from	The	National	Institute	for	Biological	standards	and	controls	(NIBSC))	MuV	 Mumps	Enders	vaccine	strain	(NIBSC)	PIV5	CPI+	 Canine	PIV5	CPI+	strain	(Southern	et	al.	1991)	PIV5	CPI-	 Canine	PIV5	CPI-	strain	that	contains	a	non-functional	IFN	antagonist	V	protein	(Southern	et	al.	1991)	PIV5	W3	 Human	Parainfluenza	virus	5	W3A	strain	(Choppin	1964)	
rPIV5mCh	 A	recombinant	strain	of	PIV5	that	contains	mCherry	fluorescent	protein	inserted	between	the	HN	and	L	genes	within	the	viral	genome	(provided	by	Dr	Biao	He,	University	of	Georgia)	SBV	 Schmallenberg	Virus	(provided	by	Professor	Richard	Elliot,	University	of	Glasgow)		 	
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2.1.3 Antibodies	All	primary	and	secondary	antibodies	used	in	this	study	are	listed	in	Table	2.4.	
Table	2.4:	List	of	Primary	and	Secondary	antibodies	used	within	this	study	
Primary	Antibodies	 Manufacturer	(catalogue	number)	Goat	anti-IFIT1	(ISG56;	polyclonal)	 Santa	Cruz	Biotechnology	(sc-82942)	Mouse	anti-PIV5	HN	(monoclonal)	 Prof	Richard	Randall,	University	of	St	Andrews	(Randall	et	al.	1987)	Mouse	anti-PIV5	F	(monoclonal)	 Prof	Richard	Randall,	University	of	St	Andrews	(Randall	et	al.	1987)	Mouse	anti-PIV5	NP	(monoclonal)	 Prof	Richard	Randall,	University	of	St	Andrews	(Randall	et	al.	1987)	Mouse	anti-β-actin	(monoclonal)	 Sigma-Aldrich	(A2228)	Mouse	anti-STAT1	(monoclonal)	 Santa	Cruz	Biotechnology	(sc-8394)	Rabbit	anti-Bunyamwera	N	protein	antisera	(polyclonal)	 Provided	by	Richard	Elliot,	University	of	Glasgow		Rabbit	anti-Mx1/2/3	(H285;	MxA;	polyclonal)	 Santa	Cruz	Biotechnology		(sc-166412)	
Secondary	Antibodies	 Manufacturer	Goat	anti-mouse	Texas	Red	(TR)	 Serotec®	(103007)	Goat	anti-mouse	alkaline	phosphatase	(AP)-conjugated	 Cell	signalling	technology	(7056)	Goat	anti-rabbit	(AP)-conjugated	 Cell	signalling	technology	(7054)	IRDye®680RD	goat	anti-mouse	 LI-COR	(925-68070)	IRDye®680RD	donkey	anti-goat	 LI-COR	(925-68074)	IRDye®680RD	goat	anti-rabbit	 LI-COR	(925-68071)	
2.1.4 IFN	inhibitors		The	IFN	inhibitor	Ruxolitinib	(Rux)	(INCB018424;	Selleck	chemicals)	is	a	potent	inhibitor	 of	 JAK1/2	 with	 an	 IC50	 of	 3.3nM.	 Stocks	 were	 prepared	 in	 dimethyl	sulfoxide	(DMSO)	at	a	concentration	of	10mM	and	stored	at	-80°C.	
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2.2 Cell	culture	and	Virological	methods		
2.2.1 Cell	maintenance		All	 cells	 described	 above	 (Table	 2.1	 and	 Table	 2.2)	 were	 cultured	 in	 25cm2,	75cm2	 or	 175cm2	 tissue	 flasks	 (Greiner	 Bio-One)	 using	 Dulbecco’s	 modified	Eagle’s	 medium	 (DMEM)(Thermo	 Fisher	 Scientific).	 This	 medium	 was	supplemented	 with	 10%	 [v/v]	 foetal	 bovine	 serum	 (FBS;	 Thermo	 Fisher	Scientific)	 and	 1%	 [v/v]	 penicillin	 and	 streptomycin	 (pen/strep).	 Cells	 were	incubated	 at	 37°C/5%	 CO2	 and	 routinely	 passaged	 when	 confluent	 using	Trypsin/ethylenediaminetetraacetic	acid	(EDTA).		
2.2.2 Cryopreserving	and	resuscitation	of	cells		Cells	 generated	 during	 this	 study	 were	 tested	 for	 mycoplasma,	 using	 PCR	Mycoplasma	Test	Kit	 II,	 following	manufacturer’s	 instructions	(Promokine)	and	only	 mycoplasma-negative	 cells	 were	 stored	 in	 liquid	 nitrogen.	 Cells	 were	prepared	for	cryopreservation	by	trypsination	of	the	cell	monolayer,	followed	by	re-suspension	 in	 10%	 [v/v]	 FBS,	 1%	 [v/v]	 pen/strep	 DMEM	 and	 pelleting	 at	1200rpm	for	5min	at	room	temperature	(RT).	Cells	were	 then	re-suspended	 in	freezing	medium	(10%	[v/v]	DMSO,	FBS),	aliquoted	into	cryovials	and	frozen	at	-80°C	 before	 storage	 in	 liquid	 nitrogen.	 To	 resuscitate	 cells,	 cryovials	 were	thawed	 rapidly	 at	 37°C,	 centrifuged	 at	 1200	 rpm	 for	 5min	 at	 RT	 and	 re-suspended	 and	 maintained	 in	 10%	 [v/v]	 FBS,	 1%	 [v/v]	 pen/strep	 DMEM	 at	37°C/5%	 CO2.	 If	 necessary,	 the	 appropriate	 antibiotic	 selection	 (puromycin	 at	2μg/ml	or	blasticidin	at	10μg/ml)	was	added	following	the	first	passage.	
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2.2.3 Preparation	of	virus	stocks		All	virus	stocks	used	within	this	study	were	prepared	using	90%	confluent	Vero	cells.	Cells	were	infected	with	the	chosen	virus	at	a	multiplicity	of	infection	(MOI)	of	0.001	PFU/cell	 in	1ml	 serum-free	DMEM	per	25cm2	 flask	or	 in	3mls	 serum-free	DMEM	per	75cm2	flask.	Following	1h	on	a	rocking	platform	at	37°C	5%	CO2,	the	media	 volume	was	 increased	 to	6mls	per	25cm2	 flask	 or	 11mls	per	75cm2	flask	 using	 serum-free	 DMEM	 and	 incubated	 for	 a	 further	 3-4	 days.	 Following	incubation,	 the	 supernatant	 containing	 virus	 was	 harvested	 then	 clarified	 at	1500rpm	 for	 5min	 before	 aliquoting	 into	 appropriate	 small	 volumes	 (<500μl)	and	storage	at	-80°C.		
2.2.4 Virus	infections			Monolayers	of	cells	were	infected	at	an	appropriate	MOI	with	virus	suspended	in	a	 low	 volume	 of	 serum-free	 or	 2%	 [v/v]	 FBS/DMEM	 (200μl	 for	 6	 well	 plate,	100μl	for	12	well).	After	an	initial	adsorption	period	of	1h	on	a	rocking	platform	at	 37°C	 5%	 CO2	 the	 virus	 inoculum	 was	 removed.	 Each	 monolayer	 was	 then	washed	with	Phosphate-Buffered	Saline	(PBS),	replaced	with	serum-free	DMEM	and	incubated	at	37°C	5%	CO2	until	harvested.		
2.2.5 Plaque	assays	Plaque	 assays	 were	 used	 for	 several	 purposes	 during	 this	 study,	 firstly,	 to	determine	 the	 titer	 of	 viral	 stocks	 following	 preparation	 and,	 secondly,	 to	determine	plaque	development	of	viruses	under	different	conditions	such	as	 in	the	presence	of	IFN	inhibitor.	Monolayers	of	cells	were	cultured	in	6	or	12	well	plates	until	80-90%	confluent.	The	virus	stock	was	diluted	10-fold	in	DMEM	2%	FBS	with	the	exception	of	BUN	WT	and	BUNΔNSs	which	was	diluted	in	PBS	2%	
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New	Calf	Serum.	Cells	were	then	infected	with	low	volume	inoculum	(200μl	for	6	well	 plate,	 100μl	 for	 12	 well)	 and	 incubated	 at	 37°C	 5%	 CO2	 for	 1	 hour	 with	horizontal	 shakes	 every	 15	 min	 to	 prevent	 the	 monolayer	 from	 drying	 out.	Inoculum	was	 then	 removed	 and	 an	 appropriate	 volume	 of	 2X	 overlay	media	(50ml	10X	MEM,	10mls	100X	Glutamax,	2%	[v/v]	Foetal	calf	serum	(FCS),	14.5ml	NaCHO3	 7.5%,	 170ml	 dH2O)	 mixed	 with	 2X	 avicel	 (final	 concentration	 0.6%	[w/v]	avicel:	Sigma-Aldrich®)	was	added.	Where	appropriate,	IFN	inhibitor	Rux	(4μM	each)	or	the	equivalent	volume	of	DMSO	was	added	directly	to	the	overlay.	Plates	were	then	incubated	for	1-6	days,	without	disturbing,	until	plaques	were	formed.		Following	incubation	plaques	were	fixed	in	5%	[v/v]	formaldehyde/PBS	for	1hour	at	4°C.		Plaques	were	visualised	by	either	crystal	violet	(CV)	staining	or	immunostaining.	To	visualise	the	plaques	using	CV	staining,	0.15%	[w/v]	CV	stain	was	added	for	5	min	on	a	rocking	platform	and	then	removed	with	water.	Virus	titre	could	then	be	determined	using	the	following	equation:	Equation	1:		𝑽𝒊𝒓𝒖𝒔	𝒕𝒊𝒕𝒆𝒓 = 𝒏𝒖𝒎𝒃𝒆𝒓	𝒐𝒇	𝒑𝒍𝒂𝒒𝒖𝒆𝒔	𝒙	𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	𝒔𝒕𝒐𝒄𝒌	
To	visualize	the	plaques	by	immunostaining,	fixed	cells	were	permeabilised	with	0.1%	[v/v]	Triton	X-100/PBS	 for	30	min	 followed	by	addition	of	500μl/well	of	appropriate	 primary	 antibody	 in	 2%	 FBS/PBS	 (Table	 2.4).	 Plates	 were	 then	incubated	for	1hour	at	RT	on	a	rocking	platform.	Afterwards,	cells	were	washed	with	 PBS	 before	 addition	 of	 the	 appropriate	 secondary	 alkaline	 phosphatase	(AP)	 conjugated	 antibody	 (Table	 2.4).	 Monolayers	 were	 then	 washed	 and	incubated	with	AP	substrate	(SIGMAFAST™	BCIP®/NBT,	Sigma-Aldrich)	prepared	
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in	water	until	plaques	were	visible.	The	monolayers	were	then	rinsed	with	water	to	stop	any	further	reaction	and	the	viral	titer	calculated	as	stated	in	Equation	1.		When	 required	 measurement	 of	 plaque	 size	 was	 completed	 using	 Pixel	 stick	(Plum	Amazing)	and	significance	calculated	using	an	unpaired	t	test.	
2.2.6 Multistep	viral	growth	curves		Multistep	viral	growth	curves	were	used	to	analyse	virus	growth	of	a	number	of	viruses	 in	 several	 different	 cell-lines	 in	 the	 presence	 and	 absence	 of	 IFN	inhibitor.	 Specifically,	 cells	were	 seeded	at	2x106	 cells	per	25cm2	 flask	 the	day	prior	to	infection.	Virus	infection	was	then	added	at	an	MOI	of	0.001	PFU/ml	in	10%	[v/v]	FBS,	1%	[v/v]	pen/strep	DMEM	and	incubated	on	a	rocking	platform	for	3	hours	at	37°C	5%	CO2.	The	inoculum	was	then	removed	and	the	monolayer	washed	 with	 PBS.	 Subsequently,	 5mls	 of	 10%	 [v/v]	 FBS,	 1%	 [v/v]	 pen/strep	DMEM	was	then	added	containing	IFN	inhibitor	Rux	(4μM)	or	equivalent	volume	of	DMSO.	 	Subsequently,	300μl	of	virus	supernatant	was	 then	collected	at	each	time	point	and	titered	on	Vero	cells	using	a	plaque	assay	(see	section	2.2.5).				
2.3 IFN	Signalling	GFP	reporter	assay	to	assess	the	stability	of	the	IFN	
inhibitors	Rux	
An	IFN	signalling	GFP	reporter	assay	was	used	to	determine	the	stability	of	the	IFN	inhibitor	Rux.	Initially,	the	inhibitor	Rux	(4μM)	or	equivalent	volume	DMSO	were	 incubated	 individually	 in	 5mls	 of	 10%	 [v/v]	 FBS,	 1%	 [v/v]	 pen/strep	DMEM	on	A549	naïve	cells	and	300μl	samples	of	the	supernatant	were	taken	for	7	 days.	 Each	 sample	 was	 then	 analysed	 by	 assessment	 of	 GFP	 knockdown	 on	A549:pr(ISRE).GFP	reporter	cells,	using	an	IFN	signalling	GFP	reporter	assay.			
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To	 conduct	 an	 IFN	 signalling	 GFP	 reporter	 assay,	 A549.pr(ISRE).GFP	 reporter	cell-lines	were	seeded	 in	triplicate	per	treatment	at	3x104	cells/well	 in	96	well	plates	(see	Table	2.2	for	a	description	of	these	cell-lines).	Notably,	this	reporter	cell-line	requires	activation	to	enable	production	of	GFP	expression.	To	activate	the	ISRE	element	in	A549.pr(ISRE).GFP	cell-lines,	cells	were	treated	with	1x104	Units/ml	of	purified	IFN-α	(Roferon,	NHS)	in	DMEM	and	incubated	for	48	hours	at	37°C	5%	CO2	before	measuring	GFP	expression.	GFP	expression	was	measured	using	 TECAN	 infinite	 200	 plate	 reader	 (TECAN)	 set	 to	 an	 excitation	 of	 488nm	and	 emission	 of	 528nm	 or	 imaged	 by	 EVOS®	 microscope	 (Thermo	 Fisher	Scientific).	 Data	 was	 then	 analysed	 using	 Magellan	 data	 analysis	 software	(TECAN)	and	presented	using	Graphpad	Prism	6	(Graphpad	software).		
2.4 Generation	of	the	A549.pr(ISRE).GFP/ISG56-/BVDV	Npro	cell-line	
using	pdl’shISG56.blast	and	pdl’BVDV	Npro.puro	lentivirus		
To	 develop	 a	 method	 to	 isolate	 IFN-sensitive	 viruses	 using	 flow	 cytometry	 a	derivative	 of	 the	 A549/pr(ISRE).GFP	 cell-line	 	 (Table	 2.2)	 was	 generated	 that	constitutively	 expresses	 both	 ISG56	 and	 BVDV	 Npro.	 The	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cell-line	(Table	2.2)	was	generated	using	second-generation	 lentivirus	 system	 that	 enables	 stable	 expression	 of	 the	inserted	gene	of	 interest	within	 target	 cells.	This	 system	required	 two	parts:	 i)	generation	 of	 lentivirus	 particles	 by	 transfection	 of	 293T	 cells	 with	 three	lentiviral	 plasmids	 and	 ii)	 transduction	 of	 target	 cells	 with	 the	 lentivirus	 to	create	a	stably	expressing	cell-line.		
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2.4.1 Generation	of	pdl’shISG56.blast	and	pdl’BVDVNpro.puro	lentiviruses		The	 generation	 of	 the	 lentiviruses	 pdl’shISG56.blast	 and	 pdl’BVDV	 Npro.puro	required	three	lentiviral	plasmids	each.	The	first	two	plasmids,	CMV-R	and	VSV-G,	are	known	as	the	packaging	plasmids.	CMV-R	encodes	the	HIV	gag	structural	protein	and	HIV	pol	gene	encoding	enzymes	for	replication	(Zufferey	et	al.	1997).	VSV-G	encodes	the	vesicular	stomatitis	virus	(VSV)	envelope	protein	(Naldini	et	al.	 1996).	 A	 third	 plasmid,	 known	 as	 the	 transfer	 vector,	 contains	 the	 gene	 of	interest	as	well	 as	all	 the	necessary	elements	 to	allow	 the	delivery	of	 the	gene	including:	 long	 terminal	 repeats	 regions	 (LTRs),	 the	 ψ	 packaging	 site,	 the	 rev	response	 element	 (RRE),	 the	 central	 polypurine	 tract	 (cPPT)	 and	 an	 spleen	focus-forming	 virus	 (SFFV)	 promoter.	 It	 also	 contains	 antibiotic	 selection	markers	 to	 allow	 selection	 of	 successfully	 transduced	 target	 cells.	 In	 this	 case,	the	 BVDV	Npro	 expressing	 plasmid,	 pdl’BVDVNpro.puro,	 expresses	 PAC	which	confers	 puromycin	 resistance	 and	 the	 shISG56	 expressing	 plasmid,	pdl’shISG56.blast,	 expresses	 blasticidin-S	 deaminase	 which	 confers	 blasticidin	resistance	 (kindly	 provided	 by	 Dr	 Lena	 Andrejeva,	 University	 of	 St	 Andrews).	Together	with	the	CMV-R	and	VSV-G	plasmids,	each	of	these	transfer	vectors	was	combined	to	create	two	lentivirus’s,	the	first	of	which	expresses	BVDV	Npro	and	the	second	of	which	expresses	shISG56.	Specifically,	each	of	 the	plasmids	were	prepared	(6μg	CMV-R,	6μg	VSV-g	and	10μg	transfer	vector)	in	1.5mls	OptiMEM	and	 incubated	 for	5min.	Subsequently,	1.5mls	of	OptiMEM	containing	4%	[v/v]	Lipofectamine	 2000	 (Thermo	 Fisher)	 was	 added	 to	 the	 plasmid	 mix	 and	incubated	 for	a	 further	30min	at	RT.	Two	75cm2	 flasks	of	50%	confluent	293T	cells	 in	 10%	 [v/v]	 FBS	 DMEM	without	 antibiotics	 were	 then	 transfected	 with	each	 plasmid	 mix	 and	 incubated	 at	 37°C/5%	 CO2	 for	 5	 hours.	 Following	
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incubation,	 the	 media	 was	 replaced	 with	 10%	 [v/v]	 FBS	 DMEM	 without	antibiotics.	 Subsequently,	48h	post	 transfection	 the	 supernatant	 containing	 the	lentivirus	was	harvested,	clarified	at	1500rpm	for	10min,	filtered	using	a	0.45μM	filter,	aliquoted	into	1ml	fractions	and	stored	at	-80°C.		
2.4.2 ii)	 Transduction	 of	 A549.pr(ISRE).GFP	 cells	 with	 pdl’shISG56.blast	 and	
pdl’BVDV	Npro.puro	lentivirus	To	 create	 a	 cell-line	 which	 expressed	 both	 shISG56	 and	 BVDV	 Npro,	A549.pr(ISRE).GFP	 cells	were	 transduced	 firstly	with	 the	 lentivirus	 expressing	shISG56	 and	 selected	 using	 blasticidin.	 Surviving	 cells	 were	 then	 transduced	again	with	the	 lentivirus	expressing	BVDV	Npro	and	selected	for	a	second	time	using	both	puromycin	and	blasticidin.	Specifically,	one	aliquot	of	 lentivirus	was	combined	with	1ml	of	serum-free	DMEM	and	polybrene	(8μg/ml)	and	added	to	a	25cm2	flask	containing	50%	confluent	target	cells.	The	cells	were	then	incubated	for	2.5hours	before	 topping	up	media	with	2ml	10%	[v/v]	FBS	DMEM	without	antibiotics	 and	 incubating	 the	 flask	 for	 a	 further	 two	days.	Antibiotic	 selection	(puromycin	 2μg/ml	 for	 2days	 and	 blasticidin	 10μg/ml	 for	 4	 days)	 was	 then	added	 to	 select	 cells	 that	 had	 been	 successfully	 transduced	 with	 the	 target	lentivirus.	The	resultant	cell-line	then	remained	under	antibiotic	selection	until	required	for	further	experiments.		
2.4.3 Characterization	 of	 A549.pr(ISRE).GFP/ISG56-/Npro	 cells	 using	 western	
blot	analysis		The	 newly	 generated	 cell-line,	 A549.pr(ISRE).GFP/ISG56-/Npro,	 was	characterized	 using	 western	 blot	 for	 expression	 of	 ISG56,	 MxA	 and	 PIV5	 NP	following	 infection	with	PIV5	CPI-.	Western	blot	analysis	contains	 two	steps:	 i)	
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separation	 of	 the	 proteins	 by	 sodium	 dodecyl	 sulphate	 polyacrylamide	 gel	electrophoresis	(SDS-PAGE)	and	ii)	transfer	of	the	proteins	to	a	PVDF	membrane	that	can	then	be	probed	with	antibodies	to	detect	specific	proteins.	Specifically,	A549/pr(ISRE).GFP	and	A549.pr(ISRE).GFP/ISG56-/Npro	cells	were	pre-treated	for	8	hours	with	IFN	at	1x104Units/ml	or	left	untreated	before	cells	were	mock	infected	 or	 infected	with	PIV5	CPI-	 at	MOI	5.	 Cell	monolayers	were	 then	 lysed	18hours	 post	 infection	 in	 disruption	 buffer	 containing:	 10M	 urea,	 20%	 [w/v]	SDS,	15%	[v/v]	β-mercaptoethanol	and	a	few	crystals	of	bromophenol	blue.	Cell	lysates	were	then	sonicated	twice	for	5	seconds	and	heated	for	10min	at	95°C	to	denature	protein	structure.	Prepared	samples	were	then	loaded	onto	12%	hand-cast	 polyacrylamide	 gels	 (30%	 Protogel,	 as	 per	 manufacturer’s	 instructions,	National	Diagnostics)	for	separation	by	SDS-PAGE	alongside	a	ladder	of	proteins	with	 known	 molecular	 weight	 (PageRular	 Plus	 Prestained	 Protein	 Ladder;	Thermo	 Fisher	 Scientific).	 Gels	 were	 run	 using	 1X	 TGS	 running	 buffer	 (25mM	Tris,	192mM	glycine,	0.1%	[w/v]	SDS,	pH8.3)	at	110V	in	Bio-Rad	electrophoresis	tanks	until	clear	separation	of	the	protein	ladder	was	obtained.		Following	SDS-PAGE	 electrophoresis,	 the	 proteins	were	 transferred	 using	 the	 Bio-Rad	 Trans-blot	 Turbo	 Transfer	 System	 onto	methanol	 activated	 polyvinylidene	 difluoride	(PVDF)	membrane	 using	 1X	 NuPage	 transfer	 buffer	 (500mM	 Bis-Tris,	 500mM	Bicine	and	20.4mM	EDTA).	The	membrane	was	then	blocked	for	1	hour	at	RT	in	blocking	buffer	 (PBS,	5%	 [w/v]	 skimmed	milk	powder	and	0.1%	 [v/v]	Tween-20).	 Once	 blocked,	 the	 membrane	 was	 incubated	 with	 appropriate	 primary	antibody	 diluted	 in	 blocking	 buffer	 (Table	 2.4).	 Here,	 Goat	 anti-IFIT1	 (ISG56),	rabbit	anti-MxA,	mouse	anti-PIV5	NP	and	mouse	anti-Actin	antibodies	were	used	sequentially	at	a	dilution	of	1:1000	overnight	at	4°C.	Following	incubation	with	
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each	 primary	 antibody,	 the	 membrane	 was	 washed	 six	 times	 using	 PBS	 0.5%	[v/v]	Tween-20	for	5	min	each	to	remove	unbound	antibody.	The	membrane	was	then	 incubated	 with	 the	 appropriate	 LiCOR	 IRDye®	 fluorescent	 secondary	antibody	 (donkey	 anti-goat,	 goat	 anti-rabbit	 and	 goat	 anti-mouse)	 diluted	1:10000	in	blocking	buffer.	Afterwards,	each	membrane	was	then	washed	again	before	visualisation	using	the	Odyssey	CLx	Imaging	system	(LiCOR	Biosciences).	
2.5 Florescence	activated	cell	sorting	(FACS)	analysis	
2.5.1 Preparation	of	cells	for	FACS	analysis	Fluorescence	 activated	 cell	 sorting	 (FACS)	 analysis	 was	 used	 to	 accurately	measure	 GFP,	 mCherry	 and	 texas	 red	 fluorescence	 from	 live	 cells	 following	infection	 of	 GFP	 reporter	 cells,	 A549.(ISRE).GFP	 or	 A549.pr(ISRE).GFP/ISG56-/BVDV	Npro.	All	cells	to	be	examined	by	FACS	analysis	were	prepared	using	the	same	 method.	 In	 brief,	 A549.(ISRE).GFP	 or	 A549.pr(ISRE).GFP/ISG56-/BVDV	Npro	 reporter	 cells	 were	 seeded	 into	 12	 well	 plates	 at	 3x105	 cells/well	 and	allowed	 to	 adhere	 overnight.	 The	 following	 day,	 cells	were	 infected	with	 virus	(rPIV5mCh,	 PIV5	W3	 or	 a	mutant	 derived	 from	 these	 viruses)	 at	 the	 specified	MOI,	 in	200μl	 serum-free	DMEM	and	 incubated	at	37°C,	5%	CO2	on	a	platform	rocker	 for	 1	 hour.	 Following	 infection,	 the	 inoculum	 was	 removed	 and	 the	monolayers	washed	with	PBS	before	addition	of	1ml	serum-free	DMEM.	After	6-8	 hours,	 primary	 antibody	 (anti-PIV5	 HN	 and	 anti-PIV5	 F)	 was	 added	 at	 a	dilution	of	1:1000	to	prevent	infection	with	progeny	virus	and	IFN-α	was	added	to	 the	 appropriate	 wells	 at	 1x104Units/ml	 to	 induce	 GFP	 expression.	 The	following	day	cell	monolayers	were	prepared	for	FACS	analysis.	Each	monolayer	was	trypsinised,	re-suspended	in	10%	[v/v]	FBS/DMEM,	centrifuged	at	1500rpm	
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for	 5min	 and	 re-suspended	 in	 1ml	 serum-free	 DMEM.	 Thereafter,	 cells	 in	suspension	 were	 filtered	 using	 a	 40μm	 cell	 strainer	 (Corning),	 collected	 in	polypropylene	 tubes	 (Corning)	 and	 kept	 on	 ice	 until	 FACs	 analysis	 and/or	sorting.		
2.5.2 Set	up	of	the	BD	FACSJazzTM	cell	sorter	and	FACS	analysis	FACS	analysis/sorting	was	accomplished	using	a	FACSJazzTM	Cell	sorter	(Becton	Dickinson	and	company,	BD)	and	FACS	sortware	sorter	software	(BD).	In	brief,	a	FACS	analyzer	organizes	cells	using	hydrodynamic	force	into	a	single-file	stream.	Lasers	 are	 then	 aligned	 to	 this	 stream	 forming	 an	 interrogation	 point.	 At	 this	point	the	lasers	excite	the	fluorochromes	expressed	within	each	cell	and	the	light	emitted	 known	 as	 the	 emission	 spectra	 is	 detected	 and	 measured.	 Following	interrogation,	the	stream	is	forced	to	form	droplets	by	application	of	an	acoustic	wave	through	a	piezoelectric	device.	Application	of	a	positive	or	negative	charge	to	these	droplets	then	allows	specific	cells	to	be	sorted	using	charged	deflection	plates.	 These	 deflection	 plates	 attract	 droplets	 of	 the	 opposite	 charge	 and	 can	therefore	guide	droplets	containing	cells	of	 interest	into	specified	plates.	To	set	up	the	FACSJazzTM	cell	sorter,	the	stream	was	aligned	and	focused	by	eye	using	the	 inbuilt	 pinhole	 camera.	 The	 two	 lasers	 (488nm	 and	 561nm)	 that	 allow	excitation	 of	 each	 fluorochrome	 were	 then	 aligned	 to	 the	 stream	 using	SPHEROTM	 Rainbow	 Calibration	 Particles	 (BD)	 (as	 per	 manufacturer’s	instructions).	 Following	 this,	 FACSTM	 Accudrop	 Beads	 (BD)	 were	 used	 to	determine	the	drop	delay	(as	per	manufacturer’s	instructions).	This	parameter	is	defined	 as	 the	 time	 between	 analysis	 of	 a	 cell	 at	 the	 interrogation	 point	 and	application	of	the	charge	to	the	droplet.	Measurement	of	this	parameter	is	vital	
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to	ensure	that	the	charge	applied	to	each	drop	is	applied	at	the	correct	time	so	that	 the	 drops	 formed	 contain	 the	 cell	 selected	 for	 sorting.	 After	 alignment,	 a	control	 sample	 of	 non-fluorescent	 cells	 is	 then	 loaded	 onto	 the	machine.	 This	allows	 specific	 gating	 to	 be	 applied	 to	 exclude	 debris	 and	 doublets	 of	 cells	(Figure	2.1).	Following	gating,	fluorescent	controls	positive	for	GFP	and	mCherry	or	Texas	red	only	are	used	to	apply	compensation	to	the	workspace.	Notably,	all	fluorochromes	emit	a	range	of	wavelengths	known	as	the	emission	spectra	and	within	 a	 FACS	 analyzer,	 this	 emission	 spectra	 is	 selected	 by	 a	 bandpass	 filter.	However,	 when	 measuring	 two	 fluorochromes	 simultaneously	 the	 emission	spectra	can	overlap	and	the	fluorescence	from	one	can	distort	the	measurement	of	the	other.	To	correct	for	this	distortion,	fluorescence	compensation	is	applied.	This	allows	the	measurement	of	two	different	fluorochromes	from	one	cell	as	it	excludes	 the	spectral	overlap	of	one	 fluorochrome	 from	the	other.	Notably,	 the	spectral	overlap	between	GFP	and	mCherry/texas	red	is	very	small	(~2%).	GFP	was	measured	using	excitation	from	a	488nm	laser	and	selected	using	a	530/40	bandpass	 filter.	mCherry	and	 texas	 red	were	measured	using	excitation	 from	a	561nm	laser	and	detected	using	a	610/20	bandpass	filter.	Following	set	up	of	the	machine	 each	 sample	 was	 loaded	 and	 analysed.	 Measurement	 of	 GFP	 and	mCherry	 or	 texas	 red	 fluorescence	 was	 taken	 from	 10000	 cells	 within	 each	sample.		
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Figure	2.1:	Cell	sorter	gating	applied	to	all	samples	 to	exclude	debris	and	
doublets	A)	Shows	‘all	events’	of	a	typical	sample	on	a	graph	that	demonstrates	forward	scatter	(FSC)	of	each	of	the	cells	versus	side	scatter	(SSC).	Notably,	FSC	indicates	the	relative	size	of	the	cells	and	SSC	indicates	the	relative	granularity	of	the	cells.	The	gate	applied	then	selects	 the	cell	population	 from	 ‘all	events’	and	excludes	 debris.	 B)	 Shows	 FCS	 versus	 trigger	 pulse	 width	 for	 the	 gated	 cell	population.	 The	 gate	 applied	 here	 selects	 for	 the	 single	 cell	 population	 and	excludes	doublets	due	to	their	appearance	at	double	the	trigger	pulse	width	of	a	single	cell.	Notably,	the	trigger	pulse	width	is	a	measurement	of	the	time	it	takes	for	the	cell	to	pass	the	detector.	Consequently,	doublets	take	double	the	time	to	pass	the	detector	than	a	single	cell	and	can	therefore	be	excluded	as	they	appear	at	 double	 the	 trigger	 pulse	 width	 of	 a	 single	 cell.	 Following	 doublet	 exclusion	samples	are	then	analysed	and	gated	for	sorting	based	on	fluorescence.		
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Chapter	2:	Materials	and	Methods		
	 54	
2.6 Isolation	of	IFN-sensitive	mutants	from	rPIV5mCh	using	flow	
cytometry	
2.6.1 Selection	and	sorting	of	potentially	IFN-sensitive	rPIV5mCh	mutants	into	96	
well	plates		A	method	 to	 isolate	 IFN-sensitive	 mutant	 viruses	 from	 a	 rPIV5mCh	 wild-type	stock	 using	 the	 newly	 generated	 GFP	 reporter	 cell-line,	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	was	developed.	To	select	and	sort	 IFN-sensitive	rPIV5mCh	mutants,	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	were	infected	 with	 a	 rPIV5mCh	 stock	 at	 MOI	 1	 and	 prepared	 for	 FACS	 analysis	 as	stated	previously	 (see	 section	2.5).	During	 analysis,	 cells	 positive	 for	both	GFP	and	 mCherry	 (potentially	 infected	 with	 an	 IFN-sensitive	 virus),	 were	 then	selected	 and	 sorted	 onto	 96	 well	 plates	 containing	 a	 monolayer	 of	A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells,	 using	 a	 1.0-drop	 pure	 single	 cell	sort	 setting.	These	 sort	 settings	provide	 the	most	 stringent	 cell	 sorting	as	 they	ensure	that	only	one	droplet	is	sorted	containing	a	single	cell.	Following	sorting,	each	96	well	plate	was	 then	 incubated	 for	3-4	days	 (depending	on	 the	 level	of	cytopathic	effect	(CPE)	seen)	and	then	subjected	to	further	analysis.		
2.6.2 Preparation	 of	 working	 stocks	 of	 potentially	 IFN-sensitive	 rPIV5mCh	
mutant	viruses	Supernatant	from	FACS	sorted	cells	(see	above	2.6.1)	was	removed	and	stored	in	a	 new	 96	 well	 plate	 at	 -80°C.	 Following	 supernatant	 removal,	 cells	 were	incubated	in	the	presence	of	1x104	Units/ml	IFN	for	18h	and	then	analysed	using	a	 fluorescent	 microscope	 (EVOS;	 Thermo	 Fisher	 Scientific).	 As	 before,	 wells	
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containing	cells	positive	for	both	GFP	and	mCherry	were	identified	as	containing	a	 potential	 IFN-sensitive	 mutant	 virus.	 Subsequently,	 stored	 supernatant	corresponding	to	each	GFP	and	mCherry	positive	well	was	then	used	to	create	a	working	 stock	 of	 the	 potential	 IFN-sensitive	 mutant	 virus.	 Specifically,	 virus	working	 stocks	 were	 prepared	 by	 inoculating	 Vero	 cells	 using	 5μl	 of	 the	previously	 selected	 supernatant	 in	 5ml	 10%	 [v/v]	 FBS,	 1%	 [v/v]	 pen/strep	DMEM.	Following	3-4	days	the	supernatant	containing	virus	was	then	harvested	and	clarified	as	stated	previously	(see	section	2.2.3).		
2.6.3 Confirmation	 of	 potentially	 IFN-sensitive	 rPIV5mCh	 mutant	 viruses	 using	
flow	cytometry		Potential	mutants	(see	section	2.6.2)	were	screened	for	IFN	sensitivity	using	flow	cytometry.	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	were	infected	with	each	potential	 mutant	 virus	 stock	 in	 the	 same	 manner	 as	 the	 primary	 selection	experiment	 (See	 section	 2.6).	 Note,	 to	 expedite	 the	 process	 of	 mutant	 virus	identification,	mutant	stocks	were	not	titered	for	analysis	using	flow	cytometry	but	 were	 instead	 estimated	 at	 1x107	 PFU/ml.	 Following	 analysis	 via	 flow	cytometry	 mutants	 displaying	 an	 attenuated	 phenotype	 (i.e.	 were	 unable	 to	block	the	IFN	signalling	pathway)	were	then	titered	on	Vero	cells	using	a	plaque	assay	(see	section	2.2.5).	Following	titration	each	mutant	was	then	prepared	for	sequencing	of	the	V/P	gene.		
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2.6.4 Sequencing	of	the	V/P	gene	of	potentially	IFN-sensitive	mutant	viruses	
2.6.4.1 RNA	Extraction	using	TRIzol	Viral	 RNA	 from	 potentially	 IFN-sensitive	 rPIV5mCh	 mutant	 viruses	 was	extracted	using	TRIzol.	Briefly,	a	25cm2	flask	containing	90%	confluent	Vero	cells	was	infected	with	each	potential	mutant	at	MOI	5	in	1ml	serum-free	DMEM.	The	cells	 were	 then	 incubated	 for	 1hour	 on	 a	 rocker	 before	 the	 inoculum	 was	replaced	with	5mls	10%	[v/v]	FBS,	1%	[v/v]	pen/strep	DMEM.	After	18hours	the	supernatant	was	removed	and	3mls	of	TRIzol	was	added	to	the	cell	monolayer.	This	was	then	rocked	for	5min	at	RT	before	collecting	and	aliquoting	 into	snap	lock	tubes	(1ml	each).	Subsequently,	200μl	of	chloroform	was	added	per	aliquot,	mixed	well	 and	 incubated	at	RT	 for	2-3min.	After	 incubation,	each	sample	was	centrifuged	 at	 12000g	 for	 15min	 at	 4°C	 to	 separate	 the	 aqueous	 and	 organic	phases.	 Specifically,	300μl	of	 the	upper	aqueous	phase	containing	both	cellular	and	 viral	 RNA	 was	 transferred	 to	 a	 clean	 tube	 and	 1μl	 Glycoblue	 was	 added.	Next,	 500μl	 of	 100%	 Isopropyl-alcohol	 (IPA)	 was	 added	 to	 each	 sample	 and	incubated	 at	 -20°C	 for	 30min.	 Samples	 were	 then	 centrifuged	 at	 12000g	 for	10min	at	4°C	and	the	supernatant	removed.	The	remaining	blue	pellet	containing	RNA	was	washed	with	1ml	75%	Ethanol	 and	centrifuged	at	7500g	 for	5min	at	4°C.	This	step	was	then	repeated	a	second	time,	followed	by	removal	of	the	EtOH	to	allow	the	pellet	to	air	dry.	The	pellet	was	then	re-suspended	in	Nuclease	free	water	 and	RNA	 concentration	determined	by	measuring	 absorbance	 at	 260nm	(A260)	 using	 a	 NanoDrop	 1000	 UV	 spectrophotometer	 (Thermo	 Fisher	Scientific).	 	 The	 purity	 of	 each	 sample	 was	 determined	 by	 A260/A280	 and	
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A260/A230	 ratio,	with	both	 ratios	 above	1.8	 considered	acceptable	 for	 further	study.	Each	sample	was	then	stored	at	-70°C		
2.6.4.2 First	strand	cDNA	synthesis	A	 primer	 specific	 to	 the	 PIV5	 V/P	 gene	 was	 used	 during	 first	 strand	 cDNA	synthesis	 to	 specifically	 reverse	 transcribe	 genomic	 V/P	 RNA	 to	 cDNA	 using	Moloney	Murine	Leukemia	Virus	Reverse	Transcriptase	 (M-MLV	RT,	Promega).	The	 sequence	 of	 the	 specific	 primer	 used	 was	 5’-GGTTCCTGCCTACCATCGG-3’.	Each	reaction	contained	1.5μl	of	100μM	specific	primer,	2μg	of	RNA	and	3.5μl	of	nuclease	 free	 H2O.	 This	 was	 then	 heated	 at	 70°C	 for	 5minutes	 to	 remove	secondary	 structure	within	 the	 template	 RNA.	Next,	 the	 following	 components	were	 added	 5μl	 of	M-MLV	 5x	 Reaction	 buffer,	 5μl	 of	 deoxynucleotide	 (dNTPs;	containing	10mM	each	nucleotide),	0.5μl	of	Recombinant	RNasin®	Ribonuclease	Inhibitor	(25units),	3.5μl	nuclease	free	H2O	and	1μl	M-MLV	RT	(200units).	This	mix	was	then	incubated	for	60mins	at	42°C	after	which	the	resulting	cDNA	was	then	stored	at	-20°C.		
2.6.4.3 Polymerase	Chain	reaction	(PCR)		PCR	was	used	to	amplify	V/P	cDNA	from	cDNA	samples.	All	PCR	reactions	were	completed	 using	 KOD	 hot	 start	 DNA	 polymerase	 (Merck	 Millipore)	 and	 the	forward	and	reverse	primers	as	follows:		PIV5	V/P	primers		Forward	primer	1		 5’-GGTTCCTGCCTACCATCGG-3’	Reverse	primer	1		 5’-GTTCGGGCTTATTTATCGTTAATC-3’	The	 expected	 PCR	 product	 using	 these	 primers	 consisted	 of	 1364bp.	 Each	reaction	 comprised	 of	 the	 following	 50μl	 mix:	 5μl	 10x	 polymerase	 buffer,	 3μl	
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25mM	MgSO4,	 5μl	 2mM	 dNTPs,	 1.5μl	 of	 10μM	 PIV5	 V/P	 forward	 and	 reverse	primers,	 100ng	 of	 template	 DNA	 and	 1μl	 KOD	 hot	 start	 DNA	 polymerase	(1Unit/μl).	 Each	 reaction	 was	 carried	 out	 in	 a	 thermocycler	 (Biometra®,	 T-gradient)	using	 the	 following	cycling	conditions:	polymerase	activation	at	95°C	for	 5min,	 denaturation	 at	 95°C	 for	 30sec,	 annealing	 at	 55°C	 for	 30sec	 and	extension	 at	 68°C	 for	 20sec.	 The	 denaturation,	 annealing	 and	 extension	 steps	were	then	repeated	for	30	cycles	before	holding	samples	at	4°C	for	storage.		
2.6.4.4 Gel	Electrophoresis		PCR	products	were	analysed	using	gel	electrophoresis	 to	 identify	 if	 the	correct	size	 of	 PCR	 product	 had	 been	 obtained.	 In	 this	 case	 the	 expected	 size	 of	 the	mutant	 V/P	 PCR	 product	 was	 ~1400bp.	 Gels	 were	 prepared	 containing	 1%	agarose	and	1μg/ml	Ethidium	Bromide	in	1X	TBE	buffer	(1M	Tris	base,	1M	Boric	acid	and	0.02M	EDTA).	Each	50μl	PCR	sample	was	prepared	in	6X	DNA	loading	buffer	(Promega)	and	loaded	onto	the	gel.	Samples	were	run	at	90V	in	TBE	buffer	for	30	minutes	and	visualised	under	UV	 light.	DNA	 ladders	of	known	size	 (1kb	and	100bp	ladders;	Promega)	were	run	alongside	the	samples	to	ensure	that	the	PCR	product	obtained	was	 the	 correct	 size.	The	PCR	product	was	 then	excised	and	 purified	 using	 QIAquick	 Gel	 Extraction	 Kit	 (following	 manufacturer’s	instructions;QIAGEN)	 and	 the	 DNA	 concentration	 determined	 by	 measuring	absorbance	 at	 260nm	 (A260)	 using	 a	 NanoDrop	 1000	 UV	 spectrophotometer	(Thermo	 Fisher	 Scientific).	 	 The	 purity	 of	 each	 sample	 was	 determined	 by	A260/A280	ratio,	with	a	ratio	above	1.8	considered	acceptable	for	further	study.	
Chapter	2:	Materials	and	Methods		
	 59	
2.6.4.5 Ligation	and	transformation		Extracted	V/P	cDNA	was	blunt	end	cloned	into	the	vector	pJET	1.2,	which	confers	ampicillin	resistance	(Thermo	Fisher	Scientific).	Each	reaction	included	40ng	of	purified	 PCR	 product,	 10μl	 of	 2X	 reaction	 buffer,	 1μl	 of	 pJET	 1.2	 vector,	 7μl	nuclease	free	H2O	and	1μl	of	T4	DNA	Ligase	(3	Weiss	Units/μl).	This	mixture	was	then	 incubated	 at	 RT	 for	 5min	 before	 transformation	 into	 competent	 cells.	Following	 incubation,	 the	mixture	was	 transformed	 into	100μl	ultra-competent	
E.	coli	 cells	 (JM109)	 primed	using	 the	 Z-competentTM	E.	coli	 transformation	 kit	(as	per	manufacturer’s	instructions,	ZYMO	Research).	Transformants	were	then	plated	 onto	 agar	 plates	 containing	 ampicillin	 overnight	 at	 37°C.	 Successfully	transformed	 bacteria	 containing	 the	 ligated	 plasmid	 express	 ampicillin	resistance	 and	 consequently	 form	 colonies	 on	 the	 ampicillin	 containing	 agar	plate.		
2.6.4.6 Colony	PCR		Colony	 PCR	 using	 GoTaq®	 green	 mastermix	 (Promega)	 was	 used	 to	 identify	colonies	containing	plasmids	with	a	correctly	ligated	V/P	sequence.	This	reaction	comprised	of	a	mastermix	of	5μl	GoTaq	mastermix,	0.5μl	of	each	of	the	forward	and	 reverse	 primers	 (supplied	 with	 the	 pJET1.2	 plasmid	 kit;	 Thermo	 Fisher	Scientific)	 and	 4μl	 of	 distilled	 H2O.	 The	 primers	 supplied	 with	 the	 pJET1.2	plasmid	flank	the	region	before	and	after	the	insertion	site	therefore	only	vector	containing	 an	 insert	 would	 produce	 a	 PCR	 product.	 A	 minimum	 of	 6	 colonies	were	selected	from	each	plate	using	a	sterile	tip	and	dipped	into	the	mastermix.	The	same	tip	was	also	used	to	dip	into	a	fresh	ampicillin	agar	plate,	numbered	to	allow	easy	identification	and	recovery	of	positive	colonies.	This	fresh	ampicillin	
Chapter	2:	Materials	and	Methods		
	 60	
plate	was	then	incubated	at	37°C	for	a	maximum	of	8hours.	During	this	time	the	colony	 PCR	was	 run	 on	 the	 thermocycler	 using	 the	 same	 conditions	 as	 stated	previously,	 with	 the	 exception	 of	 extending	 the	 extension	 time	 to	 1min	 20sec	(see	 section	 2.6.4.3).	 Each	 reaction	was	 then	 run	 directly	 on	 a	 1%	 agarose	 gel	and	 analysed	 under	 U.V	 light	 to	 identify	 if	 they	 contained	 the	 correct	 PCR	product	as	previously	stated	(see	section	2.6.4.4).	Reactions	producing	a	band	at	~1400bp	 in	 length	 were	 identified	 as	 positive	 as	 they	 contained	 a	 band	consistent	with	the	size	of	the	V/P	sequence.	The	corresponding	colonies,	stored	previously	on	the	 fresh	Ampicillin	plate,	were	then	cultured	to	prepare	enough	plasmid	DNA	for	sequencing.	At	least	three	positive	colonies	were	prepared	for	sequencing	 from	each	potential	mutant	 virus.	 Each	 colony	was	 inoculated	 into	5ml	 Luria-Bertani	 (LB)	 broth	 supplemented	 with	 50mg/ml	 ampicillin	 (Sigma)	and	 incubated	 overnight	 in	 an	 orbital	 shaker	 (225rpm,	 37°C).	 Plasmids	 were	then	 extracted	 using	 QIAprep	 Spin	 miniprep	 Kit	 (as	 per	 manufacturer’s	instructions,	 QIAGEN®).	 Afterwards,	 sequencing	was	 completed	 using	 pJET1.2	primers	 (Thermo	 Fisher	 Scientific)	 during	 capillary	 electrophoresis	 dye-terminator	sequencing	(performed	by	Dundee	Sequencing	services).		
2.6.5 Adaption	of	 the	method	 to	 isolate	 IFN-sensitive	viruses	 from	the	wild-type	
non	fluorescent	virus	PIV5	W3	In	addition	to	isolation	of	viral	mutants	from	rPIV5mCh,	we	adapted	our	method	to	 isolate	 mutants	 from	 the	 wild-type	 non-fluorescent	 virus	 PIV5	 W3.	 This	involved	 adding	 in	 two	 PIV5	 HN	 and	 F	 immunostaining	 steps	 to	 our	 method.	These	 immunostaining	 steps	 were	 added	 i)	 to	 identify	 PIV5	W3	 infected	 cells	before	FACS	analysis	and	cell	sorting	and	ii)	to	identify	potentially	IFN-sensitive	
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mutants	 following	 incubation	 of	 sorted	 cells	 i)	 Initially,	A549.pr(ISRE).GFP/ISG56-/Npro	cells	were	infected	with	PIV5	W3	at	an	MOI	0.5	for	1	hour.	After	6-8hours,	IFN	and	primary	anti-PIV5	HN/F	antibody	was	added	as	previously	stated	(see	section	2.5).	After	18	hours,	 immunostaining	for	PIV5	HN	and	F	was	then	completed.	Each	monolayer	was	washed	once	with	PBS	and	then	incubated	for	1hour	at	4°C	in	400μl	of	secondary	goat	anti-mouse	texas	red	antibody	 diluted	 1:200	 in	 ice	 cold	 3%	 [v/v]	 FBS/PBS.	 Following	 staining,	 cells	were	then	collected	for	FACS	analysis	and	dual	GFP	and	texas	red	positive	cells	were	 sorted	 into	 96	 well	 plates	 as	 previously	 stated	 (see	 section	 2.6).	 ii)	 The	second	 immunostaining	 step	 was	 added	 to	 identify	 potentially	 IFN-sensitive	mutant	viruses	following	incubation	of	sorted	cells	in	96	well	plates.	Initially,	the	supernatant	(potentially	containing	IFN-sensitive	mutant	viruses)	was	collected	from	each	well	 and	 the	 remaining	monolayers	of	 infected	cells	were	 incubated	with	 IFN,	 as	 previously	 stated	 (see	 section	 2.6.2).	 Cells	were	 then	 fixed	 in	 5%	[v/v]	formaldehyde/PBS	for	30mins	prior	to	permeabilisation	using	0.1%	[v/v]	Triton	 X-100/PBS	 for	 30min.	 Afterwards,	 cells	were	 incubated	 for	 1hour	with	primary	 anti-PIV5	 HN	 and	 F	 antibody	 diluted	 1:1000	 in	 2%	 [v/v]	 FBS/PBS.	Monolayers	were	then	washed	thrice	with	2%	[v/v]	FBS/PBS	and	incubated	for	1hour	 with	 goat	 anti-mouse	 texas	 red	 antibody	 diluted	 1:200	 in	 2%	 [v/v]	FBS/PBS.	Each	well	was	 then	analysed	using	a	 fluorescent	microscope	 (EVOS).	Those	 containing	 GFP	 and	 texas	 red	 positive	 cells	 were	 then	 identified	 as	containing	 a	 potentially	 IFN-sensitive	 mutant	 and	 the	 virus	 stock	 previously	stored	from	that	well	used	to	create	a	working	stock.	The	V/P	gene	of	this	virus	was	then	sequenced	as	previously	stated	(see	section	2.6.4).		 	
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2.6.6 Methods	 required	 for	 characterization	 of	 IFN-sensitive	 viral	 mutants	
following	isolation	Following	sequencing,	three	mutant	viruses,	rPIV5mCh-α,	rPIV5mCh-β	and	PIV5	W3-γ,	 were	 identified.	 Subsequently,	 these	 mutants	 were	 characterized	 in	 a	number	of	assays:		i) FACS	analysis	of	potentially	IFN-sensitive	mutants	at	different	MOI		ii) Western	blot	for	STAT1	degradation	iii) IFNβ	induction	and	IFN	signalling	luciferase	assays	to	analyse	mutant	V	protein	activity		iv) FACS	analysis	and	serial	passage	to	assess	mutant	stability	of	the	IFN-sensitive	mutants	rPIV5mCh-α	and	PIV5-W3-γ		v) DAPI	staining	to	assess	fusogenicity	and	apoptosis	of	the	IFN-sensitive	mutants	rPIV5mCh-α	and	PIV5-W3-γ		vi) Full	genome	sequencing			
2.6.6.1 i)	FACS	analysis	of	potentially	IFN-sensitive	mutants	at	different	MOI	Initially,	each	mutant	virus	was	analysed	by	FACS	using	the	method	as	described	in	section	2.5	with	the	following	modifications.	Specifically,	A549/pr(ISRE).GFP/	ISG56-/	 BVDV	 Npro	 cells	 were	 infected	 at	MOI	 0.1,	 1,	 5	 or	 10	 for	 1hour	with	rPIV5mCh,	 rPIV5mCh-α,	 rPIV5mCh-β,	 PIV5	W3	 and	 PIV5	W3-γ.	 After	 8	 hours,	IFN	treatment	(1x104Units/ml)	and	anti-PIV5	HN	and	F	antibody	(1:1000)	was	added.	 Following	 18hours,	 each	 sample	 was	 then	 collected,	 immunostained	 if	necessary	(see	section	2.6.5)	and	analysed	by	FACS.				
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2.6.6.2 ii)	Western	blot	analysis	of	STAT1		The	 functionality	 of	 each	mutant	V	protein	was	 assessed	by	 analysis	 of	 STAT1	degradation	 following	 infection	 using	 a	 western	 blot.	 Specifically,	 A549:	 naïve	cells	were	mock	infected	or	infected	with	the	viruses	PIV5	W3,	rPIV5mCh,	PIV5	CPI-,	rPIV5mCh-α,	PIV5mCh-β	and	PIV5	W3-γ	at	MOI	10	for	12	hours	followed	by	a	 16	 hour	 IFN	 treatment	 (1x104	Units/ml).	 Following	 incubation,	 cells	 were	collected	in	disruption	buffer,	run	on	an	SDS-PAGE	gel	and	transferred	to	a	PVDF	membrane	 as	 previously	 stated	 (See	 section	 2.4.3).	 The	 blot	 was	 then	 probed	using	mouse	anti-STAT1,	mouse	anti-PIV5	NP	and	mouse	anti-Actin	 antibodies	sequentially	at	a	dilution	of	1:1000,	overnight	at	4°C.	Following	incubation	with	each	primary	antibody,	the	membrane	was	washed	with	PBS	0.5%	[v/v]	Tween-20	as	previously	stated	(See	section	2.4.3).	Each	membrane	was	then	incubated	with	 goat	 anti-mouse	 LiCOR	 IRDye®	 fluorescent	 secondary	 antibody	 at	 a	dilution	 of	 1:10000	 and	washed	 again	 using	 PBS	 0.5%	 [v/v]	 Tween-20	 before	visualisation	using	the	Odyssey	CLx	Imaging	system	(LiCOR	Biosciences).			
2.6.6.3 iii)	IFN-β	induction	and	IFN	signalling	luciferase	reporter	assays	to	analyse	
mutant	V	protein	activity	Mutant	 rPIV5mCh-α,	 rPIV5mCh-β	 and	 PIV5	 W3-γ	 V	 protein	 sequences	 were	excised	 from	 pJET1.2	 by	 enzyme	 digest	 using	 XhoI	 and	 XbaI	 (as	 per	manufacturer’s	 instructions;	 Promega)	 and	 ligated	 into	 the	 pcDNA3.1-	expression	vector	(Thermo	Fisher	Scientific)	using	T4	DNA	ligase	(Promega).	V	protein	functionality	was	then	analysed	using	two	luciferase	reporter	assays.				
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A	 luciferase	 assay	 was	 used	 to	 analyse	 the	 effects	 of	 mutant	 rPIV5mCh-α,	rPIV5mCh-β	and	PIV5	W3-γ	V	protein	on	the	IFN	induction	pathway.	This	assay	required	 a	 plasmid	 containing	 firefly	 luciferase	 under	 the	 control	 of	 the	 IFN-β	promoter	 (pIFΔ(-116)lucter;	 provided	 by	 Dr	 Lena	 Andrejeva,	 University	 of	 St	Andrews)	 and	 a	 second	plasmid	 expressing	Mda5	 (pEF.mda-5;	 provided	by	Dr	Lena	 Andrejeva,	 University	 of	 St	 Andrews).	 When	 expressed	 together,	 Mda5	activates	 the	 induction	 of	 the	 IFN-β	 promoter	 and	 subsequent	 luciferase	expression.	 A	 third	 plasmid	 containing	 β-galactosidase	 (pJATlacZ;	 provided	 by	Dr	Lena	Andrejeva,	University	of	St	Andrews)	was	used	as	a	transfection	control	and	 enabled	 the	 data	 to	 be	 normalised	 to	 a	 standard.	 A	 transfection	 mix	including	 all	 three	 plasmids	 (250ng/well	 each)	 as	 well	 as	 a	 plasmid	 that	expresses	 one	 of	 the	 V	 proteins	 to	 be	 assessed	 (wild-type,	 rPIV5mCh-α,	rPIV5mCh-β	 or	 PIV5	 W3-γ	 V	 protein)	 (750ng/well	 each)	 and	 4%	 [v/v]	Lipofectamine	2000	(Thermo	Fisher	Scientific)	was	prepared	in	500μl	OptiMEM	and	 incubated	 for	 30	mins.	 Subsequently,	 90%	 confluent	monolayers	 of	 293T	cells	 in	 12	 well	 plates	 were	 then	 transfected	 with	 this	 mix	 and	 incubated	 at	37°C/5%	CO2	 for	 5	 hours.	 Following	 incubation,	 1ml	 of	 10%	 [v/v]	 FBS	DMEM	without	 antibiotics	 was	 added	 and	 cells	 were	 incubated	 for	 48hours	 before	collection	 in	 100μl	 lysis	 buffer	 (Promega).	 Each	 lysate	 was	 then	 clarified	 at	1500rpm	for	5mins	and	20μl	each	transferred	into	two	fresh	tubes	for	analysis	of	both	firefly	 luciferase	and	β-galactosidase	activity.	To	measure	firefly	 luciferase	activity,	the	luminometer	(GloMax)	was	programmed	to	automatically	add	100μl	of	firefly	luciferase	substrate	(Promega)	to	one	aliquot	of	the	lysate	and	measure	luminescence	 following	 a	 10	 second	 incubation.	 To	 measure	 β-galactosidase	activity,	100μl	of	β-glo	substrate	(Promega)	was	added	to	the	second	aliquot	of	
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lysate	 and	 incubated	 for	 30mins	 at	 RT.	 The	 luminescence	was	 then	measured	using	 the	 luminometer	 and	 used	 to	 normalise	 the	 luciferase	 activity	 of	 each	sample.	Each	sample	was	set	up	 in	 triplicate	allowing	standard	deviation	 to	be	calculated	and	added	to	each	graph	created	using	Graphpad	Prism	6	(Graphpad	Software).			A	second	luciferase	assay	was	used	to	analyse	the	effects	of	mutant	rPIV5mCh-α,	rPIV5mCh-β	and	PIV5	W3-γ	V	protein	on	the	IFN	signalling	pathway.	This	assay	required	 a	 plasmid	 (p(9-27)4tkΔ(-39)lucter;	 provided	 by	 Dr	 Lena	 Andrejeva,	University	of	St	Andrews)	containing	firefly	luciferase	under	the	control	of	four	tandem	repeat	sequences	of	the	ISRE	from	the	IFN-inducible	gene	9-27	(Didcock	et	al.	1999).	This	element	is	found	within	the	promoters	of	hundreds	of	ISGs	and	is	activated	upon	the	addition	of	IFN.	Thus	in	this	assay	addition	of	IFN	following	transfection	 with	 this	 plasmid	 results	 in	 the	 expression	 of	 luciferase.	 This	plasmid	 was	 therefore	 transfected	 along	 with	 the	 plasmid	 expressing	 β-galactosidase	 and	 another	 that	 expresses	 one	 of	 the	mutant	 V	 proteins	 (wild-type,	rPIV5mCh-α,	rPIV5mCh-β	or	PIV5	W3-γ	V	protein;	250ng/well	each)	in	the	same	 manner	 as	 described	 above.	 Following	 transfection	 and	 incubation	 for	48hours,	 IFN	 treatment	 (104Units/ml)	 was	 added	 for	 6	 hours.	 Samples	 were	then	collected	and	analysed	as	previously	stated.		
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2.6.6.4 iv)	FACS	analysis	and	serial	passage	to	assess	the	ability	of	the	IFN-sensitive	
viruses	rPIV5mCh-α	and	PIV5-W3-γ	to	regain	IFN	antagonist	function	Ability	of	the	mutant	viruses	rPIV5mCh-α	and	PIV5-W3-γ	to	revert	to	regain	IFN	antagonist	 function	 was	 assessed	 using	 two	 methods	 i)	 FACS	 analysis	 and	 ii)	serial	passage	of	each	virus.	i)	Firstly,	we	infected	A549:pr(ISRE).GFP	cells	with	both	 rPIV5mCh-α	 and	 PIV5-W3-γ	 at	 MOI	 1.	 Samples	 were	 then	 prepared	 and	subjected	 to	 FACS	 analysis	 as	 previously	 stated	 (see	 section	 2.5).	 Following	analysis	of	PIV5-W3-γ,	texas	red	only	positive	cells	were	sorted	and	the	V/P	gene	sequenced	 from	 10	 samples	 as	 stated	 previously	 (see	 section	 2.6).	 Notably,	following	 analysis	 of	 rPIV5mCh-α,	 very	 few	 mCherry	 only	 positive	 cells	 were	present.	Further	analysis	of	the	selected	viruses	then	showed	that	viruses	were	still	 unable	 to	 block	 IFN	 signalling	 and	 were	 therefore	 not	 sequenced	 ii)	rPIV5mCh-α	 and	 PIV5-W3-γ	 were	 also	 passaged	 through	 A549:pr(ISRE).GFP	cells	 for	 60	 days	 following	 an	 initial	 infection	 at	 an	MOI	 5.	 Following	 60	 days,	each	 population	 of	 cells	was	 seeded	 at	 3x105	 cells/well	 in	 a	 12	well	 plate	 and	allowed	 to	 adhere	 overnight.	 The	 next	 day	 cells	 were	 treated	 with	 IFN	 for	18hours.	Following	 incubation,	 samples	containing	rPIV5mCh-α	 infection	could	be	 collected	 directly	 and	 analysed	 by	 FACS.	 By	 contrast,	 samples	 containing	PIV5-W3-γ	 virus	 were	 immunostained	 and	 analysed	 by	 FACS	 as	 previously	stated	(See	section	2.5	and	2.6.5).	
2.6.6.5 v)	DAPI	staining	to	assess	fusogenicity	and	apoptosis	of	the	IFN-sensitive	
mutants	rPIV5mCh-α	and	PIV5-W3-γ		Mutants	 rPIV5mCh-α	 and	 PIV5-W3-γ	were	 analysed	 for	 i)	 fusogenicity	 and	 ii)	apoptosis	 using	 DAPI	 (4’,6-diamidino-2-phenylindole)	 staining	 following	 viral	
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infection.	 i)	To	analyse	for	fusogensity,	Vero	cells	seeded	onto	coverslips	(1mm	thick)	were	mock	infected	or	infected	with	rPIV5mCh,	PIV5	W3,	PIV5mCh-α	and	PIV5	W3-γ	at	MOI	10	for	1	hour	in	200μl	serum-free	DMEM.	The	virus	inoculum	was	 the	 replaced	 with	 1ml	 serum-free	 DMEM	 and	 incubated	 for	 48hours.	Following	incubation,	cells	were	fixed	in	5%	[v/v]	formaldehyde/PBS	for	30min.	Fixed	cells	were	 then	washed	 thrice	with	2%[v/v]	FBS/PBS	and	permeabilised	using	 0.1%	 [v/v]	 Triton	 X-100/PBS	 for	 30min.	 Following	 a	 second	wash	 step,	30μl	 DAPI	 stain	 diluted	 1:200	 was	 added	 and	 incubated	 for	 20mins.	 The	coverslips	 were	 then	 washed	 for	 a	 final	 time	 before	 inversion	 and	 mounting	multiple	 coverslips	 onto	 large	 glass	 slides	 using	 citifluor	 (Citifluor	 Ltd).	Afterwards,	 images	 were	 taken	 at	 10X	 Magnification	 using	 Microphot-FXA	immunofluorescence	 microscope	 (Nikon).	 ii)	 To	 analyse	 for	 apoptosis,	 A549	naïve	 cells	 seeded	 onto	 coverslips	 were	 infected	 with	 rPIV5mCh,	 PIV5	 W3,	PIV5mCh-α	and	PIV5	W3-γ	at	MOI	10	 for	1	hour	 in	200μl	SF-DMEM.	The	virus	inoculum	was	then	replaced	with	serum-free	DMEM	-/+	4μM	Rux	or	equivalent	volume	DMSO	and	incubated	for	48	or	72	hours.	Afterwards,	cells	were	stained	using	DAPI	staining,	mounted	onto	glass	slides	and	analysed	using	a	fluorescence	microscope	as	previously	stated.	Note	images	were	taken	at	20X	Magnification.		
2.6.6.6 vi)	Full	genome	sequencing	of	each	mutant	virus		Full	genome	sequencing	of	each	viral	mutant	was	completed	by	Elizabeth	Wignall-Fleming	at	the	University	of	Glasgow.	In	brief,	each	viral	mutant	was	prepared	for	directional	sequencing	by	RNA	extraction	(see	section	2.6.4.1).	A	library	preparation	for	each	mutant	was	then	completed	using	TruSeq	stranded	
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Total	RNA	with	Ribo-Zero	Gold	(Illumina)	and	sequenced	using	MiSeq	(Illumina).	Bioinformatics	analysis	was	then	completed	to	separate	genomic	and	antigenomic	RNA	reads.	Following	this,	a	consensus	sequence	was	generated	from	the	wild-type	PIV5	W3	and	rPIV5mCh	sample.	Subsequently,	the	genomic	reads	from	each	mutant	virus	preparation	were	aligned	to	the	appropriate	reference	sequence	using	Burrows-Wheeler-Alignment	(BWA)	or	Bowtie2.	Each	alignment	was	then	analysed	to	identify	mutations	within	the	viral	genome.		
Chapter	3:	Analysis	of	the	IFN	inhibitor	Rux		
	 69	
3 Chapter	3	
3.1 Inhibitors	of	the	IFN	response	enhance	virus	replication	in	vitro	
3.1.1 Introduction	and	aims		Manipulation	of	a	virus’s	capacity	to	circumvent	the	IFN	response	is	an	essential	tool	used	 to	advance	our	knowledge	of	viruses	and	how	 they	 interact	with	 the	immune	system.	As	well	 as	being	of	 fundamental	 interest,	 this	ability	may	also	have	many	practical	applications	such	as	facilitating	the	design	of	live-attenuated	vaccines.	Despite	the	many	benefits	of	disabling	a	virus’s	capacity	to	circumvent	the	IFN	response,	 these	IFN-sensitive	viruses	are	often	difficult	to	grow	to	high	titer	 as	 many	 cell-lines	 produce	 and	 respond	 to	 IFN	 (Young	 et	 al.	 2003).	 The	default	option	for	growth	of	these	viruses	is	therefore	limited	to	a	select	number	of	cell-lines	such	as	Vero	cells,	that	do	not	have	an	intact	IFN	system,	however,	as	viruses	 exhibit	 host	 cell	 specificity	 not	 all	 viruses	 can	 be	 grown	 in	 such	 cells	(Desmyter	 et	 al.	 1968;	 Mosca	 &	 Pitha	 1986).	 To	 tackle	 this	 issue,	 we	 have	previously	 engineered	 cell-lines	 with	 an	 intact	 IFN	 response	 to	 express	 IFN	antagonists	that	 inhibit	this	IFN	response,	such	as	the	BVDV	Npro	protein	from	BVDV,	 which	 blocks	 the	 IFN	 induction	 pathway	 by	 targeting	 IRF3	 for	proteasome-mediated	degradation,	or	the	V	protein	from	PIV5,	which	blocks	the	IFN	 signalling	 pathway	 by	 targeting	 STAT1	 for	 proteasome-mediated	degradation	(Young	et	al.	2003;	Didcock	et	al.	1999;	Hilton	et	al.	2006).	However,	the	creation	of	genetically	engineered	cell-lines	is	time	consuming	and	the	use	of	such	cells	 can	create	regulatory	problems	 in	vaccine	production.	Consequently,	our	 laboratory	set	out	 to	attain	another,	more	 flexible	method	to	 improve	viral	growth.		
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Prior	 to	 my	 study,	 it	 was	 hypothesised	 that	 blocking	 the	 IFN	 induction	 or	signalling	 pathways	 using	 a	 small	molecule	 inhibitor	would	 offer	 a	 simple	 and	flexible	solution	to	increase	viral	growth,	as	an	inhibitor	could	easily	supplement	the	 tissue	 culture	 medium	 of	 cell-lines	 of	 choice.	 To	 test	 this,	 eight	 inhibitors	known	 to	 target	 different	 components	 of	 the	 IFN	 response	 (TBK-1,	 IKKb	 and	JAK1)	 were	 tested	 for	 their	 ability	 to	 block	 their	 corresponding	 pathways.	 Of	these	 eight	 inhibitors,	 Rux,	 which	 blocks	 the	 JAK1/2	 component	 of	 the	 IFN	signalling	 pathway,	 was	 identified	 as	 the	 most	 effective	 inhibitor	 of	 the	 IFN	response	(Stewart	et	al.	2014).	Specifically,	 it	was	shown	to	 increase	growth	of	numerous	 IFN-sensitive	 viruses	 that	 were	 sensitive	 to	 IFN	 due	 to	 i)	 loss	 of	function	of	the	viral	IFN	antagonist	or	ii)	mutations	that	slowed	virus	replication	enough	 to	 allow	 the	 IFN	 response	 to	 overcome	 the	 infection.	 This	 was	demonstrated	using	a	diverse	range	of	viruses,	 including,	viruses	with	disabled	IFN	 antagonists	 that	 exemplify	 live-attenuated	 vaccine	 candidates	 (RSV	 and	Influenza	virus),	traditionally	attenuated	vaccine	strains	(MuV	Enders	strain	and	MeV	Edmonston	strain)	and	a	slow	growing	wild-type	virus	(RSV)	(Stewart	et	al	2014).			 	
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My	study	aimed	to	further	characterise	the	use	of	the	IFN	inhibitor,	Rux,	using	a	number	of	assays	including:	i. Monitoring	the	stability	of	the	inhibitor	in	vitro	ii. Analysing	its	effect	on	virus	growth	in	Vero	cells	iii. Analysing	 the	 effect	 on	 virus	 growth	 of	 pre-treating	 cells	 with	 the	inhibitor	prior	to	infection		iv. Analysing	the	effect	of	the	inhibitor	on	virus	growth:	a) 	in	multiple	cell-lines		b) 	of	other	previously	untested	viruses.		The	results	of	such	studies	are	outlined	in	the	following	chapter.	 	
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3.1.2 Monitoring	the	stability	of	Rux	in	vitro		Further	 characterisation	 of	 the	 IFN	 inhibitor,	 Rux,	 in	 the	 context	 of	 virus	infection	required	that	experiments	be	performed	over	several	days.	Therefore,	we	 firstly	 set	 out	 to	 analyse	 the	 activity	 of	 the	 inhibitor	 over	 time	 to	 decipher	whether	chemical	degradation	or	cellular	metabolism	reduced	the	drugs	ability	to	 inhibit	 the	 IFN	 response.	To	 test	 inhibitor	 stability	 over	 time,	 the	 inhibitory	activity	of	Rux	was	analysed,	following	incubation	of	the	inhibitor	in	the	media	of	A549	 naïve	 cells,	 using	 an	 IFN	 signalling	 GFP	 reporter	 assay.	 	 Specifically,	 we	incubated	4μM	of	the	drug,	Rux,	 in	the	culture	medium	of	A549	naïve	cells	and	harvested	 samples	 of	 the	 culture	medium	at	 numerous	 time-points	 for	 7	 days.	Collected	Rux	 test	 samples	were	 then	 added	 to	 an	 IFN	 signalling	GFP	 reporter	assay	to	analyse	for	loss	in	inhibitor	activity.			The	assay	commenced	with	the	addition	of	each	test	sample	to	the	IFN	signalling	GFP	reporter	cell	line,	A549:pr(ISRE).GFP.	This	cell-line	contains	GFP	under	the	control	of	the	mouse	Mx1	promoter,	which	is	activated	following	induction	of	the	IFN	signalling	pathway.	Subsequently,	the	IFN	signalling	pathway	and	thus	GFP	expression	 was	 optimally	 activated	 by	 addition	 of	 IFNα/β.	 Notably	 the	 Mx1	promoter	 contains	 an	 ISRE	 element,	 which	 is	 found	 within	 the	 promoters	 of	many	 ISGs.	 Hence,	 when	 IFN-α/β	 is	 added	 to	 A549:pr(ISRE).GFP	 cells,	 this	activates	 the	 IFN	 signalling	 pathway	 which	 switches	 on	 the	 Mx1	 (ISRE	containing)	 promoter	 and	 results	 in	 expression	 of	 GFP.	 Importantly,	 previous	work	has	demonstrated	that	addition	of	the	IFN	inhibitor,	Rux	(4μM)	to	the	IFN	signalling	GFP	reporter	assay,	results	in	a	significant	reduction	in	GFP	expression	by	blocking	the	IFN	signalling	pathway.	Consequently,	this	enabled	us	to	examine	
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the	 stability	 of	 the	 activity	 of	 the	 inhibitor	 present	 in	 the	 test	 samples,	 as	 any	reduction	 in	 inhibitor	 activity	 following	 their	 incubation	 in	 A549:	 naïve	 cells	would	result	 in	a	 regain	of	GFP	expression.	The	results	 from	the	 IFN	signalling	GFP	 reporter	 assay	 demonstrated	 that	 there	was	 no	 regain	 in	 GFP	 expression	following	addition	of	 the	 incubated	Rux	 test	samples	 (Figure	3.1).	 In	summary,	this	 indicates	 that	 there	was	no	 loss	 in	 inhibitor	 activity	 of	Rux	 over	 time	 and	therefore	the	drug	was	considered	stable	in	cell	culture	for	up	to	7	days.		
	
Figure	3.1:	Analysis	of	 the	stability	of	 the	 IFN	 inhibitor	Rux	 in	vitro.	A549	naïve	cells	were	cultured	in	the	presence	of	media	supplemented	with	Rux	(4μM)	or	equivalent	volume	of	DMSO.	Samples	of	 the	medium	were	then	harvested	at	numerous	 time-points	 for	 7	 days.	 The	 inhibitory	 activity	 of	 culture	 medium	containing	Rux	was	then	tested	in	A549:pr(ISRE).GFP	reporter	cells	using	an	IFN	signalling	GFP	 reporter	 assay.	 Briefly,	 the	A549:pr(ISRE).GFP	 reporter	 cell-line	was	activated	with	purified	IFN,	following	incubation	with	the	test	samples,	and	GFP	measured	48	hours	post-IFN	treatment.	
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3.1.3 Analysis	 of	 growth	 kinetics	 of	 the	 IFN-sensitive	 virus,	 BUNΔNSs,	 in	 A549	
naïve	and	Vero	cells	supplemented	with	the	IFN	inhibitor,	Rux	Throughout	the	following	studies	BUNΔNSs	was	used	as	a	model	virus	to	study	the	 effects	 of	 the	 IFN	 inhibitor	 Rux	 on	 the	 IFN	 response	within	 different	 cell-lines.	Notably,	BUNΔNSs	 is	 IFN-sensitive	as	 the	 IFN	antagonist	NSs	protein	has	been	deleted,	consequently,	it	is	unable	to	grow	efficiently	in	the	presence	of	an	active	 IFN	response	 (Bridgen	et	al.	2001).	Blockage	of	 the	 IFN	response	by	 the	IFN	inhibitor,	Rux,	could	therefore	be	assessed	by	analysing	increased	growth	of	this	virus.			Previously	it	has	been	shown	that	the	IFN	inhibitor	Rux	can	increase	the	growth	of	 the	IFN-sensitive	virus	BUNΔNSs	 in	A549	cells	using	both	plaque	assays	and	multistep	viral	growth	curves	(Stewart	et	al.	2014).	Following	this,	the	effect	of	the	IFN	inhibitor,	Rux,	on	BUNΔNSs	plaque	development	was	then	compared	in	A549	naïve	and	Vero	cells	(Figure	3.2).	Notably,	Vero	cells	are	currently	one	of	a	limited	 number	 of	 cell-lines	 approved	 in	 vaccine	 production	 therefore	 any	improvement	 on	 viral	 growth	 achieved	 in	 these	 cells	 may	 be	 of	 interest	 to	vaccine	 manufacturers	 (Barrett	 et	 al.	 2009).	 Interestingly,	 this	 comparison	demonstrated	 two	 intriguing	 effects	 i)	 Firstly,	 BUNΔNSs	 plaque	 size	 appeared	slightly	 increased	 in	Vero	 cells	 supplemented	with	 inhibitor	 compared	 to	Vero	cells	 supplemented	 with	 the	 equivalent	 volume	 of	 DMSO	 (Figure	 3.2).	 ii)	Secondly,	BUNΔNSs	plaque	development	was	significantly	faster	 in	A549:	naïve	cells	supplemented	with	the	IFN	inhibitor,	Rux,	than	in	Vero	cells	(Figure	3.2).	In	this	 section	 we	 set	 out	 to	 quantify	 these	 effects	 using	 multistep	 viral	 growth	curves	 to	 identify	 if	 virus	 growth	 of	 the	 IFN-sensitive	 virus	 BUNΔNSs	 i)	 is	
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increased	 in	 the	 presence	 of	 the	 IFN	 inhibitor,	 Rux,	 in	 Vero	 cells	 compared	 to	Vero	cells	supplemented	with	the	equivalent	volume	of	DMSO	and	ii)	is	faster	in	A549	naïve	cells	supplemented	with	IFN	inhibitor	compared	to	Vero	cells.	
	
Figure	3.2:	BUNΔNSs	plaque	development	in	A549	naïve,	A549/PIV5-V	and	
Vero	cells	supplemented	with	Rux.	BUNΔNSs	plaque	 formation	was	analysed	following	 42	 or	 72-hour	 incubation	 in	 the	 presence	 of	 the	 IFN	 inhibitor	 Rux	(4μM)	or	 the	equivalent	volume	of	DMSO	on	A549,	A549/PIV5	V	or	Vero	cells.	Plaques	were	visualised	using	CV	stain	(Data	prepared	by	C.	Adamson).		
42
	h
ou
rs
	PI
72
	h
ou
rs
	PI
DM
SO
	
RU
X	
RU
X/
TP
CA
-1
	
TP
CA
-1
	
A549	
A549	
PIV5-V	
Vero	
Vero	
42
	h
rs
	p
.i.
	
72
	h
rs
	p
.i.
	
DMSO Rux
A549
A549	
PIV5-V
Vero
Vero
Chapter	3:	Analysis	of	the	IFN	inhibitor	Rux		
	 76	
Firstly,	we	set	out	to	identify	if	virus	growth	of	the	IFN-sensitive	virus,	BUNΔNSs,	is	increased	in	the	presence	of	the	IFN	inhibitor,	Rux,	in	Vero	cells.	Previously,	it	had	 been	 shown	 that	 plaque	 size	 was	 slightly	 increased	 in	 Vero	 cells	supplemented	 with	 the	 inhibitor,	 Rux,	 compared	 to	 Vero	 cells	 supplemented	with	 the	equivalent	volume	of	DMSO	(Figure	3.2).	This	was	 intriguing	as	 it	has	been	 shown	 previously	 that	 Vero	 cells	 do	 not	 have	 an	 intact	 IFN	 response	(Desmyter	et	al.	1968),	therefore	addition	of	IFN	inhibitor	should	have	no	effect.	It	 was	 therefore	 decided	 to	 quantify	 this	 effect	 using	 a	multistep	 viral	 growth	curve.	Specifically,	BUNΔNSs	growth	in	the	presence	of	Rux	(4μM)	or	equivalent	volume	 of	 DMSO	was	 compared	 in	 Vero	 cells.	 The	 results	 indicated	 that	 there	was	 no	 significant	 increase	 in	 viral	 titre	 in	 Vero	 cells	 in	 the	 presence	 of	 the	inhibitor,	 Rux,	 compared	 to	 the	 control,	 DMSO	 (Figure	 3.3).	 In	 summary,	 this	indicates	that	the	IFN	inhibitor,	Rux,	has	no	effect	on	viral	growth	in	Vero	cells	therefore	the	slight	 increase	seen	previously	 in	plaque	development	appears	to	be	insignificant.		 	
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Figure	 3.3:	 Analysis	 of	 the	 effect	 of	 the	 IFN	 inhibitor,	 Rux,	 on	 BUNΔNSs	
growth	in	Vero	cells	using	a	multistep	viral	growth	curve.	BUNΔNSs	growth	was	monitored	 for	5	days	 in	Vero	 cells	 following	 infection	at	MOI	0.001	 in	 the	presence	 of	 the	 IFN	 inhibitor,	 Rux	 (4μM),	 or	 equivalent	 volume	 of	 DMSO.	Samples	 of	 the	media	 were	 taken	 at	 numerous	 time-points.	 PFU/ml	 was	 then	determined	 by	 titration	 of	 these	 samples	 on	 Vero	 cells	 using	 a	 plaque	 assay.	(Data	representative	of	two	independent	repeats	with	a	lower	limit	of	detection	of	1x	103	PFU/ml)	
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Secondly,	 we	 set	 out	 to	 identify	 if	 virus	 growth	 of	 the	 IFN-sensitive	 virus,	BUNΔNSs,	 is	 faster	 in	 A549	 naïve	 cells	 supplemented	 with	 the	 IFN	 inhibitors,	Rux,	compared	to	growth	in	Vero	cells	in	the	absence	of	IFN	inhibitor.	Previously,	it	was	noted	that	BUNΔNSs	plaque	development	was	significantly	faster	in	A549	naïve	cells	supplemented	with	 the	 IFN	 inhibitors,	Rux,	 than	 in	Vero	cells	 in	 the	absence	of	 IFN	 inhibitor	 (Figure	3.2).	 It	was	 therefore	decided	 to	quantify	 this	using	 a	multistep	viral	 growth	 curve.	 Specifically,	 growth	of	BUNΔNSs	 in	A549	naïve	cells	supplemented	with	the	IFN	inhibitor,	Rux,	was	compared	to	growth	in	Vero	 cells	 (Figure	 3.4).	 Note,	 that	 A549/PIV5-V	 cells	 were	 used	 as	 a	 positive	control	 in	 this	 experiment	 as	 they	 express	 the	 IFN	 antagonist	 V	 protein	 from	PIV5	and	have	previously	demonstrated	 that	blockage	of	 the	 IFN	response	can	result	in	an	increase	in	viral	growth	of	IFN-sensitive	viruses	(Young	et	al.	2003).	The	 results	demonstrate	 that	 the	viral	 titer	of	BUNΔNSs	was	~2	 logs	higher	 in	A549	naïve	cells	supplemented	with	Rux	than	in	Vero	cells	without	IFN	inhibitor	when	 compared	 at	 48	 hours	 post	 infection.	 Vero	 cells	 in	 the	 absence	 of	 IFN	inhibitor	 then	 achieved	 a	 similar	 titer	 to	 that	 seen	 in	 A549	 naïve	 cells	supplemented	 with	 Rux	 24hours	 later	 (Figure	 3.4).	 Notably,	 the	 increased	growth	of	BUNΔNSs	in	A549:	naïve	cells	in	the	presence	of	Rux	was	comparable	to	 the	 positive	 control	 cell	 line,	 A549/PIV5-V,	 at	 48hours	 post	 infection	indicating	 that	 other	 host-cell	 constraints	must	 limit	 infection	 in	 Vero	 cells.	 In	summary,	 growth	 of	 the	 IFN-sensitive	 virus,	 BUNΔNSs,	 is	much	 faster	 in	A549	naive	cells	supplemented	with	Rux	than	in	Vero	cells.		
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Figure	 3.4:	 Comparison	 of	 growth	 of	 the	 IFN-sensitive	 virus,	 BUNΔNSs,	 in	
A549:	naïve	cells	supplemented	with	Rux	compared	to	growth	in	Vero	and	
A549/PIV5-V	 cells	 using	 a	multistep	 viral	 growth	 curve.	 BUNΔNSs	 growth	was	monitored	over	5	days	following	infection	at	MOI	0.001	in	A549	naïve	cells	in	the	presence	of	4μM	Rux	or	the	equivalent	volume	of	DMSO	in	comparison	to	Vero	and	A549/PIV5-V	cells.	Samples	of	the	media	were	taken	at	numerous	time-points.	PFU/ml	was	then	determined	by	titration	of	these	samples	on	Vero	cells	using	 a	 plaque	 assay	 (Data	 representative	 of	 two	 independent	 repeats	 with	 a	lower	limit	of	detection	of	1x	103	PFU/ml).			
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Interestingly,	 it	 was	 noted	 that	 growth	 of	 BUNΔNSs	 was	 slightly	 faster	 in	 the	engineered	cell-line,	A549/PIV5-V,	 than	 in	A549	naïve	cells	supplemented	with	Rux	 (~1	 log	 greater	 at	 36hours	 post	 infection)(Figure	 3.4).	 We	 therefore	hypothesised	that	as	V	is	constitutively	expressed	and	hence	shut	off	of	the	IFN	response	is	present	in	A549/PIV5-V	cells	prior	to	infection	then	this	may	provide	a	significant	advantage	over	addition	of	IFN	inhibitor	zero	hours	post	 infection.	We	therefore	sought	to	determine	if	pre-treating	the	cells	with	the	inhibitor,	Rux,	prior	to	infection	would	result	in	increased	growth	of	BUNΔNSs	that	matches	the	speed	seen	in	A549/PIV5-V	cells.	Specifically,	A549	naïve	cells	were	incubated	in	the	presence	and	absence	of	the	IFN	inhibitor	Rux	for	24hours	before	infection	with	 BUNΔNSs.	 Subsequently	 these	 cells	were	 then	 analysed	 in	 comparison	 to	A549/PIV5-V	 cells	 via	 a	multistep	 viral	 growth	 curve	 (Figure	 3.5).	 The	 results	demonstrate	that	there	was	no	increase	in	viral	growth	in	A549	naïve	cells	pre-treated	 with	 Rux	 for	 24hours	 compared	 to	 A549	 naïve	 cells	 where	 Rux	 was	added	 0hours	 post	 infection.	 In	 summary,	 this	 indicates	 that	 pre-treatment	 of	A549	naïve	cells	with	Rux,	prior	to	infection	with	BUNΔNSs,	has	no	effect	on	viral	growth	and	cannot	increase	the	speed	of	viral	growth	to	that	seen	in	A549/PIV5-V	cells.			
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Figure	3.5:	Analysis	of	the	effect	of	pre-treatment	of	A549:	naïve	cells	with	
the	IFN	inhibitor,	RUX,	on	BUNΔNSs	growth,	using	a	multistep	viral	growth	
curve.	BUNΔNSs	 growth	was	monitored	 for	 5	 days	 following	 infection	 at	MOI	0.001	 in	 A549:	 naïve	 cells	 pre-treated	 with	 Rux	 (4μM)	 for	 24hours	 before	infection.	This	was	compared	to	growth	of	BUNΔNSs	following	infection	at	MOI	0.001	in	A549:	naïve	cells	treated	with	Rux	at	0hours	post	infection	and	growth	in	 A549/PIV5-V	 cells	 and	 Vero	 cells.	 	 Samples	 of	 the	 media	 were	 taken	 at	numerous	 time-points.	 PFU/ml	 was	 then	 determined	 by	 titration	 of	 these	samples	 on	 Vero	 cells	 using	 a	 plaque	 assay.	 (Data	 representative	 of	 two	independent	repeats	with	a	lower	limit	of	detection	of	1x	103	PFU/ml)	
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To	 summarize,	we	 have	 demonstrated	 that	 supplementing	 the	media	with	 the	IFN	inhibitor,	Rux,	had	no	effect	on	growth	of	the	IFN-sensitive	virus	BUNΔNSs	in	Vero	 cells.	 Reiterating	 that	 Vero	 cells	 do	 not	 have	 an	 intact	 IFN	 response.	We	then	demonstrated	 that	BUNΔNSs	growth	was	much	 faster	 in	A549	naïve	 cells	supplemented	 with	 Rux	 than	 in	 Vero	 cells.	 Indicating	 that	 inhibiting	 the	 IFN	response	 within	 mammalian	 cells	 with	 IFN	 inhibitors	 may	 provide	 a	 valuable	alternative	 to	 the	 current	 method	 used	 for	 Vaccine	 production.	 Expanding	 on	this,	it	was	noted	that	growth	of	BUNΔNSs	in	A549/PIV5-V	cells	was	faster	than	in	A549:	naïve	cells	supplemented	with	the	inhibitor	Rux.	We	then	demonstrated	that	pre-treatment	of	A549:	naïve	cells	with	Rux	did	not	increase	viral	growth	to	that	 seen	 in	 A549/PIV5-V	 cells.	 Thus	 indicating	 that	 expression	 of	 the	 IFN	antagonist	 V	 protein	 may	 provide	 other	 advantages	 to	 increase	 viral	 growth.	Despite	this,	addition	of	the	IFN	inhibitor,	Rux,	may	provide	the	best	alternative	to	growth	in	Vero	cells	for	the	manufacture	of	vaccines	as	the	use	of	genetically	engineered	cell-lines	can	create	regulatory	problems	for	vaccine	manufacturers.	
3.1.4 Effects	of	Rux	on	replication	of	various	viruses	from	the	Bunyaviridae	family	
in	a	range	of	cell-lines	derived	from	different	mammalian	species		In	 the	 following	 section	 we	 set	 out	 to	 further	 characterise	 the	 use	 of	 the	 IFN	inhibitor,	 Rux,	 by	 examining	 its	 effect	 on	 growth	 of	 BUNΔNSs,	 BUN	 WT	 and	several	other	viruses	from	the	Bunyaviridae	family,	on	MRC5	(human	foetal	lung	fibroblast)	 cells	 and	 a	 number	 of	 other	 cell-lines	 derived	 from	 different	mammalian	species.	
Chapter	3:	Analysis	of	the	IFN	inhibitor	Rux		
	 83	
3.1.4.1 Analysis	of	the	effects	of	the	IFN	inhibitor,	Rux,	on	BUNΔNSs	growth	in	
MRC5	cells		Currently,	 only	a	 few	cell-lines	are	approved	 for	use	 in	vaccine	production,	 for	example,	Vero	and	MRC5	cells	(Barrett	et	al.	2009).	As	we	have	already	examined	the	effects	of	Rux	on	the	growth	of	BUNΔNSs	in	IFN	incompetent	Vero	cells,	we	then	 extended	 our	 study	 to	 analyse	 its	 effect	 on	 viral	 growth	 in	 the	 IFN	competent	MRC5	 cell-line,	 and	 compared	 this	 to	 growth	 in	 the	 engineered	 IFN	incompetent	 MRC5/PIV5-V	 expressing	 cell-line.	 To	 examine	 this,	 plaque	development	 of	 the	 IFN-sensitive	 virus,	 BUNΔNSs,	 was	 analysed	 following	incubation	with	 Rux	 (4μM)	 or	 equivalent	 volume	 of	 DMSO	 in	 each	 of	 the	 cell-lines.	 Notably,	 we	 also	 included	 A549:	 naïve	 and	 A549/PIV5-V	 cells	 as	 a	comparable	positive	and	negative	control.	The	results	demonstrate	that	addition	of	Rux	 increased	BUNΔNSs	plaque	 size	 in	 the	 IFN	 competent	MRC5	naïve	 cells	equivalent	to	that	seen	in	the	engineered	cell	line	MRC5/PIV5-V	in	the	absence	of	inhibitor,	but	had	no	effect	on	plaque	size	in	IFN	incompetent	MRC5/PIV5-V	cells	(Figure	 3.6).	 This	 demonstrates	 that	 Rux	 can	 block	 the	 IFN	 response	 in	MRC5	naïve	 cells	 to	allow	an	 increase	of	viral	 growth	equivalent	 to	expression	of	 the	PIV5-V	 protein.	 Furthermore,	 as	 the	 IFN	 response	 in	 MRC5/PIV5-V	 cells	 is	already	 blocked	 by	 expression	 of	 PIV5-V	we	 see	 no	 further	 increase	 in	 plaque	size	 in	 the	presence	 of	 inhibitor.	As	MRC5	 cells	 are	 commonly	used	 in	 vaccine	production	(in	addition	to	Vero	cells)	the	use	of	the	IFN	inhibitor	Rux	may	be	of	interest	to	vaccine	manufacturers	to	increase	viral	growth	of	vaccine	strains.			
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Figure	3.6:	Effects	of	 IFN	 inhibitor,	Rux,	on	BUNΔNSs	and	BUN	WT	plaque	
formation	in	a	range	of	mammalian	cell-lines.	BUNΔNSs	and	BUN	WT	plaque	size	was	determined	following	incubation	with	4μM	Rux	in	A549,	A549/PIV5	V,	MRCV,	MRC5/PIV5	V,	BalB/C,	RK.13,	MDBK,	MDCK	and	PKIBRS2	cells.	Plaques	were	 fixed	 on	 the	 day	 indicated	 and	 visualized	 by	 immunostaining	 for	Bunyamwera	N	protein	(Data	representative	of	three	independent	repeats).	
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3.1.4.2 Analysis	of	the	effects	of	the	IFN	inhibitor,	Rux,	on	BUNΔNSs	growth	in	a	
number	of	different	mammalian	cell-lines	Next	 we	 set	 out	 to	 further	 characterise	 the	 use	 of	 the	 IFN	 inhibitor,	 Rux,	 by	examining	its	effect	on	viral	growth	of	BUNΔNSs	in	a	number	of	cell-lines	derived	from	different	mammalian	species.	Specifically,	plaque	development	of	the	IFN-sensitive	virus,	BUNΔNSs,	was	analysed	following	incubation	with	Rux	(4μM)	or	equivalent	volume	of	DMSO	in	five	commonly	used	mammalian	cell-lines,	namely	BalB/C	 (murine	 fibroblast),	 RK.13	 (leporine	 kidney	 epithelial	 cells),	 MDBK	(bovine	 kidney	 epithelial	 cells),	 MDCK	 (canine	 kidney	 epithelial	 cells)	 and	PKIBRS2	 (porcine	 kidney	 epithelial	 cells).	 The	 results	 demonstrated	 that,	 Rux	increased	 plaque	 size,	 to	 a	 varying	 degree,	 in	 all	 mammalian	 cell-lines	 tested	(Figure	3.6).	Thus	indicating	that	Rux	can	block	the	IFN	response	in	each	of	these	cell-lines.	 In	 summary,	 this	 provides	 further	 evidence	 that	 supplementing	 the	media	of	IFN	competent	cells	with	Rux	provides	a	flexible	approach	to	increase	viral	growth	of	IFN-sensitive	viruses	in	a	cell-line	of	choice.	
3.1.4.3 Analysis	of	the	effects	of	IFN	inhibitor,	Rux,	on	BUN	WT	infection	in	A549,	
MRC5	and	five	other	commonly	used	mammalian	cell-lines	Next	we	sought	to	analyse	the	effects	of	the	inhibitors	on	BUN	WT.	This	virus	can	infect	 humans	 and	 contains	 an	 IFN	 antagonist	 (NSs),	 which	 blocks	 the	 IFN	response	successfully	in	human	derived	cell-lines.	Here	we	set	out	to	analyse	the	host	 cell	 range	 of	 the	 NSs	 protein	 further	 by	 examining	 BUN	 WT	 plaque	development	 following	 addition	 of	 IFN	 inhibitor,	 Rux,	 in	 several	 different	mammalian	 cell-lines	 (A549:	 naive,	 A549/PIV5	 V,	MRCV:	 naive,	MRC5/PIV5	 V,	BalB/C,	RK.13,	MDBK,	MDCK	and	PKIBRS2).	Specifically,	plaque	development	of	
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BUN	 WT	 was	 analysed	 following	 incubation	 with	 Rux	 (4μM)	 or	 equivalent	volume	of	DMSO	in	each	of	the	cell-lines	(Figure	3.6).			As	expected,	the	results	demonstrate	that	the	presence	of	inhibitor,	Rux,	had	no	effect	 on	 BUN	 WT	 plaque	 size	 in	 any	 of	 the	 human	 derived	 cell-lines	 (A549:	naïve,	A549/PIV5-V,	MRC5:	naïve	and	MRC5/PIV5-V)	as	the	IFN	antagonist	NSs	is	functional	within	human	cell-lines,	therefore	there	can	be	no	further	increase	in	viral	growth	in	the	presence	of	inhibitor.	Next	it	was	noted	that	in	the	absence	of	 Rux,	 BUN	WT	 grew	well	 in	 RK.13	 and	 BalB/C	 cell-lines	 and	when	 Rux	was	added	there	was	only	a	slight	increase	in	plaque	size	(Figure	3.6).	These	results	suggest	 that	 the	 NSs	 protein	 is	 functional	 within	 RK.13	 and	 BalB/C	 cells	 as	growth	occurs	 in	 the	 absence	of	 inhibitor	 and	 is	 only	moderately	 increased	by	the	presence	of	inhibitor.	Interestingly,	in	the	absence	of	inhibitor	BUN	WT	grew	poorly	in	MDCK	and	PKIBRS2	cells	however,	when	the	inhibitor,	Rux,	was	added	there	 was	 a	 substantial	 increase	 in	 plaque	 size.	 This	 indicates	 that	 the	 NSs	protein	 is	 not	 functional	 in	 these	 cell-lines	 as	 addition	 of	 the	 IFN	 inhibitor	relieves	the	strain	of	the	IFN	response	and	this	allows	viral	growth.	Finally,	the	results	from	analysis	of	growth	of	BUN	WT	in	the	presence	and	absence	of	Rux	in	MDBK	cells	represented	an	interesting	case,	which	we	then	chose	to	investigate	further	
3.1.4.3.1 Further	analysis	of	viral	growth	of	BUN	WT	in	MDBK	bovine	cells	in	the	
presence	and	absence	of	the	IFN	inhibitor,	Rux.	In	the	previous	analysis	of	plaque	development	of	BUN	WT	in	the	presence	and	absence	of	Rux,	plaques	were	visualised	by	immunostaining	for	Bunyamwera	N	
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protein	following	fixation.	Looking	closely	at	the	MDBK	cell	monolayer	following	staining	it	was	noted	that	in	the	absence	of	the	inhibitor,	Rux,	large	holes	in	the	monolayer	 remained	 unstained.	 These	 holes	 looked	 identical	 to	 the	 size	 of	plaques	that	were	stained	in	monolayers	in	the	presence	of	Rux.	It	was	therefore	hypothesised	 that	Bunyamwera	 infection	had	begun	 to	grow	and	 form	plaques	but	 following	 incubation,	 the	 MDBK	 cells	 had	 been	 able	 to	 overcome	 the	infection.	These	plaques	then	remained	unstained	at	the	time	of	immunostaining	because	 infected	 cells	 were	 no	 longer	 present.	 To	 examine	 this	 further,	 viral	plaque	formation	of	BUN	WT	was	analysed	over	7	days	with	and	without	the	IFN	inhibitor,	 Rux,	 in	 MDBK	 cells.	 The	 monolayers	 were	 then	 immunostained	 for	Bunyamwera	N	protein	to	visualise	infected	cells	and	then	subsequently	stained	with	CV	stain	to	visualise	holes	within	the	monolayer	(Figure	3.7A).	The	results	show	that	consistently,	in	the	absence	of	Rux,	immunostained	plaques	would	be	present	and	increase	in	size	until	day	3.	From	Day	3,	these	plaques	would	then	begin	 to	 reduce	 in	 size	 and	 also	 gradually	 become	 undetectable	 by	immunostaining	for	Bunyamwera	N	protein.	By	contrast,	in	the	presence	of	Rux,	plaque	 size	 would	 increase	 until	 the	 monolayer	 was	 destroyed	 by	 day	 7.	 We	therefore	hypothesised	 that	 the	NSs	protein	 is	non-functional	 (or	has	a	 limited	function)	 in	 MDBK	 bovine	 cells	 or	 the	 IFN	 response	 in	 MDBK	 bovine	 cells	 is	particularly	 powerful,	 and	 therefore	 infection	 can	 be	 overcome	 under	 these	conditions.	 Subsequently,	 viral	 growth	 of	 BUN	 WT	 in	 A549	 naïve	 and	 MDBK	bovine	cells	was	quantified	in	the	presence	or	absence	of	the	inhibitor,	Rux,	using	a	multistep	viral	growth	curve	(Figure	3.7B).	Conversely,	the	results	showed	that	growth	in	MDBK	bovine	cells	was	not	restricted	in	the	absence	of	Rux	and	was	also	not	increased	by	the	presence	of	Rux.	These	conflicting	results	indicate	that	
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the	NSs	protein	 is	 functional	 in	 this	 cell-line	or	 that	 the	MDBK	bovine	 cell	 line	does	not	have	a	more	powerful	IFN	response.	In	summary,	the	ability	to	regress	BUN	 WT	 virus	 appears	 to	 be	 dependent	 on	 the	 conditions	 of	 the	 assay	 and	further	studies	would	be	required	to	elucidate	this	feature.		
	
Figure	 3.7:	 	 BUN	 WT	 growth	 in	 MDBK	 bovine	 cells.	 A)	 BUN	 WT	 plaque	formation	was	analysed	in	MDBK	bovine	cells	for	7	days	in	the	presence	of	Rux	or	 equivalent	 volume	 of	 DMSO,	 visualized	 firstly	 by	 immunostaining	 for	Bunyamwera	N	protein	 followed	by	CV	staining.	B)	BUN	WT	virus	growth	was	monitored	 in	 the	presence	of	4μM	Rux	or	equivalent	volume	of	DMSO	 in	A549	naïve	 cells	 and	 MDBK	 bovine	 cells	 (Data	 representative	 of	 three	 independent	repeats	with	a	lower	limit	of	detection	of	1x	103	PFU/ml).	
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As	BUN	WT	growth	in	MDBK	cells	had	produced	an	interesting	result	in	both	the	plaque	assay	and	multistep	viral	growth	curve	it	was	important	to	demonstrate	that	this	was	an	isolated	case	and	all	other	mammalian	cell	types	did	not	produce	a	similar	effect.	Consequently,	we	decided	to	analyse	BUN	WT	growth	in	all	other	mammalian	 cell-lines	 (BalB/C,	 RK.13,	 MDCK	 and	 PKIBRS2)	 using	 a	 multistep	viral	 growth	 curve.	 Specifically,	 BUN	 WT	 growth	 was	 analysed	 following	incubation	 with	 Rux	 (4μM)	 or	 equivalent	 volume	 of	 DMSO,	 in	 each	 of	 the	mammalian	cell-lines	using	a	multistep	viral	growth	curve	(Figure	3.8).		As	 expected,	 the	 results	 indicate	 that	 BUN	 WT	 growth	 is	 increased	 in	 the	presence	 of	 IFN	 inhibitor,	 Rux,	 in	 both	MDCK	 and	 PKIBRS2	 cells.	 The	 effect	 is	most	prominent	in	PKIBRS2	cells,	as	BUN	WT	is	unable	to	grow	until	Day	5	in	the	absence	of	Rux	but	reaches	titers	of	~1x108	in	the	presence	of	Rux.	Furthermore,	there	 is	 an	 increase	 in	 viral	 titer	 of	~2logs	 at	 48hours	post	 infection	 in	MDCK	cells.	 Lastly,	 there	was	no	 significant	 increase	 in	BUN	WT	viral	 growth	 seen	 in	BalB/C	 and	 RK.13	 cells.	 This	 was	 expected	 as	 the	 previous	 plaque	 analysis	 of	BUN	WT	growth	in	these	cell-lines	demonstrated	only	a	small	increase	in	plaque	size	in	the	presence	of	Rux	(Figure	3.6).	In	summary,	the	results	from	each	BUN	WT	viral	growth	curve	reflect	the	previous	analysis	of	BUN	WT	growth	using	a	plaque	 assay.	 This	 confirmed	 that	 viral	 growth	 was	 significantly	 increased	 in	MDCK	 and	 PK1BRS2	 cells	 but	 not	 in	 BalB/C	 or	 RK.13	 in	 the	 presence	 of	 Rux.	Importantly	this	confirms	that	the	interesting	effect	on	BUN	WT	growth	in	MDBK	cells,	in	the	presence	and	absence	of	Rux	(Figure	3.7),	is	an	isolated	case.		 	
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Figure	3.8:	Viral	growth	curves	of	BUN	WT	in	the	presence	of	IFN	inhibitor	
Rux	 (4μM)	 or	 equivalent	 volume	 DMSO.	 A)	 BalB/C	 murine	 cells	 B)	 RK.13	leporine	cells.	C)	MDCK	canine	cells.	D)	MDBK	bovine	cells.	(Data	representative	of	two	independent	repeats	with	a	lower	limit	of	detection	of	1x	103	PFU/ml).	
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In	summary,	addition	of	the	inhibitor,	Rux,	had	no	effect	on	plaque	development	of	BUN	WT	in	the	human	derived	cell-lines	A549	or	MRC5.	This	suggests	that	the	NSs	 protein	 is	 functional	 within	 these	 cell-lines.	 Furthermore,	 addition	 of	 Rux	only	 moderately	 increased	 growth	 in	 RK.13	 and	 BalB/C	 cells.	 Thus	 indicating	that	 the	 NSs	 protein	 is	 also	 functional	 within	 these	 mammalian	 cell-lines.	 By	contrast	 addition	 of	 Rux	 substantially	 increased	 viral	 growth	 in	 MDCK	 and	PKIBRS2	 cells.	 This	 striking	 difference	 indicates	 that	 the	 NSs	 protein	 is	 non-functional	in	these	cell-lines	as	addition	of	the	inhibitor	has	relieved	the	strain	of	the	IFN	response	and	allowed	a	significant	increase	in	viral	growth.	Interestingly,	these	 results	 demonstrate	 that	 the	 use	 of	 IFN-inhibitors	 may	 offer	 a	 general	approach	 to	 initiate	 fundamental	 studies	 to	 investigate	 species-specific	constraints	on	viral	IFN	antagonist	function.	
3.1.4.4 Effects	of	the	IFN	inhibitor,	Rux,	on	several	viruses	from	the	Bunyaviridae	
family		Finally,	 we	 extended	 our	 study	 to	 analyse	 the	 effect	 of	 the	 inhibitor,	 Rux,	 on	growth	 of	 several	 viruses	 from	 the	 Bunyaviridae	 family	 in	 a	 number	 of	mammalian	 cell-lines.	 In	 particular,	 we	 examined	 plaque	 development	 of	Anopheles	 A	 virus	 (ANAV),	 Bwamba	 virus	 (BWAV),	 Cache	 Valley	 virus	 (CVV),	Kairi	virus	(KIRV),	Main	Drain	virus	(MDV)	and	SBV	in	the	presence	and	absence	of	Rux	in	each	of	the	following	cell-lines:	A549	naïve,	BalB/C,	MDBK,	MDCK,	NBL-6	and	RK.13.	Notably,	the	NBL-6	(equine)	cell-line	was	added	as	MDV	has	been	shown	previously	to	infect	horses	(Emmons	et	al.	1983).	Furthermore,	all	viruses	express	an	 IFN	antagonist,	NSs	protein,	with	 the	exception	of	ANAV.	This	virus	has	 been	 shown	 to	 be	 unable	 to	 block	 the	 IFN	 induction	 pathway	 and	
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consequently	 leads	 to	 the	 induction	 of	 IFN-α/β	 (Mohamed	 et	 al.	 2009).	Specifically,	 plaque	 development	 of	 each	 virus	 was	 examined	 following	incubation	with	 Rux	 (4μM)	 or	 equivalent	 volume	 of	 DMSO	 in	 each	 of	 the	 cell-lines	(Figure	3.9).	Note	that	virus	titre	was	kept	constant	across	all	cell-lines	to	enable	comparison	between	growth	 in	different	cell-lines	however	viral	 titre	 is	not	 the	 same	 for	 each	 virus	 so	 comparisons	 between	 viruses	 cannot	 be	made.	Next	we	will	outline	the	results	for	each	virus	across	each	cell	line	individually.		
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Figure	 3.9:	 Plaque	 development	 of	 seven	 different	 viruses	 from	 the	
Bunyaviridae	 family	 (ANAV,	 BWAV,	 CVV,	 KRIV,	 MDV	 and	 SBV)	 in	 six	
mammalian	 cell-lines	 (A549	 naïve,	 BalB/C,	 MDBK,	 MDCK,	 NBL-6	 and	
RK.13).	A)	Plaques	were	fixed	at	the	day	indicated	and	stained	using	CV	stain	B)	This	 table	summarizes	 the	results	 from	each	plaque	assay.	 ‘-‘	 indicates	 that	 the	virus	 did	 not	 produce	 plaques	 in	 that	 cell	 line,	 ‘+’	 indicates	 that	 the	 virus	produced	 plaques	 at	 least	 pin	 point	 plaques	 in	 that	 cell	 line	 and	 ‘++’	 indicates	that	plaque	size	increased	in	the	presence	of	the	IFN	inhibitor	Rux	in	comparison	to	growth	in	the	absence	of	inhibitor.	(Data	representative	of	three	independent	repeats).	
	
Figure	3.10:	Plaque	development	of	Cache	Valley	virus	in	A549	naïve	cells.	Plaques	 were	 fixed	 at	 the	 day	 indicated	 and	 stained	 using	 CV	 stain.	 (Data	representative	of	three	independent	repeats).	
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The	 results	 demonstrate	 that	 ANAV	 did	 not	 grow	 in	 BalB/C,	MDBK,	 NBL-6	 or	RK.13	cells	in	the	presence	or	absence	of	Rux.	In	contrast,	ANAV	did	grow	small	plaques	 in	 the	 absence	 of	Rux	 in	A549:	 naïve	 cells	 and	 in	 the	 presence	 of	Rux	plaque	size	is	increased	dramatically.	Finally,	ANAV	did	not	plaque	in	MDCK	cells	in	the	absence	of	inhibitor	but	in	the	presence	of	inhibitor	larger	plaques	appear.	This	indicates	that	the	presence	of	an	active	IFN	response	restricts	growth	of	the	virus	 in	A549:	 naïve	 and	MDCK	 cells	 as	 addition	 of	 the	 IFN	 inhibitor,	 Rux,	 can	increase	viral	growth.	However,	other	constraints	must	also	limit	ANAV	infection	in	BalB/C,	MDBK,	NBL-6	or	RK.13,	as	addition	of	IFN	inhibitor	had	no	effect	on	viral	growth.			Likewise,	BWAV	did	not	grow	in	A549:	naïve,	BalB/C,	MDBK	or	NBL-6	cells	in	the	presence	or	absence	of	Rux.	By	contrast,	it	did	grow	in	RK.13	cells	in	the	absence	of	 inhibitor	 with	 a	 small	 increase	 in	 plaque	 size	 in	 the	 presence	 of	 inhibitor.	Finally,	BWAV	did	not	plaque	in	MDCK	cells	in	the	absence	of	inhibitor	but	in	the	presence	 of	 inhibitor	 small	 plaques	 appeared.	 Hence	 differences	 in	 NSs	 target	proteins	may	 limit	 host	 cell	 range	 in	MDCK	and	RK.13	 cells	 as	 addition	 of	 IFN	inhibitor	 can	 increase	 viral	 growth	 in	 such	 cells.	 However,	 other	 host	 cell	constraints	must	restrict	BWAV	infection	within	A549:	naïve,	BalB/C,	MDBK	and	NBL-6	cells	as	addition	of	IFN	inhibitor	had	no	effect	on	viral	growth.			Next	 CVV,	 KRIV	 and	 MDV	 produced	 similar	 results	 across	 all	 cell-lines	 with	growth	 of	 all	 viruses	 in	 the	 absence	 of	 inhibitor	 increased	 in	 the	 presence	 of	inhibitor.	Note	that	both	monolayers	of	A549:	naïve	cells	were	destroyed	using	the	original	dilution	of	CVV	therefore	a	second	lower	dilution	of	CVV	was	set	up	
Chapter	3:	Analysis	of	the	IFN	inhibitor	Rux		
	 97	
to	 enable	 us	 to	 determine	 if	 plaque	 size	 was	 increased	 in	 the	 presence	 of	inhibitor	 (Figure	 3.10).	 This	 demonstrated	 that	 CVV	 infection	 can	 grow	 in	 the	absence	 of	 inhibitor	 but	 growth	 is	 also	 increased	 in	 the	 presence	 of	 inhibitor.	Together	 this	 demonstrates	 the	 CVV,	 KRIV	 and	 MDV	 are	 not	 as	 restricted	 as	ANAV	and	BWAV	by	host	cell	constraints	as	they	can	grow	well	in	each	cell-line	in	the	absence	of	inhibitor.	However,	each	virus	is	restricted	by	the	IFN	response	in	all	cell-lines,	as	the	presence	of	inhibitor	increases	growth	in	all	cases.			Finally,	SBV	did	not	grow	in	any	of	the	cell-lines	in	the	absence	of	inhibitor	with	the	 exception	 of	 MDCK	 cells	 where	 SBV	 produced	 pin	 point	 plaques.	 In	 the	presence	of	inhibitor	plaques	are	greatly	increased	in	MDCK	cells	and	appear	in	RK.13	cells.	Hence	differences	in	NSs	target	proteins	must	limit	host	cell	range	in	MDCK	and	RK.13	cells	as	addition	of	 IFN	 inhibitor	can	 increase	viral	growth	 in	such	 cells.	 However,	 other	 host	 cell	 constraints	 must	 also	 restrict	 BWAV	infection	within	A549:	naïve,	BalB/C,	MDBK	and	NBL-6	cells	as	addition	of	 IFN	inhibitor	had	no	effect	on	viral	growth.			In	 summary,	 the	 presence	 of	 inhibitor,	 Rux,	 has	 increased	 viral	 growth	 of	 a	number	 of	 these	 viruses	 in	 different	 cell-lines.	 Importantly,	 these	 results	demonstrate	 that	 use	 of	 the	 inhibitor,	 Rux,	 could	 aid	 fundamental	 studies	 of	these	viruses	as	high	 titer	virus	stocks	can	be	produced	by	addition	of	 the	 IFN	inhibitor,	 Rux,	 to	 an	 appropriate	 cell-line.	 Furthermore,	 the	 use	 of	 the	 IFN	inhibitor	 Rux	 could	 also	 be	 used	 to	 initiate	 the	 fundamental	 study	 of	 host	 cell	constraints	 as	 these	 results	 demonstrate	 that	 other	 host	 cell	 constraints	 exist	aside	 from	 the	 IFN	 response	 that	 prevent	 the	 infection	 of	 a	 number	 of	 these	
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viruses	in	different	cell-lines.	Finally,	these	results	also	support	the	concept	that	addition	 of	 Rux	 provides	 a	 flexible	 method	 to	 improve	 techniques	 to	 isolate	emerging	viruses	by	improving	virus	growth	of	a	number	of	different	viruses	in	a	range	of	cell-lines	derived	from	different	mammalian	species.			To	 summarise,	 in	 this	 section	we	 have	 further	 characterised	 the	 IFN	 inhibitor,	Rux	by	investigating	its	effect	on	growth	of	BUNΔNSs,	BUN	WT	and	several	other	members	 of	 the	 Bunyaviridae	 family,	 in	 a	 number	 of	 mammalian	 cell-lines.	Firstly,	we	have	demonstrated	that	addition	of	IFN	inhibitor	can	increase	growth	of	 BUNΔNSs	 in	 MRC5	 cells,	 which	 are	 commonly	 used	 in	 vaccine	 production.	Thus	providing	further	evidence	that	the	IFN	inhibitor	could	be	useful	in	vaccine	production.	Secondly,	we	have	demonstrated	that	addition	of	 the	 IFN	 inhibitor,	Rux,	 increased	 viral	 growth	 of	 BUNΔNSs	 in	 several	 mammalian	 cell-lines	(BalB/C,	 RK.13,	 MDBK,	 MDCK	 and	 PKIBRS2).	 This	 supports	 the	 concept	 that	supplementing	 the	 media	 with	 Rux	 provides	 a	 flexible	 approach	 to	 increase	growth	 of	 IFN-sensitive	 viruses	 in	 a	 cell-line	 of	 choice.	 Thirdly,	 we	 have	demonstrated	 that	 addition	 of	 IFN	 inhibitor	 increases	 growth	 of	 BUN	 WT	significantly	 in	 PKIBRS2	 and	MDCK	 cells.	 Thus	 indicating	 that	 species-specific	constraints	on	the	function	of	the	IFN	antagonist,	NSs	protein,	exist	in	these	cell-lines.	 These	 results	 therefore	 demonstrate	 that	 the	 use	 of	 IFN-inhibitors	 may	offer	 a	 general	 approach	 to	 initiate	 fundamental	 studies	 to	 investigate	 species-specific	 constraints	on	viral	 IFN	antagonist	 function.	Notably	 the	effects	of	Rux	on	growth	of	BUN	WT	 in	MDBK	cells	 represented	an	 interesting	 case	 that	 also	initiated	further	investigation	into	NSs	function	and	host	cell	constraints.	Finally,	we	 have	 demonstrated	 that	 addition	 of	 the	 IFN	 inhibitor,	 Rux,	 increased	 viral	
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growth	 of	 several	 viruses	 from	 the	Bunyaviridae	 family	 in	 several	mammalian	cell-lines.	These	results	therefore	indicate	that	the	addition	of	the	IFN	inhibitor,	Rux,	can	aid	i)	fundamental	studies	of	these	viruses	and	the	host	cell	constraints	that	prevent	their	infection	and	ii)	isolation	of	emerging	viruses.	
3.1.5 Conclusions	To	 conclude,	 in	 this	 chapter	we	 have	 further	 characterised	 the	 use	 of	 the	 IFN	inhibitor,	 Rux,	 by	 demonstrating	 its	 effectiveness	 in	 numerous	 assays.	Specifically,	 we	 have	 demonstrated	 i)	 that	 addition	 of	 the	 IFN	 inhibitor,	 Rux,	could	provide	a	faster	and	therefore	more	efficient	alternative	for	growth	of	IFN-sensitive	 vaccine	 strains	 than	 Vero	 cells,	 which	 are	 used	 widely	 in	 vaccine	production	and	ii)	that	addition	of	the	IFN	inhibitor,	Rux,	can	increase	growth	of	the	 IFN-sensitive	 virus	 BUNΔNSs,	 BUN	WT	 and	 several	 other	 viruses	 from	 the	
Bunyaviridae	family	in	a	number	of	cell-lines	derived	from	different	mammalian	species.	 Thus	 indicating	 that	 addition	 of	 IFN	 inhibitors	 could	 aid	 in	 practical	applications	 such	 as	 vaccine	 production	 and	 techniques	 to	 isolate	 emerging	viruses.	Furthermore,	we	have	demonstrated	 that	 i)	growth	of	BUN	WT	can	be	significantly	 increased	 in	 cell-lines	where	 species-specific	 constraints	 limit	 IFN	antagonist	function	(PKIBRS2	and	MDCK	cells)	and	ii)	other	host	cell	constraints	aside	 from	 the	 IFN	 response	 limit	 the	 infection	 of	 several	 viruses	 from	 the	
Bunyaviridae	family	in	cell-lines	derived	from	different	mammalian	species.	Thus	demonstrating	 that	 addition	 of	 IFN	 inhibitor	 can	 initiate	 fundamental	 studies	into	 species-specific	 host	 cell	 constraints	 on	 IFN	 antagonists	 as	 well	 as	investigation	 of	 other	 host	 cell	 constraints	 that	 limit	 virus	 growth.	 Together,	these	 findings	highlight	 that	supplementing	 the	media	with	 IFN	 inhibitor	could	
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become	a	 valuable	 technique	 that	 could	 aid	 in	numerous	 aspects	 of	 virological	research.		Following	this	study,	the	IFN	inhibitor,	Rux,	was	used	to	aid	characterisation	of	several	 IFN-sensitive	 viral	mutants	 following	 their	 isolation	 using	 FACS.	 In	 the	following	 chapters,	 we	will	 discuss	 the	 development	 of	 this	method	 to	 isolate	IFN-sensitive	mutants	 using	 FACS	 and	 the	 subsequent	 characterisation	of	 each	IFN-sensitive	viral	mutant.				
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4 Chapter	4	
4.1 Development	of	A	Novel	Method	to	Isolate	IFN-Sensitive	Viruses	Using	
FACS			
4.1.1 Introduction	and	aims			Circumventing	 the	 host	 IFN	 response	 is	 an	 essential	 component	 of	 all	 viruses,	with	 most	 viruses	 producing	 at	 least	 one	 IFN	 antagonist.	 Consequently,	 this	opens	up	opportunities	 for	prophylactic	 intervention	 through	 the	development	of	‘IFN-sensitive’	viruses	as	attenuated	virus	vaccines.	Current	methods	to	obtain	live	attenuated	vaccines	include	i)	traditional	methods	such	as	serial	passage	of	the	 virus	 in	 a	 foreign	 host	 or	 at	 abnormal	 temperatures	 or	 ii)	 rational	 design.	However,	traditional	methods	can	be	lengthy	and	rational	design	can	result	in	an	over-attenuated	 virus	 that	 is	 not	 viable	 for	 vaccine	 production,	 particularly	 in	RNA	viruses	where	the	IFN	antagonists	are	often	multifunctional	in	nature.	Here	we	aimed	to	develop	a	novel	method	to	rapidly	select	IFN-sensitive	viruses	from	stocks	 of	 paramyxoviruses	 using	 flow	 cytometry,	 utilizing	 PIV5	 as	 our	experimental	model	for	defining	parameters	of	selection.	This	method	would	not	only	 speed	 the	 process	 of	 traditional	 methods	 but	 also	 allow	 selection	 of	naturally	occurring	mutant	viruses	within	the	population.	Primarily,	this	method	would	further	our	understanding	of	paramyxoviruses	and	their	interaction	with	the	 IFN	 response.	 Specifically,	 we	 would	 expect	 that	 mutations	 would	 occur	within	the	IFN	antagonist	V	protein.	This	would	potentially	allow	us	to	map	areas	within	 the	 IFN	 antagonist	where	 no	 function	 had	 been	 assigned	 and	 give	 us	 a	greater	 understanding	 of	 structural	 and	 functional	 relationships	 of	 the	antagonist.	Furthermore,	we	may	also	 find	mutations	within	other	areas	of	 the	
Chapter	4:	Development	of	A	Novel	Method	to	Isolate	IFN-sensitive	Viruses	Using	FACS		
	 102	
viral	 genome.	 This	 would	 allow	 us	 to	 gain	 insight	 into	 other	 aspects	 of	 the	biology	 of	 these	 viruses,	 such	 as	 the	 control	 of	 virus	 transcription	 and	replication.	 In	 summary,	 not	 only	 would	 this	 method	 lead	 to	 insights	 into	paramyxovirus	 interactions	 with	 the	 IFN	 system	 but	 it	 may	 also	 have	applications	 in	 vaccine	manufacture	 as	 the	 IFN-sensitive	 viruses	 obtained	may	be	 further	 developed	 as	 potential	 IFN-sensitive	 live	 attenuated	 vaccine	candidates.	
4.1.2 Method	concept	To	 develop	 this	method	we	 utilized	 the	 IFN-responsive	 GFP	 reporter	 cell-line,	A549/pr(ISRE).GFP,	which	as	 explained	previously,	was	engineered	within	our	laboratory	 to	 contain	 a	GFP	gene	under	 the	 control	 of	 the	Mx1	promoter.	This	promoter	 contains	 an	 ISRE,	 which	 is	 the	 universal	 element	 found	 in	 the	promoters	 of	 hundreds	 of	 ISGs.	 Hence,	 upon	 activation	 of	 the	 IFN	 signalling	pathway,	 via	 addition	 of	 IFN,	 this	 promoter	 is	 activated	 and	 results	 in	 the	expression	 of	 GFP.	 The	 basic	 method	 concept	 used	 to	 isolate	 IFN-sensitive	viruses	 using	 these	 cells	 is	 outlined	 in	 Figure	 4.1.	 Briefly,	 A549/pr(ISRE).GFP	cells	would	be	infected	using	a	stock	of	the	paramyxovirus	PIV5	and	then	treated	with	 IFN	 to	optimally	 activate	 the	 IFN	 signalling	pathway	and	 subsequent	GFP	expression.	The	cells	would	then	be	analysed	by	FACS	and	sorted	based	on	GFP	expression.	As	the	wild-type	virus	blocks	IFN	signalling	via	the	IFN	antagonist	V	protein,	GFP	expression	would	also	be	blocked.	Consequently,	GFP	negative	cells	would	be	discarded,	as	they	would	be	infected	with	a	wild-type	virus.	In	contrast,	GFP	positive	cells	may	be	infected	with	an	IFN-sensitive	attenuated	virus	unable	to	block	 the	 IFN	signalling	pathway	due	 to	 either	mutation	 in	 the	V	protein	or	
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mutations	elsewhere	in	the	viral	genome	(e.g.	those	that	slow	virus	replication).	These	 GFP	 positive	 cells	 could	 then	 be	 selected	 and	 sorted	 onto	 preformed	monolayers	of	cells	in	96	well	micro-titre	plates	for	isolation	of	potentially	IFN-sensitive	mutant	viruses	unable	to	block	IFN	signalling.	
					 		
Figure	 4.1:	 Method	 concept	 to	 isolate	 IFN-sensitive	 viruses	 using	 FACS.	Following	infection	of	A549/pr(ISRE).GFP	cells	with	the	paramyxovirus	PIV5	and	subsequent	 treatment	 with	 IFN,	 cells	 are	 then	 subjected	 to	 FACS	 analysis	 and	sorted	based	on	GFP	expression.	If	the	cell	is	infected	with	a	wild-type	virus,	then	the	 viral	 IFN	 antagonist	 V	 protein	 blocks	 the	 IFN	 signalling	 pathway	 and	subsequent	expression	of	GFP	following	IFN	treatment.	If	the	cell	is	infected	with	an	IFN-sensitive	virus,	then	this	virus	is	unable	to	block	the	activation	of	the	IFN	signalling	pathway	and	consequently,	GFP	is	expressed	following	addition	of	IFN.	GFP	 negative	 cells	 will	 be	 discarded	while	 the	 GFP	 positive	 cells	 selected	 and	sorted	 in	 96	 well	 micro-titre	 plates	 during	 FACs	 analysis	 for	 isolation	 of	potentially	 IFN-sensitive	 mutant	 viruses	 unable	 to	 block	 IFN	 signalling.
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Following	 the	 creation	of	 this	method	concept	 it	was	evident	 that	a	number	of	elements	within	the	method	would	require	optimisation.	The	optimisation	of	this	method	concept	is	therefore	discussed	further	in	the	following	section.			
4.1.3 Optimisation	of	the	method	concept	
4.1.3.1 Optimising	the	time	of	IFN	treatment	following	infection	A	number	of	 steps	 in	 the	method	concept	 required	optimisation.	Firstly,	 it	was	important	to	determine	the	optimum	time	to	treat	cells	with	IFN	following	their	infection	 with	 PIV5.	 IFN	 addition	 is	 required	 to	 up-regulate	 GFP	 expression	following	 infection	allowing	us	 to	determine	 if	 the	 cell	 is	 infected	with	an	 IFN-sensitive	virus	or	not.	However,	if	IFN	is	added	too	early,	then	cells	may	start	to	produce	GFP,	 indicating	an	active	 IFN	signalling	 response,	before	 the	virus	has	had	time	to	block	IFN	signalling.	As	GFP	has	a	half-life	of	around	26hours	(Corish	&	Tyler-Smith	1999),	 then	this	could	result	 in	cells	being	positive	 for	GFP	even	though	they	might	have	been	 infected	by	a	wild-type	virus.	Subsequently	 these	cells	would	be	selected	as	 false	positives.	By	contrast,	 if	 IFN	were	added	much	later,	 then	 the	 length	 of	 the	 experiment	 would	 have	 to	 be	 increased	 to	 allow	sufficient	time	for	the	 induction	of	GFP.	Consequently,	 this	may	mean	that	cells	infected	 with	 IFN-sensitive	 viruses	 may	 subsequently	 become	 infected	 with	progeny	virus,	 including	wild-type	viruses,	 from	other	 infected	cells	within	 the	population.	It	was	therefore	important	to	identify	the	optimum	timeframe	to	add	IFN.		To	 analyse	 the	 optimum	 time	 to	 add	 IFN,	 GFP	 expression	 was	 monitored	following	 mock	 or	 PIV5	 CPI+	 infection	 combined	 with	 treatment	 of	 IFN	
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(1x104Units/ml)	 at	 different	 time	 points	 post	 infection	 (Figure	 4.2).	 Note	 here	that	 this	 analysis	 was	 carried	 out	 using	 PIV5	 CPI+,	 a	 wild-type	 strain	 of	 PIV5	commonly	 used	within	 the	 laboratory.	 Following	mock	 infection,	maximal	 GFP	expression	 (>93%)	 was	 observed	 after	 16-24	 hours	 IFN	 treatment.	 Following	PIV5	CPI+	infection	at	MOI	5	all	cells	should	be	infected	and	block	the	expression	of	GFP,	however,	12%	of	 cells	 express	GFP	 following	 IFN	 treatment	at	0	hours	post	infection	(PI).	This	then	dropped	to	below	5%	if	IFN	was	added	at	4,8	or	12	hours	PI.	 It	was	therefore	decided	to	add	IFN	6-8	hours	PI	to	allow	infection	to	establish	and	then	to	incubate	with	IFN	overnight	for	18hours	to	allow	maximal	GFP	expression	within	a	24hour	experimental	timeframe.	
		
Figure	4.2:	Determining	the	optimum	time	to	treat	cells	with	IFN	following	
infection.	A549/pr(ISRE).GFP	cells	were	mock	 infected	and	 infected	with	PIV5	CPI+	at	MOI	5	for	1	hour	before	addition	of	IFN	at	0,	4,	8	and	12	hours	PI.	Cells	were	then	collected	24hours	PI	and	immunostained	for	PIV5	HN	protein	before	analysis	 for	GFP	using	 flow	 cytometry.	Gating	was	 applied	using	 the	untreated	(U/T)	 sample	 as	 the	 no	 fluorescence	 control.	 (Data	 representative	 of	 two	independent	repeats).	 	
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4.1.3.2 Generation	 of	 the	 A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	 to	 create	 a	more	
suitable	environment	to	propagate	IFN-sensitive	viruses	Initially	 A549/pr(ISRE).GFP	 cells	 were	 used	 in	 our	 method	 to	 isolate	 IFN-sensitive	viruses.	However,	 it	was	quickly	realised	that	upon	addition	of	 IFN	to	these	cells,	to	induce	GFP	expression	following	infection,	hundreds	of	ISGs	would	also	be	expressed	creating	an	antiviral	state	within	the	infected	cells.	This	would	therefore	create	a	difficult	environment	for	an	attenuated	virus	to	propagate.	To	tackle	this	issue	we	further	developed	the	A549/pr(ISRE).GFP	cell-line	to	create	a	 cell-line	 that	was	more	 suitable	 to	 propagate	 IFN-sensitive	 viruses.	 Previous	studies	have	shown	that	expression	of	ISG56	is	primarily	responsible	for	the	IFN-induced	inhibition	of	PIV5	replication	(Andrejeva	et	al.	2013;	Young	et	al.	2016).	We	 therefore	 used	 a	 lentivirus	 expressing	 shRNA	 to	 ISG56	 to	 knockdown	expression	 of	 ISG56	 in	A549/pr(ISRE).GFP	 cells.	 In	 addition,	we	 reasoned	 that	infection	 with	 an	 IFN-sensitive	 virus	 might	 also	 rapidly	 activate	 the	 IFN	induction	 pathway	 resulting	 in	 production	 of	 IFN,	 before	 the	 addition	 of	exogenous	IFN.	As	this	might	have	also	inhibited	the	replication	of	IFN-sensitive	attenuated	viruses	we	 further	 engineered	 the	 cell	 line	 so	 that	 it	was	unable	 to	produce	 IFN.	 Previously,	 BVDV	 NPro	 protein	 has	 been	 shown	 to	 block	 IFN	induction	by	targeting	IRF3	for	proteasomal	degradation	(Hilton	et	al.	2006).	We	therefore	 created	a	dual	 cell-line	 that	 constitutively	 expressed	BVDV	Npro	and	shRNA	 targeting	 ISG56	 (Figure	4.3).	Analysis	of	 the	newly	engineered	cell-line,	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro,	demonstrated	that	IFN	still	induced	the	expression	of	GFP	in	this	cell-line	(Figure	4.3A).	Furthermore,	BUNΔNSs	plaqued	on	the	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	but	not	 in	 the	parental	cell-line,	A549/pr(ISRE).GFP	 (Figure	 4.3B).	 As	 BUNΔNSs	 does	 not	 replicate	 in	 cells	 that	
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can	 produce	 and	 respond	 to	 IFN	 (Hilton	 et	 al.	 2006),	 this	 result	 shows	 that	constitutive	 expression	 of	 BVDV/Npro	 in	 these	 cells	 has	 knocked	 out	 the	 IFN	system	 as	 predicted.	 Lastly,	 knockdown	 of	 ISG56	 using	 shRNA	 facilitated	 the	replication	of	the	ISG56-sensitive	strain	of	PIV5,	termed	CPI-	(Chatziandreou	et	al.	 2002),	 within	 cells	 pre-treated	 with	 IFN	 (Figure	 4.3C).	 In	 summary,	 these	changes	 provide	 a	 more	 suitable	 environment	 for	 IFN-sensitive	 viruses	 to	propagate	by	preventing	the	antiviral	responses	that	may	inhibit	the	replication	of	IFN-sensitive	mutants	of	PIV5.		 	
Chapter	4:	Development	of	A	Novel	Method	to	Isolate	IFN-sensitive	Viruses	Using	FACS		
	 108	
	
	
Figure	 4.3:	 A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cell-line	 analysis.	 A)	A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells	 were	 (+)	 or	 were	 not	 (-)	 treated	with	IFN		for	48	hours	before	GFP	images	were	taken	using	an	EVOS	microscope	at	10x	magnification.	B)	Plaque	development	of	the	IFN-sensitive	virus	BUNΔNSs	was	 compared	 in	 A549/pr(ISRE).GFP	 and	 A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells.	Cells	were	then	fixed	3	days	post	infection	and	stained	using	CV	stain	
C)	 A549/pr(ISRE).GFP	 and	 A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells	 were	(+)	 or	 were	 not	 (-)	 pre-treated	 for	 8	 hours	 with	 IFN	 before	 cells	 were	 mock	infected	or	 infected	with	PIV5	CPI-	 at	MOI	5.	 Samples	were	 then	harvested	18	hours	post	 infection	and	analysed	by	western	blot	 for	 ISG56,	MxA,	PIV5	NP	an	Actin.		
A549/pr(ISRE).GFP/ISG56-/BVDV	Npro		
-	
+	
IF
N
	
A	
ISG56	
MxA		
Ac>n		
A549/pr(ISRE).GFP		
ISG56-/	BVDV	Npro	
CPI-	 CPI-	
IFN	 -	 +	 +	 +	 +	-	 -	 -	
PIV5	NP	
C	
A549/pr(ISRE)	.GFP		
ISG56-/	BVDV	Npro	
BU
N
ΔN
Ss
	
B	
Chapter	4:	Development	of	A	Novel	Method	to	Isolate	IFN-sensitive	Viruses	Using	FACS		
	 109	
4.1.3.3 Use	 of	 rPIV5mCh	 virus	 to	 distinguish	 between	 uninfected	 cells	 and	 cells	
infected	with	a	virus	unable	to	block	IFN	signalling	Rationally,	it	was	decided	to	infect	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	with	virus	at	an	MOI	0.5	so	that	it	would	be	unlikely	that	the	same	cell	would	be	infected	 with	 more	 than	 one	 virus.	 However,	 at	 an	 MOI	 0.5,	 according	 to	Poisson’s	distribution,	around	60%	of	the	cells	in	this	population	would	remain	uninfected.	We	 therefore	 needed	 a	way	 to	 distinguish	 between	 cells	 that	were	GFP	 positive,	 because	 they	 were	 uninfected	 and	 those	 that	 were	 GFP	 positive	because	 they	had	been	 infected	with	a	virus	unable	 to	block	 IFN	signalling.	To	initially	tackle	this	issue,	we	used	a	recombinant	PIV5	virus,	termed	rPIV5mCh,	in	which	a	gene	expressing	the	mCherry	fluorescent	protein	(mCherry)	had	been	inserted	 between	 the	 HN	 and	 L	 genes	 in	 the	 viral	 genome.	 Theoretically,	 this	would	allow	us	to	easily	distinguish	between	uninfected	cells	and	cells	 infected	with	a	potentially	IFN-sensitive	virus;	as	uninfected	cells	would	be	positive	only	for	 GFP	whereas	 cells	 infected	with	 a	 potentially	 IFN-sensitive	 virus	would	 be	positive	for	both	GFP	and	mCherry.	This	method	is	summarised	in	Figure	4.4.	
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Figure	 4.4:	 Method	 outline	 for	 isolation	 of	 IFN-sensitive	mutants	 viruses	
from	rPIV5mCh.	Following	infection	of	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	with	rPIV5mCh	and	subsequent	treatment	with	IFN,	cells	are	then	subjected	to	FACS	analysis	and	three	different	fluorescent	outcomes	are	identified	i)	If	the	cell	 remains	 uninfected	 then	 the	 IFN	 signalling	 pathway	 is	 activated	 following	IFN	 treatment	and	 the	 cell	produces	GFP.	 ii)	 If	 the	 cell	 is	 infected	with	a	wild-type	rPIV5mCh	virus,	the	viral	IFN	antagonist	V	protein	blocks	the	IFN	signalling	pathway	and	subsequent	expression	of	GFP	following	IFN	treatment.	These	cells	are	therefore	mCherry	positive	but	GFP	negative	iii)	If	the	cell	is	infected	with	a	
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potentially	IFN-sensitive	virus,	then	this	virus	is	unable	to	block	the	activation	of	the	 IFN	 signalling	 pathway	 and	 consequently,	 GFP	 is	 expressed	 following	addition	 of	 IFN.	 These	 cells	 are	 therefore	 positive	 for	 mCherry	 and	 for	 GFP	expression.	Consequently,	GFP	positive	only	and	mCherry	positive	only	cells	will	be	discarded	while	the	GFP	and	mCherry	dual	positive	cells	selected	and	sorted	in	 96	 well	 micro-titre	 plates	 during	 FACs	 analysis	 for	 isolation	 of	 potential	mutant	viruses	unable	to	block	IFN	signalling.		
4.1.3.4 Use	 of	 neutralising	 antibody	 to	 inactivate	 progeny	 viruses	 released	 from	
infected	cells		During	 analysis	 of	 rPIV5mCh	 infected	 cells	 it	 was	 noted	 that	 the	 intensity	 of	mCherry	 fluorescence	 varied	widely	 from	 cell	 to	 cell	 (Figure	 4.5,	 panel	 A).	 As	mCherry	expression	 is	used	as	a	marker	 for	 infection,	 this	 indicated	 that	 there	was	variation	in	the	stage	of	infection	within	the	population	of	cells	analysed.	It	was	 therefore	 hypothesised	 that	 cells	 were	 becoming	 infected	 at	 later	 stages	during	the	experiment	due	to	the	release	of	progeny	viruses	from	the	originally	infected	 cells.	 This	 problem	 could	 result	 in	 false	 positives,	 as	 cells	 already	expressing	 GFP	 due	 to	 IFN	 treatment	may	 subsequently	 become	 infected	with	progeny	wild-type	viruses,	 resulting	 in	 the	cell	becoming	positive	 for	both	GFP	and	mCherry.	 To	 solve	 this	 problem	 high	 titres	 of	 neutralizing	 antibody	were	added	 to	 each	 sample	 during	 the	 experiment	 (PIV5	 anti-HN	 and	 anti-F	antibodies),	thereby	inactivating	any	progeny	virus	from	the	infected	cells.	Such	a	procedure	 enabled	us	 to	 clearly	distinguish	between	 infected	 and	uninfected	cells	 (Figure	 4.5,	 compare	 panels	 A	 and	 B).	 Next,	 rPIV5mCh	 infected	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	were	incubated	in	the	presence	of	
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IFN	 in	 combination	with	 the	 presence	 and	 absence	 of	 neutralising	 antibody	 (-/+Ab)	 (Figure	 4.5,	 compare	 panels	 C	 and	 D).	 As	 observed	 previously,	 in	 the	absence	of	neutralizing	antibody	there	is	a	wide	range	of	mCherry	fluorescence	intensities	seen	 following	 infection	and	subsequent	 IFN	treatment.	However,	 in	the	 presence	 of	 neutralizing	 antibody	 the	 four	 populations	 of	 cells	 are	 clearly	defined	 i.e.	 non-fluorescent	 cells	 in	 Q4,	 cells	 infected	with	 wild-type	 virus	 Q1,	dual	 fluorescent	 cells	 potentially	 infected	 with	 viruses	 unable	 to	 block	 IFN	signalling	 in	 Q2	 and	 uninfected	 cells	 in	 Q3.	 Thus,	 the	 presence	 of	 neutralizing	antibody	has	reduced	the	number	of	false	positive	cells	by	neutralizing	progeny	virus	 released	 by	 initial	 infection.	 In	 summary,	 the	 optimized	 concept	 for	isolating	mutant	PIV5	viruses	unable	to	block	IFN	signalling	 is	shown	in	Figure	4.6.				
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Figure	4.5:	Addition	of	neutralising	antibody	to	inactivate	progeny	viruses	
released	by	infected	cells.	A549/pr(ISRE).GFP/	ISG56-/	BVDV	Npro	cells	were	infected	 at	 MOI	 0.5	 for	 1	 hour	 on	 a	 rocking	 platform	 in	 5%	 CO2	 at	 37°C.	 The	inoculum	was	 then	 removed,	 cells	washed	with	 PBS	 and	 replaced	with	 serum	free-media.	 After	 6	 hours,	 a	 mixture	 of	 anti-HN	 antibody	 and	 F	 monoclonal	antibodies	and/or	 IFN	treatment	was	added	as	 indicated	(-/	+	Ab	and	-	/+	 IFN	respectively).	After	24	hours,	single	cell	suspensions	were	made	from	rPIV5mCh	infected	cells	incubated	in	the	absence	of	antibody	and	IFN	(panel	A,	-Ab,	-IFN),	in	the	presence	of	neutralizing	antibody	(panel	B,	+Ab,	-IFN),	in	the	presence	of	IFN	(panel	C,	 -Ab,	+IFN)	and	 in	 the	presence	of	both	neutralizing	antibody	and	IFN	(panel	D	+Ab,	+IFN)	prior	to	FACS	analysis.		
rPIV5mCh	(-Ab,	 -IFN)	 rPIV5mCh	(+Ab,	-IFN)	
rPIV5mCh	(-Ab,	 +IFN)	 rPIV5mCh	(+Ab,	+IFN)	
BA
C D
m
Ch
er
ry
	ex
pr
es
sio
n
GFP	expression
Chapter	4:	Development	of	A	Novel	Method	to	Isolate	IFN-sensitive	Viruses	Using	FACS		
	 114	
	
Figure	4.6:	Optimised	method	concept	for	isolation	of	IFN-sensitive	viruses	
from	 rPIV5mCh	 via	 FACS.	 Initially,	 A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	cells	are	infected	with	rPIV5mCh	at	MOI	0.5.	Following	6-8h,	IFN	and	a	mixture	of	PIV5	anti-HN	and	anti-F	antibodies	are	added	to	initiate	GFP	expression	and	to	neutralise	 progeny	 viruses,	 respectively.	 Following	 24h,	 GFP	 and	 mCherry	positive	 cells	 are	 then	 selected	 and	 sorted	 onto	 96	 well	 plates	 containing	A549/pr(ISRE).GFP/	 ISG56-/	 BVDV	 Npro	 cells,	 to	 facilitate	 the	 growth	 and	isolation	of	mutant	viruses	unable	to	block	IFN	signalling.		
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5 Chapter	5	
5.1 Isolation	of	potentially	IFN-sensitive	mutant	viruses	using	FACS	
5.1.1 FACS	analysis	and	selection	of	potentially	IFN-sensitive	mutant	viruses	from	
rPIV5mCh		Following	optimisation,	we	then	implemented	this	method	to	isolate	potentially	IFN-sensitive	 mutant	 viruses	 from	 rPIV5mCh.	 A	 total	 of	 four	 samples	 were	prepared,	three	control	samples	plus	one	experimental	sample.	The	three	control	samples	consisted	of	mock	infected	A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	that	were	 (+)	or	were	not	 (-)	 treated	with	 IFN	 (1x104Units/ml)	and	rPIV5mCh	infected		A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells	that	were	not	treated	with	IFN	 (-IFN).	 The	 experimental	 sample	 consisted	 of	 rPIV5mCh	 infected	A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells	 treated	 with	 IFN	 which	 would	subsequently	 be	 used	 for	 selection	 of	 cells	 containing	potentially	 IFN-sensitive	mutant	viruses.			Examination	of	the	mock	infected	controls	 indicated	that	 in	the	absence	of	IFN,	all	 cells	 were	 GFP	 and	 mCherry	 negative	 (Figure	 5.1,	 panel	 A)	 and	 in	 the	presence	 of	 IFN,	 95%	 of	 cells	 were	 GFP	 positive	 (Figure	 5.1,	 panel	 B).	Importantly,	these	two	controls	demonstrated	that	the	cells	were	uninfected	and	remained	 responsive	 to	 IFN	 in	 the	 absence	 of	 infection.	 Examination	 of	 the	rPIV5mCh	 infected	 control,	 indicated	 that	 in	 the	 absence	 of	 IFN,	 24%	 of	 cells	were	mCherry	positive	only	(P14-Q1)	and	the	rest	(76%)	of	the	cells	were	both	GFP	 and	 mCherry	 negative	 (P14-Q4)	 (Figure	 5.1,	 panel	 C).	 Importantly,	 this	control	demonstrates	that	infection	leads	to	the	production	of	mCherry	but	does	
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not	induce	IFN	signalling	and	subsequent	GFP	expression.	Following	analysis	of	the	 controls,	 the	 experimental	 sample	was	 then	 used	 to	 select	 cells	 that	 could	contain	 potentially	 IFN-sensitive	 mutant	 viruses	 (Figure	 5.1,	 panel	 D).	Specifically,	 21%	of	 cells	 in	 this	 sample	were	mCherry	 positive	 only	 (P14-Q1),	70%	 of	 cells	were	 GFP	 positive	 only	 (P14-Q3)	 and	 a	 further	 9%	 of	 cells	were	both	GPF	and	mCherry	negative	 (P14-Q4).	 	The	 latter	 indicates	 that	 these	cells	were	infected	with	a	virus	that	is	unable	to	produce	mCherry,	which	can	occur	if	the	 recombinant	 virus	 mutates	 so	 that	 it	 no	 longer	 expresses	 mCherry.	 Most	importantly,	1%	of	cells	were	positive	for	both	GFP	and	mCherry	(P14-Q2).	This	indicated	that	these	cells	could	contain	a	potentially	IFN-sensitive	mutant	virus,	as	the	 infecting	virus	could	not	block	GFP	expression.	Consequently,	 these	cells	were	 selected	 and	 single	 cell	 sorted	 into	 96	well	micro-titer	 plates	 containing	confluent	 monolayers	 of	 A549/pr(ISRE).GFP/ISG56-/Npro	 cells	 that	 facilitate	the	 growth	 and	 isolation	 of	 IFN-sensitive	 viruses.	 These	 plates	 were	 then	incubated	for	3-4	days	to	allow	virus	amplification	for	further	analysis,	which	is	outlined	in	the	following	section.			
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Figure	5.1:	FACS	analysis	and	selection	of	potentially	IFN-sensitive	mutant	
viruses	 from	 rPIV5mCh.	 A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells	 were	mock	infected	or	infected	with	rPIV5mCh	virus	at	MOI	0.5	for	1h.	Virus	inoculum	was	 then	 removed,	 cells	washed	with	 PBS	 and	 incubated	 in	 SF	media.	 After	 6	hours,	a	mixture	of	PIV5	anti-HN	and	anti-F	neutralizing	antibody	was	added	to	all	 samples	 and	 cells	 were	 treated	 with	 or	 without	 IFN	 as	 indicated	 (-/+IFN).	After	 24hours,	 single	 cell	 suspensions	 were	 made	 from	 mock	 infected	 cells	(panel	A,	 -IFN),	mock	 infected	 cells	 incubated	 in	 the	 presence	 of	 IFN	 (panel	B,	+IFN),	 rPIV5mCh	 infected	 cells	 (panel	 C,	 -IFN)	 and	 rPIV5mCh	 infected	 cells	incubated	 in	 the	 presence	 of	 IFN	 (panel	 D,	 +IFN).	 Each	 sample	 was	 then	subjected	to	FACS	analysis.	Cells	from	panel	D	P14-Q2	were	then	sorted	into	96	well	 plates	 containing	 confluent	 monolayers	 of	 A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells.	(Data	representative	of	two	independent	repeats).	
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5.1.2 Selection	of	potentially	IFN-sensitive	mutants	Having	 selected	 and	 sorted	 GFP	 and	 mCherry	 positive	 cells	 onto	 preformed	monolayers	 of	 A549/pr(ISRE).GFP/ISG56-/Npro	 cells	 and	 incubating	 these	plates	 for	3-4	days,	next	we	needed	 to	determine	which	monolayers	 contained	potentially	 IFN-sensitive	 mutant	 viruses.	 The	 primary	 rationale	 for	 using	preformed	monolayers	of	A549/pr(ISRE).GFP/ISG56-/Npro	cells	was	that	these	cells	 allowed	 a	 suitable	 environment	 for	 IFN-sensitive	 viruses	 to	 propagate,	however,	 they	 were	 also	 essential	 to	 enable	 us	 to	 identify	 potentially	 IFN-sensitive	 mutants	 following	 their	 incubation.	 Specifically,	 the	 supernatant	containing	 virus	 was	 harvested	 from	 each	 well	 and	 stored	 in	 a	 fresh	 96	 well	micro-titer	 plate	 at	 -80°C.	 Subsequently,	 IFN	 was	 added	 to	 the	 remaining	infected	 monolayers	 and	 incubated	 for	 18	 hours.	 Each	 monolayer	 was	 then	examined	 for	 the	 presence	 of	 GFP	 and	mCherry	 using	 fluorescent	microscopy.	Three	distinct	fluorescent	outcomes	then	allowed	us	to	determine	differences	in	viral	 infection	 of	 the	 monolayer	 (Figure	 5.2).	 The	 first	 outcome	 was	 that	 the	monolayer	was	GFP	positive	only.	This	indicated	that	the	cells	were	uninfected,	potentially	 because	 the	 sorted	 cell	 died.	 The	 second	 was	 that	 the	 cells	 were	positive	 for	 mCherry	 but	 negative	 for	 GFP	 expression	 indicating	 that	 the	monolayer	 was	 infected	 with	 a	 wild-type	 virus	 or	 that	 it	 was	 infected	 with	 a	mutant	 virus	 unable	 to	 block	 IFN	 signalling	 that	 had	 subsequently	 reverted	 to	wild-type.	The	 final	outcome	was	 that	 the	well	was	mCherry	and	GFP	positive,	indicating	 that	 the	 monolayer	 was	 infected	 with	 a	 potentially	 IFN-sensitive	mutant	 virus	 unable	 to	 block	 IFN-signalling.	 During	 the	 first	 experiment,	 8	potentially	 IFN-sensitive	 viruses	 were	 identified	 from	 two	 96	well	 plates.	 The	experiment	was	then	repeated	and	a	further	25	potentially	IFN-sensitive	viruses	
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were	identified	from	six	96	well	plates.	Thus	providing	us	with	an	approximate	yield	of	4	%	from	each	sort.	The	corresponding	viruses	were	then	selected	from	the	 96	 well	 micro-titer	 plates	 stored	 previously	 in	 -80°C	 and	 amplified	 using	Vero	cells.	
	
Figure	 5.2:	 Examples	 of	 the	 three	 potential	 outcomes	 following	 sorting.	Monolayers	of	A549/pr(ISRE).GFP/	ISG56-/	BVDV	Npro	cells	were	seeded	with	single	A549/pr(ISRE).GFP/	ISG56-/	BVDV	Npro	cells	that	were	either	uninfected,	infected	 with	 rPIV5mCh	 wild-type	 virus	 or	 infected	 with	 an	 rPIV5mCh	potentially	IFN-sensitive	mutant	virus	following	FACS	analysis.	The	monolayers	were	 then	 incubated	 for	3-4	days	before	 the	 supernatant	 containing	virus	was	removed	and	IFN	treatment	was	added	for	18hours.	Cells	were	then	analysed	for	GFP	and	mCherry	expression	and	 images	 taken	using	a	 fluorescent	microscope	(EVOS;	10x	Magnification).		
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5.1.3 Confirmation	 of	 potentially	 IFN-sensitive	 rPIV5mCh	 mutants	 using	 FACS	
analysis		To	 determine	 if	 the	 selected	 viruses	 did	 in	 fact	 display	 an	 IFN-sensitive	 virus	phenotype	 and	 ultimately	 select	 which	 viruses	 would	 be	 taken	 forward	 for	sequencing,	each	stock	of	potentially	IFN-sensitive	virus	was	analysed	by	FACS.	Specifically,	 A549/pr(ISRE).GFP/ISG56-/Npro	 cells	 were	 infected	 with	 each	 of	the	32	newly	generated	virus	stocks	in	the	same	manner	to	the	original	selection	experiment	 and	 subjected	 to	 FACS	 analysis.	 Note	 to	 expedite	 the	 process	 of	mutant	 virus	 identification,	 mutant	 virus	 stocks	 were	 not	 titered	 for	 this	analysis.	Interestingly,	FACS	analysis	of	the	potential	mutants	demonstrated	two	different	phenotypes	(Figure	5.3,	compare	panels	D	and	E).	The	first	phenotype,	attenuated	mutant	 phenotype	 1,	 demonstrated	 that	 all	 cells	 infected	 (mCherry	positive)	were	also	GFP	positive,	clearly	indicating	that	the	virus	was	unable	to	block	 IFN	 signalling.	 By	 contrast,	 the	 second	 phenotype,	 attenuated	 mutant	phenotype	 2,	 demonstrated	 a	 ‘smear’	 of	 infected	 cells	 expressing	 various	intensities	of	GFP.	This	indicated	that	this	virus	was	not	definitively	able	to	block	the	IFN	signalling	response.	Note	that	infection	by	two	different	viruses	was	not	ruled	out	but	deemed	unlikely	as	simultaneous	infection	by	a	wild	type	virus	and	a	 virus	 displaying	 attenuated	 mutant	 phenotype	 1	 resulted	 in	 two	 distinct	populations,	 infected	 GFP	 negative	 and	 infected	 GFP	 positive,	 rather	 than	 a	‘smear’	of	 infected	cells	expressing	various	 intensities	of	GFP	(Figure	5.3,	panel	F).	Furthermore,	the	population	could	not	be	enriched	by	re-selection	of	the	dual	positive	cells,	which	can	be	achieved	when	 two	differing	 infections	are	present	(Data	 not	 shown),	 thus	 indicating	 that	 one	 population	 of	 virus	 exhibited	 the	phenotype.	 Following	 this	 analysis,	 a	 total	 of	 28	 out	 of	 33	 potentially	 IFN-
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sensitive	 mutant	 viruses	 were	 taken	 forward	 for	 sequencing,	 with	 26	demonstrating	 the	 attenuated	 mutant	 phenotype	 1,	 and	 2	 demonstrating	attenuated	mutant	phenotype	2.	The	other	5	potential	mutants	were	disregarded	as	each	demonstrated	a	wild-type	infection	phenotype.		
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Figure	 5.3:	 FACS	 analysis	 of	 potentially	 IFN-sensitive	 mutant	 viruses.	A549/pr(ISRE).GFP/	 ISG56-/	 BVDV	 Npro	 cells	 were	mock	 infected	 or	 infected	with	rPIV5mCh	or	a	potentially	IFN-sensitive	mutant	virus	at	an	MOI	0.5	for	1h.	Virus	 Inoculum	was	 then	 removed,	 cells	washed	with	PBS	and	 incubated	 in	SF	media.	After	6hours,	a	mixture	of	PIV5	anti-HN	and	anti-F	neutralizing	antibody	was	added	to	all	samples	and	cells	were	treated	with	or	without	IFN	as	indicated	(-/+IFN).	 After	 24hours,	 single	 cell	 suspensions	 were	 prepared	 from	 mock	infected	 cells	 (panel	 A,	 -IFN),	mock	 infected	 cells	 incubated	 in	 the	 presence	 of	IFN	 (panel	 B,	 +IFN),	 rPIV5mCh	 infected	 cells	 incubated	 in	 the	 presence	 of	 IFN	(panel	 C,	 +IFN),	 potentially	 IFN-sensitive	 mutant	 virus	 infected	 cells	 that	represent	 an	 example	 of	 attenuated	 mutant	 phenotype	 1	 (panel	 D,	 +IFN),	potentially	IFN-sensitive	mutant	virus	infected	cells	that	represent	an	example	of	attenuated	mutant	phenotype	2	 (panel	E,	 +IFN)	 and	 rPIV5mCh	and	potentially	IFN-sensitive	mutant	virus	infected	cells	(attenuated	mutant	phenotype	1;	panel	F,	+IFN).	Each	suspension	was	then	analysed	by	FACS	analysis.	
5.1.4 Sequencing	of	the	V/P	gene	from	rPIV5mCh	mutants		The	 28	 potentially	 IFN-sensitive	 viruses	 selected	 via	 FACS	 analysis	 were	 then	sequenced	in	an	attempt	to	identify	mutations	within	the	rPIV5mCh	genome	that	could	contribute	to	their	inability	to	block	IFN	signalling.	As	it	was	expected	that	mutations	 leading	 to	 this	phenotype	would	occur	 in	 the	 viral	 IFN	antagonist	V	protein,	we	first	set	out	 to	sequence	the	V/P	gene	of	each	mutant	 that	encodes	both	the	V	and	P	proteins	due	to	a	process	known	as	‘RNA	editing’.	Notably,	PIV5	V	mRNA	 is	a	 faithful	 transcript	of	 the	V/P	gene,	whereas	 the	P	mRNA	contains	two	non-templated	G	 residues	which	 are	 added	during	 transcription	when	 the	
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viral	 polymerase	 stutters	 on	 a	 specific	 site,	 upstream	 of	 the	 insertion	 site	(reviewed	 in	 Parks	 et	 al	 2011).	 This	 results	 in	 both	 the	 V	 and	 P	 proteins	containing	a	common	N	terminus	but	each	having	a	unique	C	terminus.			To	 sequence	 the	 V/P	 gene	 of	 each	 of	 the	 potentially	 IFN-sensitive	 virus,	 Vero	cells	were	infected	with	each	of	the	viruses	at	MOI	5	and	incubated	for	18	hours	before	RNA	extraction.	Genomic	viral	RNA	was	then	reverse	transcribed	to	cDNA	using	a	primer	targeted	against	the	sequence	flanking	the	downstream	sequence	outside	 of	 the	 V/P	 open	 reading	 frame	 (ORF).	 This	 fragment	 was	 then	 PCR	amplified,	using	the	same	primers	and	blunt	end	cloned	into	the	vector	pJET	1.2.	Colony	 PCR	 using	 primers	 specific	 for	 pJET1.2	was	 then	 completed	 to	 identify	colonies	 containing	 the	 correct	 insert.	 Sequencing	 of	 the	 insert	 was	 then	completed	from	three	individual	positive	colonies	and	sequences	aligned	to	the	published	 PIV5	 W3	 P	 (AFE48445.1)	 and	 V	 gene	 sequences	 (AFE48446.1).	Surprisingly,	26	of	the	28	viruses	sequenced	were	found	to	contain	the	same	set	of	 8	 nucleotide	 mutations,	 subsequently	 named	 rPIV5mCh-α.	 Notably,	 each	 of	these	 mutants	 displayed	 the	 attenuated	 mutant	 phenotype	 1	 during	 FACS	analysis.	 The	 other	 two	 mutants	 contained	 a	 different	 set	 of	 2	 nucleotide	mutations,	 subsequently	 named	 rPIV5mCh-β.	 Notably,	 each	 of	 these	 mutants	displayed	 the	 attenuated	 mutant	 phenotype	 2	 during	 FACS	 analysis.	 Both	rPIV5mCh-α	 and	 rPIV5mCh-β	 nucleotide	 and	 corresponding	 amino	 acid	mutations	are	catalogued	in	Figure	5.4.	To	aid	visualisation,	each	of	these	amino	acid	mutations	was	mapped	relatively	onto	 the	V	and	P	proteins	also	 in	Figure	5.4.		
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Figure	5.4:	Nucleotide	and	amino	acid	mutations	in	V	and	P	genes/proteins	
of	rPIV5mCh-α	and	β.		The	nucleotide	and	corresponding	amino	acid	mutations	in	V	and	P	genes/proteins,	followed	by	an	illustration	of	the	relative	positions	of	the	 amino	 acid	 mutations	 in	 the	 V	 and	 P	 proteins	 are	 demonstrated	 for	rPIV5mCh-α	(panel	A)	and	rPIV5mCh-β	(panel	B).	
	The	 mutant	 rPIV5mCh-α	 contains	 eight	 nucleotide	 changes	 from	 thymine	 to	cytosine	in	the	V/P	gene.	Specifically,	7	of	these	nucleotide	mutations	correspond	to	6	amino	acid	changes	within	the	V	protein	and	5	amino	acid	changes	within	the	P	protein.	Interestingly,	the	5	mutations	found	within	the	region	common	to	both	 the	 V	 and	 P	 gene	 correspond	 to	 4	 amino	 acid	 changes	 from	 Leucine	 to	Proline	(L51P,	L102P,	L122P	and	L132P)	and	the	other	converts	a	Phenylalanine	to	a	Serine	(F135S).	This	was	somewhat	surprising,	as	we	know	that	amino	acid	changes	to	Proline,	which	is	a	cyclic	amino	acid,	can	dramatically	change	protein	structure.	Furthermore	we	know	that	the	P	protein	is	essential	to	viral	synthesis	(Fuentes	 et	 al.	 2010),	 yet	 despite	 these	 mutations	 it	 appears	 that	 this	 viral	mutant	can	replicate	efficiently.	The	final	mutation,	which	is	synonymous	in	the	P	protein	but	non-synonymous	 in	 the	V	protein,	mutates	Tyrosine	 to	Histidine	(Y175H).	In	contrast,	the	rPIV5mCh-β	mutant	contains	only	2	nucleotide	changes	in	 the	 V/P	 gene,	 one	 thymine	 to	 adenine	 and	 one	 adenine	 to	 guanine.	 These	correspond	 to	 2	 amino	 acid	 changes	within	 the	 V	 protein	 and	 one	 amino	 acid	change	within	the	P	protein.	The	mutation	found	in	the	common	region	of	the	V	and	P	protein	mutates	Phenylalanine	to	Isoleucine	(F144I).	The	other	mutation,	which	 is	 synonymous	 in	 the	 P	 protein	 but	 non-synonymous	 in	 the	 V	 protein,	
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mutates	 Threonine	 to	 Alanine	 (T214A).	 Once	 identified,	 each	 of	 the	 V	 protein	amino	acid	mutations	were	mapped	onto	the	V	protein	structure,	unfortunately	no	structure	has	been	solved	for	the	PIV5	P	protein	(Figure	5.5).	This	highlighted	that	rPIV5mCh-α	and	rPIV5mCh-β	mutations	both	appear	in	structured	regions	of	the	V	protein	such	as	beta	sheets	and	alpha	helices.			In	 summary,	 two	 different	 mutant	 viruses	 were	 isolated	 from	 a	 stock	 of	rPIV5mCh	multiple	times	and	both	were	found	to	contain	mutations	with	their	V	and	P	proteins.	Before	we	attempted	to	analyse	these	viruses	further	we	decided	to	try	to	increase	the	total	number	of	potential	mutants	isolated	whilst	adapting	this	method	for	use	with	non-fluorescent	viruses.	This	was	important	as	not	all	viruses	 have	 a	 readily	 available	 recombinant	 expressing	 a	 fluorescent	 protein	and	 we	 wanted	 to	 create	 an	 adaptable	 method	 that	 can	 be	 used	 on	 multiple	viruses.			 	
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Figure	5.5:	Mapping	the	positions	of	amino	acid	mutations	rPIV5mCh-α	and	
rPIV5mCh-β	 to	 the	 wild-type	 V	 protein	 structure	 (Protein	 Data	 Bank	
accession	 number	 2B5L).	 The	 structure	 of	 wild-type	 V	 protein	 with	 the	positions	 of	 rPIV5mCh-α	 (panel	 A)	 and	 rPIV5mCh-β	 (panel	 B)	 mutations	highlighted	(structures	adapted	using	PyMOL	(Schrodinger)).		 	
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5.1.5 Adapting	the	method	to	isolate	viruses	from	PIV5	W3		Having	successfully	isolated	mutants	from	rPIV5mCh,	next	we	decided	to	adapt	this	method	 for	 use	with	 the	 non-fluorescent	 virus	 PIV5	W3,	 a	wild-type	 PIV5	virus	commonly	used	within	our	laboratory.	To	adapt	this	method,	we	added	two	immunostaining	steps	to	track	for	 infected	cells	(Figure	5.6).	The	first	step	was	inserted	 prior	 to	 collection	 of	 the	 cells	 in	 single	 cell	 suspensions	 for	 FACS	analysis.	 Prior	 to	 collection,	 neutralising	 antibody	 targeting	 the	 HN	 and	 F	proteins	 of	 PIV5	 is	 added	 to	 inactivate	 progeny	 virus.	 As	 this	 neutralising	antibody	would	 also	 bind	 to	HN	 and	 F	 viral	 protein	 on	 the	 surface	 of	 infected	cells	 we	 could	 therefore	 take	 advantage	 of	 this	 to	 immunostain	 infected	 cells	using	 secondary	 goat	 anti-mouse	 Texas	 Red	 antibody.	 Cells	 would	 then	 be	prepared	as	single	cell	suspensions	and	analysed	by	FACS	in	the	same	manner	as	rPIV5mCh	infected	cells	with	the	exception	that	GFP	and	Texas	Red	positive	cells	(instead	of	mCherry	positive)	would	be	 selected	and	single	 cell	 sorted	onto	96	well	 plates	 containing	 preformed	 monolayers	 of	 A549/pr(ISRE).GFP/ISG56-/Npro	cells.	Plates	containing	sorted	cells	would	then	be	incubated	for	3-4	days	to	allow	virus	to	propagate.	The	second	immunostaining	step	was	then	inserted	here,	 following	 IFN	 treatment,	 to	 enable	 us	 to	 distinguish	 between	 cells	 that	were	 uninfected	 (GFP	 positive	 only),	 infected	with	wild-type	 virus	 (Texas	 Red	positive	only)	and	infected	with	a	virus	unable	to	block	IFN	signalling	(GFP	and	Texas	Red	positive).	Addition	of	each	of	 these	 steps	 is	highlighted	 in	a	method	workflow	in	Figure	5.6.			
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Figure	5.6:	PIV5	W3	method	workflow	for	the	isolation	of	potentially	IFN-
sensitive	 mutant	 viruses	 using	 FACS.	 Initially,	 A549/pr(ISRE).GFP/	 ISG56-/	BVDV	Npro	cells	would	be	infected	with	PIV5	W3	at	MOI	0.5.	Then	6-8h	PI,	IFN	and	PIV5	anti-HN	and	anti-F	antibody	would	be	added	to	initiate	GFP	expression	and	to	neutralize	progeny	virus,	respectively.	Following	24h,	cells	would	then	be	immunostained	with	goat	anti-mouse	Texas	Red	antibody	and	prepared	as	single	cell	suspensions	for	FACS	analysis.	GFP	and	Texas	Red	positive	cells	would	then	be	 selected	 and	 single	 cell	 sort	 onto	 96	 well	 micro-titer	 plates	 containing	A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells.	 After	 3-4	 days	 the	 supernatant	containing	virus	would	be	harvested	to	a	fresh	96	well	plate	and	stored	at	-80°C.	The	 remaining	 monolayers	 containing	 virus-infected	 cells	 would	 then	 be	incubated	 in	 the	presence	of	 IFN	 for	18h,	 fixed,	 immunostained	with	goat	anti-mouse	 Texas	 Red	 antibody	 and	 then	 analysed	 for	 fluorescence.	 Uninfected	monolayers	 and	 monolayers	 infected	 with	 wild-type	 viruses	 would	 be	 GFP	positive	 only	 and	 Texas	 Red	 positive	 only,	 respectively,	 whereas	 monolayers	infected	with	a	virus	unable	 to	block	 IFN-signalling	would	be	positive	 for	both	GFP	 expression	 and	 Texas	 Red	 staining	 allowing	 for	 their	 selection.	 The	corresponding	viruses	would	then	be	selected	from	the	96	well	micro-titer	plates	stored	 previously	 in	 -80°C,	 amplified	 in	 Vero	 cells	 and	 then	 subjected	 to	sequencing	analysis.	
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Following	addition	of	these	two	staining	steps,	we	implemented	this	method	to	isolate	potentially	IFN-sensitive	viruses	from	PIV5	W3	(Figure	5.7).	Dual	GFP	and	Texas	Red	positive	 cells	 (~1%	of	 the	population)	were	 selected	and	 single	 cell	sorted	 onto	 preformed	 monolayers	 of	 A549/pr(ISRE).GFP/ISG56-/Npro	 cells	from	P13-Q2	(Figure	5.7,	panel	D),	following	examination	of	the	control	samples.	However,	despite	several	attempts	(12	x	96	well	plates)	we	 identified	only	one	potential	mutant	from	the	PIV5	W3	stock	following	sorting	and	subsequent	FACS	analysis.	 This	mutant,	 named	PIV5	W3-γ,	was	 sequenced	 and	 found	 to	 contain	only	one	nucleotide	mutation	from	thymine	to	cytosine.	This	corresponds	to	the	amino	acid	mutation	Leucine	to	Proline	(L132P),	which	is	common	to	both	the	V	and	P	 protein	 (Figure	 5.8).	 This	 amino	 acid	mutation	was	 then	mapped	 to	 the	wild	type	V	protein	structure,	which	highlights	that	this	mutation	occurs	 in	the	centre	of	an	alpha	helix	(Figure	5.9).	 In	summary,	one	potentially	 IFN-sensitive	mutant	 virus	 was	 isolated	 from	 a	 stock	 of	 PIV5	 W3	 and	 this	 was	 shown	 to	contain	one	mutation	within	the	V	and	P	proteins.	Logically,	further	optimisation	of	 the	 method	 would	 be	 required	 to	 obtain	 more	 mutants,	 for	 example,	mutagenizing	 the	 original	 stock	 may	 increase	 the	 number	 of	 potentially	 IFN-sensitive	mutant	viruses	present	for	isolation.				 	
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Figure	 5.7:	 FACS	 analysis	 of	 PIV5	 W3	 virus.	 A549/pr(ISRE).GFP/	 ISG56-/	BVDV	 Npro	 cells	 were	 infected	 with	 PIV5	 W3	 virus	 at	 MOI	 0.5	 for	 1h.	 Virus	Inoculum	was	then	removed,	cells	washed	with	PBS	and	incubated	in	SF	media.	After	 6hours,	 a	mixture	 of	 PIV5	 anti-HN	 and	 anti-F	 neutralizing	 antibody	was	added	to	all	samples	and	cells	were	treated	with	or	without	IFN	as	 indicated	(-/+IFN).	 After	 24hours	 single	 cell	 suspensions	 were	 made	 from	mock	 infected	cells	(panel	A,	-IFN),	mock	infected	cells	incubated	in	the	presence	of	IFN	(panel	B,	 +IFN),	 PIV5	 W3	 infected	 cells	 (panel	 C,	 -IFN)	 and	 PIV5	 W3	 infected	 cells	incubated	 in	 the	 presence	 of	 IFN	 (panel	 D,	 +IFN).	 Each	 sample	 was	 then	subjected	to	FACS	analysis.	Cells	from	panel	D	P13-Q2	were	then	sorted	into	96	well	 plates	 containing	 confluent	 monolayers	 of	 A549/pr(ISRE).GFP/ISG56-/BVDV	Npro	cells.	(Data	representative	of	three	independent	repeats).	
Te
xa
s	r
ed
	st
ai
ni
ng
	
GFP	expression	
A)	Mock	(-IFN)	 B)	Mock	(+IFN)	
C)	PIV5	W3	(-IFN)	 D)	PIV5	W3	(+IFN)	
Chapter	5:	Isolation	of	potentially	IFN-sensitive	viruses	using	FACS		
	 134	
	 	
Figure	5.8:	Mutations	in	V	and	P	proteins	of	PIV5	W3-γ.	A)	Demonstrates	the	nucleotide	and	corresponding	amino	acid	changes	in	the	V	and	P	genes/proteins	of	PIV5	W3-γ	B)	 Illustrates	 the	 relative	position	of	 the	amino	acid	mutation	 in	the	V	and	P	proteins	for	PIV5	W3-γ		
		
Figure	5.9:	Mapping	the	position	of	amino	acid	mutation	found	in	PIV5	W3-	
γ	 to	wild-type	 V	 protein	 structure	 (Protein	 Data	 Bank	 accession	 number	
2B5L).	 The	 structure	 of	 wild-type	 PIV5	 W3	 V	 protein	 is	 depicted	 with	 the	positions	 of	 the	 PIV5	 W3-	 γ	 mutation	 highlighted	 (structures	 adapted	 using	PyMOL	(Schrodinger)).	
Nucleotide 
changes in V 
mRNA   	 Amino acid changes in V protein	 Nucleotide changes in P mRNA	 Amino acid changes in P protein	
T395C! L132P! T395C! L132P!
A	
L1
32
P	
L1
32
P	
V	
P	
B	
Common	region	shared	between	V/P	 Unique	C	terminal	region	
Wild-type	V	protein		
Highligh2ng	posi2on	of	PIV5	W3-γ	muta2on		
Chapter	5:	Isolation	of	potentially	IFN-sensitive	viruses	using	FACS		
	 135	
In	 conclusion,	 a	 total	 of	 three	 potentially	 IFN-sensitive	 mutant	 viruses,	containing	 mutations	 within	 both	 the	 V	 and	 P	 proteins,	 were	 successfully	isolated	 using	 our	 method,	 namely,	 rPIV5mCh-α,	 rPIV5mCh-β	 and	 PIV5	W3-γ.	Specifically,	 rPIV5mCh-α	 and	 rPIV5mCh-β	 were	 isolated	 multiple	 times	 from	rPIV5mCh	and	PIV5	W3-γ	was	isolated	once	from	PIV5	W3.	In	the	next	chapter	we	 further	 examine	 each	 of	 these	 mutant	 viruses	 to	 investigate	 a	 number	 of	features	including	V	protein	function	and	sensitivity	to	IFN.		
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6 Chapter	6	
6.1 Analysis	of	PIV5	mutants	rPIV5mCh-α,	rPIV5mCh-β	and	PIV5	W3-γ		
6.1.1 Analysis	 of	 PIV5	 mutants	 rPIV5mCh-α,	 rPIV5mCh-β	 and	 PIV5	 W3-γ	 and	
ability	to	block	IFN	signalling	
6.1.1.1 FACS	analysis	of	mutant	PIV5	viruses	at	different	MOI		Following	 their	 isolation,	 mutant’s	 rPIV5mCh-α,	 rPIV5mCh-β	 and	 PIV5	 W3-γ	were	further	analysed	using	several	methods.	Initially,	we	decided	to	investigate	the	 interesting	 phenotype	 (attenuated	mutant	 phenotype	 2)	 seen	 during	 FACS	analysis	of	the	mutant	rPIV5mCh-β.	This	mutant	presented	a	distinctive	‘smear’	across	 the	 top	 two	quadrants	 during	 FACS	 analysis	 as	 infected	 cells	 expressed	varying	 intensities	 of	 GFP	 (Figure	 5.3).	 As	 some	 of	 the	 infected	 cells	 were	negative	for	GFP	expression	indicating	that	IFN	signalling	was	blocked	and	some	were	 positive	 for	 GFP	 indicating	 that	 IFN	 signalling	 was	 active	 it	 was	hypothesised	 that	 the	 mutant	 V	 protein	 of	 rPIV5mCh-β	 may	 be	 partially	functional.	 Consequently,	 it	 was	 predicted	 that	 this	 mutant	 might	 respond	differently	 at	 different	 MOI’s.	 Here	 we	 sought	 to	 analyse	 this	 further	 by	comparing	each	of	the	mutants	by	FACS	analysis	following	infection	at	different	MOI.			Specifically,	 A549/pr(ISRE).GFP/ISG56-/BVDV	 Npro	 cells	 were	 infected	 with	rPIV5mCh,	rPIV5mCh-α,	rPIV5mCh-β,	PIV5	W3	and	PIV5	W3-γ	at	MOI	0.1,	1,	5	or	10	 for	 1hour.	 Six	 hours	 post	 infection	 IFN	 and	 PIV5	 anti-HN	 and	 anti-F	monoclonal	 antibodies	were	 added	 to	 induce	GFP	expression	 and	 to	 inactivate	progeny	 virus,	 respectively.	 Cells	 were	 then	 immunostained	 for	 PIV5	 HN	 if	
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required	(PIV5	W3	and	PIV5	W3-γ)	and	then	prepared	as	single	cell	suspensions	for	FACS	analysis.	As	before,	mCherry	expression	or	Texas	red	staining	combined	with	GFP	expression	indicates	that	the	infecting	virus	is	unable	to	block	the	IFN	response.			The	 results	 show	 that	 increasing	 the	MOI	 of	 wild	 type	 rPIV5mCh	 or	 PIV5	W3	increased	the	number	of	cells	 that	were	mCherry	positive	only,	reiterating	that	these	 wild-type	 viruses	 can	 block	 IFN	 signaling	 (Figure	 6.1).	 In	 contrast,	increasing	 the	 MOI	 of	 the	 mutants	 rPIV5mCh-α	 and	 PIV5	W3-γ	 increased	 the	number	 of	 mCherry	 and	 GFP	 positive	 cells,	 reiterating	 that	 these	 viruses	 are	potentially	 IFN-sensitive	 as	 they	 cannot	 block	 IFN-signalling.	 Conversely,	rPIV5mCh-β	infection	presented	an	interesting	result.	At	low	MOI	of	rPIV5mCh-β	infection	the	majority	of	infected	cells	are	also	GFP	positive,	thus	indicating	that	at	 low	MOI	this	virus	cannot	block	IFN-signalling.	However,	as	MOI	increases	 it	appears	 that	 the	 ability	 to	 block	 IFN-signalling	 also	 increases.	 At	 MOI	 1	 this	creates	a	 ‘smear’	of	 infected	cells	 (as	 seen	previously)	each	expressing	varying	intensities	of	GFP.	At	MOI	10	the	majority	of	infected	cells	are	GFP	negative,	thus	indicating	 that	at	high	MOI	 this	virus	can	block	 IFN-signalling.	One	explanation	for	 this	 is	 that	 rPIV5mCh-β	has	 at	 least	 a	 partially	 functional	V	protein	 as	 at	 a	higher	 MOI	 the	 increase	 in	 abundance	 of	 partially	 functional	 V	 protein	 may	overcome	 the	 IFN	 signalling	 pathway	 leading	 to	 an	 increased	 block	 of	 GFP	expression,	however,	further	investigation	into	V	protein	functionality	would	be	required	to	determine	if	this	was	the	case.	Subsequently	we	sought	to	specifically	analyse	the	V	protein	activity	of	each	mutant	using	a	number	of	assays.		
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Figure	 6.1:	 FACS	 analysis	 of	 isolated	 PIV5	 mutants	 at	 different	 MOI.	A549/pr(ISRE).GFP/	ISG56-/	BVDV	Npro	cells	were	infected	at	MOI	0.1,	1,	5	or	10	for	1hour	with	rPIV5mCh	(A),	rPIV5mCh-α	(B),	rPIV5mCh-β	(C),	PIV5	W3	(D)	and	PIV5	W3-γ	(E).	6	hours	post	infection	IFN	and	anti-HN	antibody	was	added,	respectively.	 Samples	 were	 then	 collected	 as	 single	 cell	 suspensions	 and	analysed	by	FACS	analysis.		
6.1.1.2 Analysis	of	mutant	V	protein	ability	to	cause	STAT1	degradation	Initially,	we	set	out	to	examine	the	mutant	V	proteins	ability	to	target	STAT1	for	proteasome-mediated	degradation.	Previously,	it	has	been	shown	that	the	wild-type	 V	 protein	 of	 PIV5	 can	 hijack	 the	 DDB1-Cul4A-Roc1	 E3	 ligase	 complex	 to	target	STAT1	 for	proteasome-mediated	degradation,	 thus	preventing	activation	of	the	IFN	signalling	pathway	(Didcock	et	al.	1999;	Li	et	al.	2006).	To	determine	mutant	 V	 protein	 function,	 we	 analysed	 STAT1	 expression	 by	 western	 blot	following	infection	by	each	of	mutant	PIV5	viruses.	Specifically,	A549:	naïve	cells	were	 mock	 infected	 or	 infected	 with	 the	 control	 viruses	 PIV5	W3,	 rPIV5mCh,	PIV5	 CPI-	 and	 the	 mutant	 viruses	 rPIV5mCh-α,	 PIV5mCh-β	 and	 PIV5	W3-γ	 at	MOI	10	followed	by	treatment	with	or	without	IFN	for	16hours	(to	induce	STAT1	expression)	before	collection	and	analysis	via	western	blot.		
	Importantly,	 the	 positive	 control	 samples	 demonstrate	 that	 infection	 with	 the	wild-type	 viruses	 rPIV5mCh	 and	 PIV5	W3,	 which	 both	 contain	 a	 functional	 V	protein,	both	lead	to	the	degradation	of	STAT1.	In	addition,	the	negative	control	demonstrates	that	infection	with	the	IFN-sensitive	virus	PIV5	CPI-	that	does	not	contain	 a	 functional	 V	 protein	 does	 not	 lead	 to	 the	 degradation	 of	 STAT1.	
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Interestingly,	 the	 experimental	 results	 demonstrate	 that	 infection	 with	 the	mutant’s	 rPIV5mCh-α	 and	 PIV5	 W3-γ	 did	 not	 lead	 to	 degradation	 of	 STAT1	(Figure	6.2).	 Furthermore,	 the	 same	 levels	 of	 STAT1	were	 expressed	 following	infection	 with	 these	 mutants	 as	 was	 seen	 following	 infection	 with	 the	 IFN-sensitive	virus	PIV5	CPI-,	 thus	 indicating	 that	 the	V	protein	of	 these	mutants	 is	non-functional.	 By	 contrast,	 infection	with	 the	mutant	 rPIV5mCh-β	 did	 lead	 to	the	degradation	of	STAT1	to	the	same	extent	as	the	wildtype	viruses’	rPIV5mCh	and	PIV5	W3,	thus	indicating	that	the	V	protein	of	this	mutant	is	fully	functional	with	 regards	 to	 blocking	 the	 IFN	 signaling	 pathway.	 This	 disagrees	 with	 our	initial	 hypothesis	 that	 rPIV5mCh-β	V	 protein	was	 partially	 functional.	Next	we	decided	to	specifically	analyse	V	protein	function	independent	of	virus	infection.		
	
Figure	 6.2:	 Analysis	 of	 STAT1	 expression	 following	 infection	 by	 isolated	
PIV5	mutant	viruses.	A549:	naïve	cells	were	mock	infected	or	infected	with	the	control	 viruses	 PIV5	 W3,	 rPIV5mCh,	 PIV5	 CPI-	 and	 the	 mutant	 viruses	rPIV5mCh-α,	PIV5mCh-β	and	PIV5	W3-γ	at	MOI	10	 for	12	hours,	 followed	by	a	16	 hour	 IFN	 treatment	 to	 induce	 STAT1	 expression	 before	 collection	 in	disruption	buffer	and	analysis	via	western	blot	for	STAT1,	PIV5	NP	and	Actin.		
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6.1.1.3 Analysis	of	mutant	V	protein	activity	independent	of	virus	infection		To	analyse	V	protein	activity	independent	of	virus	infection,	the	V	protein	from	each	mutant	was	cloned	into	the	expression	vector	pcDNA3.1(-).	This	expression	vector	 could	 then	 be	 used	 in	 both	 an	 IFN	 signalling	 and	 an	 IFN	 induction	luciferase	 reporter	 assay	 to	 determine	 V	 protein	 activity	 against	 each	 of	 these	pathways.		
6.1.1.3.1 IFN	 signalling	 luciferase	 reporter	 assay	 to	 analyse	 mutant	 V	 protein	
function	Initially,	an	IFN	signalling	luciferase	reporter	assay	was	used	to	determine	if	the	mutant	V	proteins	could	block	IFN	signalling	in	a	similar	manner	to	the	wild-type	V	 protein.	 Briefly	 this	 assay	 required	 transfection	 of	 each	 mutant	 V	 protein	alongside	a	reporter	plasmid	containing	firefly	luciferase	under	the	control	of	an	ISRE.	 As	 stated	 previously	 this	 element	 is	 found	 within	 the	 promoters	 of	numerous	 ISGs	 and	 is	 triggered	 following	 activation	 of	 the	 IFN	 signalling	pathway	 by	 addition	 of	 IFN.	 Hence,	 treatment	 of	 the	 cells	 with	 IFN	 following	transfection	 with	 this	 plasmid	 would	 result	 in	 luciferase	 expression	 and	indicates	 that	 the	 IFN	 signalling	 pathway	 is	 intact.	 Consequently,	 mutant	 V	protein	activity	can	then	be	analysed	by	its	ability	to	block	luciferase	expression.				Specifically,	each	mutant	V	protein	plasmid	was	transfected	(with	the	exception	of	the	control	sample	which	was	set	up	in	the	absence	of	a	V	protein	expressing	plasmid)	 into	 293T	 cells	 in	 combination	 with	 two	 plasmids	 that	 expressed	 i)	firefly	luciferase	under	the	control	of	four	tandem	repeat	sequences	of	the	ISRE	from	 the	 IFN-inducible	 gene	9-27	 and	 ii)	 β-galactosidase,	which	was	used	 as	 a	transfection	 control	 to	 determine	 transfection	 efficiency.	 At	 48h	 post	
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transfection	 the	 media	 was	 then	 supplemented	 with	 IFN	 (+IFN)	 to	 activate	luciferase	 expression	 or	 left	 untreated	 (-IFN).	 After	 6h	 the	 cells	 were	 lysed	 in	buffer	 and	 the	 luciferase	 activity	 was	 measured	 and	 normalised	 to	 β-galactosidase	 activity.	 Relative	 luciferase	 activity	 was	 then	 graphed	 using	GraphPad	Prism	6	(-/+	Standard	Deviation)	and	is	demonstrated	in	Figure	6.3.				Importantly,	 the	 control	 sample,	 excluding	 the	 V	 protein	 expressing	 plasmid,	demonstrated	that	luciferase	is	produced	following	IFN	treatment.	Furthermore,	the	positive	control,	expressing	wild-type	V	protein,	demonstrated	that	an	active	V	protein	blocks	expression	of	luciferase	following	IFN	treatment.	Interestingly,	the	 experimental	 results	 showed	 that	 expression	 of	 the	 mutant	 V	 proteins	 of	rPIV5mCh-α	 and	 PIV5	 W3-γ	 did	 not	 block	 expression	 of	 luciferase	 in	 the	presence	 of	 IFN,	 thus	 reiterating	 our	 previous	 analysis	 that	 the	 V	 proteins	 of	these	two	mutants	cannot	block	the	IFN	signalling	pathway.	On	the	other	hand,	expression	 of	 the	 mutant	 rPIV5mCh-β	 V	 protein	 blocked	 the	 expression	 of	luciferase	to	a	similar	level	as	the	Wild-type	V	protein,	thus	reiterating	that	the	mutant	rPIV5mCh-β	V	protein	can	block	IFN	signalling.	
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Figure	6.3:	Analysis	of	mutant	V	proteins	ability	to	block	the	IFN	signalling	
pathway	using	an	 IFN	signalling	 luciferase	reporter	assay.	293T	 cells	were	transfected	in	triplicate	with	(A)	plasmids	expressing	wildtype	(WT),	rPIV5mCh-α	and	rPIV5mCh-β	V	protein	and	(B)	plasmids	expressing	WT	and	PIV5	W3-γ	V	protein	 with	 the	 exception	 of	 the	 control	 sample.	 Each	 sample	 was	 also	transfected	with	two	other	plasmids,	one	that	expresses	firefly	luciferase	under	the	control	of	 an	 ISRE	and	another	 that	expresses	β-galactosidase.	At	48h	post	transfection	 the	 media	 was	 supplemented	 with	 IFN	 to	 activate	 luciferase	expression	(+IFN)	or	left	untreated	(-IFN).	After	6h	the	cells	were	lysed	in	buffer	and	the	luciferase	activity	measured	and	normalised	to	β-galactosidase	activity.	Relative	luciferase	activity	was	then	graphed	using	GraphPad	Prism	6	(mean	-/+	Standard	Deviation;	Data	representative	of	three	independent	repeats)	
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6.1.1.3.2 IFN	 induction	 luciferase	 reporter	 assay	 to	 analyse	 mutant	 V	 protein	
function.	Next	we	sought	to	determine	the	mutant	V	proteins	ability	to	block	IFN	induction	using	an	IFNβ	induction	luciferase	reporter	assay.	In	addition	to	blocking	the	IFN	signalling	 pathway,	 previous	 research	 has	 shown	 that	 the	wild-type	 V	 protein	also	 interacts	with	Mda5	 to	 block	 the	 IFN	 induction	 pathway	 (Andrejeva	 et	 al.	2004).	This	second	luciferase	reporter	assay	therefore	sought	to	determine	if	the	mutant	V	proteins	could	inhibit	the	IFN	induction	pathway	in	a	similar	manner	to	the	wild-type	 V	 protein.	 Briefly	 this	 assay	 required	 transfection	 of	 each	 of	 the	mutant	 V	 proteins	 in	 combination	with	 a	 plasmid	 expressing	 firefly	 luciferase	under	 the	 control	 of	 the	 IFN	 promoter	 and	 a	 plasmid	 that	 expressed	 Mda5.	Previous	 work	 has	 demonstrated	 that	 over	 expression	 of	 Mda5	 and	 other	signalling	 intermediates	 activates	 IFN	 induction	 (Andrejeva	 et	 al.	 2004),	therefore,	overexpression	of	Mda5	was	used	here	to	trigger	activation	of	the	IFN	promoter	 and	 subsequent	 luciferase	 expression,	 thus	 demonstrating	 an	 intact	IFN	 induction	pathway.	Consequently,	mutant	V	protein	activity	would	 then	be	analysed	by	its	ability	to	block	luciferase	expression.	Specifically,	each	mutant	V	protein	 plasmid	 was	 transfected	 into	 293T	 cells	 in	 combination	 with	 three	plasmids	 that	 expressed	 i)	 firefly	 luciferase	 under	 the	 control	 of	 the	 IFNβ	promoter,	 ii)	 Mda5	 and	 iii)	 β-galactosidase,	 which	 was	 used	 to	 determine	transfection	efficiency.	Notably	a	negative	control	 (excluding	 the	V	protein	and	Mda5	expressing	plasmids)	and	a	positive	control	(excluding	the	V	protein)	were	also	set	up.	At	48h	post	transfection	the	cells	were	then	lysed	in	buffer	and	the	luciferase	activity	measured	and	normalised	to	β-galactosidase	activity.	Relative	
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luciferase	activity	was	then	graphed	using	GraphPad	Prism	6	(mean	-/+	Standard	Deviation)	and	is	demonstrated	in	Figure	6.4.				Importantly,	 the	 negative	 and	 positive	 control	 demonstrated	 that	 Mda5	expression	 results	 in	 luciferase	 expression	 via	 activation	 of	 the	 IFN	 signalling	pathway.	Furthermore,	expression	of	the	wild-type	V	protein	demonstrated	that	luciferase	 expression	 is	 blocked	 in	 the	 presence	 of	 an	 active	 V	 protein.	Interestingly,	 the	 experimental	 results	 show	 that	 expression	 of	 each	 of	 the	mutant	V	proteins	blocked	luciferase	expression	comparable	to	the	wild-type	V	protein.	Thus	 indicating	 that	 all	mutant	V	proteins	have	 retained	 the	 ability	 to	block	 the	 IFN	 induction	 pathway	 irrespective	 of	 their	 activity	 against	 the	 IFN	signalling	pathway.		 	
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Figure	6.4:	Analysis	of	mutant	V	protein	ability	 to	block	IFN	induction	via	
an	 IFN	 induction	 luciferase	 reporter	 assay.	 293T	 cells	 were	 transfected	 in	triplicate	 with	 plasmids	 expressing	 wildtype	 (WT),	 rPIV5mCh-α,	 rPIV5mCh-β	and	PIV5	W3-γ	V	protein	in	combination	with	two	other	plasmids	that	express	i)	firefly	luciferase	under	the	control	of	the	IFNβ	promoter	and	ii)	β-galactosidase	(with	the	exception	of	the	negative	(–ve)	and	positive	(+ve)	control	which	were	both	set	up	in	the	absence	of	a	V	expressing	protein).	Finally,	a	third	plasmid	that	expresses	Mda5	was	also	transfected	to	the	samples	as	indicated	(-/+	Mda5)	to	activate	the	IFN	induction	pathway	and	subsequent	luciferase	expression.	At	48h	post	 transfection	 the	 cells	 were	 lysed	 in	 buffer	 and	 the	 luciferase	 activity	measured	and	normalised	to	β-galactosidase	activity.	Relative	luciferase	activity	was	then	graphed	using	GraphPad	Prism	6	(mean	-/+	Standard	Deviation;	Data	representative	of	three	independent	repeats)	
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In	conclusion,	we	set	out	to	examine	the	activity	of	the	mutant	V	proteins	found	within	 each	mutant	 PIV5	 virus.	 Interestingly,	 the	 results	 have	 determined	 that	rPIV5mCH-α	and	PIV5	W3-γ	mutant	V	proteins	have	lost	the	ability	to	block	the	IFN	signalling	pathway	however	they	have	retained	the	ability	to	block	the	IFN	induction	pathway.	Furthermore,	despite	initially	hypothesizing	that	rPIV5mCh-β	contained	a	partially	functional	mutant	V	protein	the	results	have	shown	that	rPIV5mCh-β	 remains	 functional	 and	 can	 block	 both	 the	 IFN	 induction	 and	signalling	pathways	in	a	similar	manner	to	the	wild-type	V	protein.	Now	that	we	had	 established	 V	 protein	 activity	 in	 the	 IFN	 induction	 and	 IFN	 signalling	pathways,	next	we	examined	each	mutant’s	sensitivity	to	IFN	by	comparing	their	viral	growth	in	the	presence	and	absence	of	an	active	IFN	response.		 	
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6.1.2 Analysis	of	IFN	sensitivity	of	PIV5	mutant	viruses.		Now	that	we	had	established	IFN	antagonist	activity,	next	we	wanted	to	examine	each	mutant’s	sensitivity	to	IFN.	Previously	we	have	demonstrated	that	the	IFN	inhibitor,	Rux,	 can	block	 the	 IFN	signalling	pathway	and	subsequently	 increase	the	growth	of	IFN-sensitive	viruses.	Consequently,	we	used	this	drug	to	compare	growth	of	each	of	 the	mutant	viruses	 in	 the	presence	and	absence	of	 an	active	IFN	response	using	both	plaque	assays	and	multistep	viral	growth	curves.		
6.1.2.1 Comparison	of	plaque	development	of	PIV5	mutant	viruses	 in	the	presence	
and	absence	of	an	active	IFN	response.		To	 determine	 the	 IFN	 sensitivity	 of	 each	 mutant	 virus	 we	 examined	 plaque	development	 of	 each	 mutant	 in	 the	 presence	 and	 absence	 of	 an	 active	 IFN	response.	Specifically,	we	compared	plaque	development	of	each	virus	 in	A549	naïve	 cells	 -/+	 Rux	 and	 in	 Vero	 cells	 (which	 do	 not	 contain	 an	 intact	 IFN	response)	(Figure	6.5).		The	results	demonstrate	that	in	A549:	naive	cells	in	the	absence	of	Rux	the	wild-type	 viruses	 rPIV5mCh	 and	 PIV5	 W3	 produced	 small	 plaques.	 Also	 note	 that	rPIV5mCh	plaques	were	of	varied	size	indicating	a	heterogeneous	population.	In	contrast,	 rPIV5mCh-α	 did	 not	 produce	 any	 visible	 plaques	 and	 PIV5	 W3-γ	produced	 plaques	 that	 are	 slightly	 smaller	 than	 the	wild-type	 virus,	 PIV5	W3,	thus	indicating	that	the	mutant	virus	is	more	sensitive	to	an	active	IFN	response.	Furthermore,	 rPIV5mCh-β	 produced	 plaques	 similar	 in	 size	 to	 the	 wild-type	virus	thus	indicating	that	this	virus	is	not	sensitive	to	an	active	IFN	response.	In	A549:	 naive	 cells	 in	 the	 presence	 of	 Rux,	 the	 plaque	 size	 of	 all	 viruses	 was	
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increased	 compared	 to	 that	 seen	 in	 the	 absence	 of	 Rux,	 with	 the	 greatest	increases	demonstrated	by	each	of	the	mutant	viruses.	Interestingly,	rPIV5mCh-α	and	rPIV5mCh-β	appeared	to	produce	larger	plaques	than	the	wild-type	virus	in	A549	naïve	cells	in	the	presence	of	Rux,	a	similar	trend	although	less	obvious	also	appeared	for	rPIV5mCh-α	in	Vero	cells.	We	therefore	quantified	the	plaque	size	 of	 rPIV5mCh-α	 and	 rPIV5mCh-β	 and	 compared	 this	 to	 the	wild-type	 virus	rPIV5mCh	 in	 each	 condition	 (Figure	 6.6).	 Plaque	 size	 was	 measured	 using	PixelStick	and	normalised	to	rPIV5mCh.	Significance	was	then	determined	using	an	unpaired	T	test.	This	indicated	that	there	was	a	significant	increase	in	plaque	size	 for	 both	 rPIV5mCh-α	 (P	 <0.0001)	 and	 rPIV5mCh-β	 (P=	 0.0002)	 viruses	compared	 to	 the	 wild-type	 virus	 in	 A549	 naïve	 cells	 in	 the	 presence	 of	 Rux.	Furthermore,	 there	 was	 a	 small	 but	 significant	 increase	 (P=0.0484)	 in	 rPIV5-mCh-α	plaque	size	compared	 to	 the	wild-type	virus	 in	Vero	cells.	 Interestingly,	this	could	indicate	that	these	mutant	viruses	and	particularly	rPIV5mCh-α	had	a	growth	advantage	 in	IFN	incompetent	cells	compared	to	the	wild-type	virus.	 In	summary,	 this	 data	 indicates	 that	 rPIV5mCh-α	 and	 PIV5	 W3-γ,	 which	 do	 not	contain	a	 functional	V	protein,	 are	 sensitive	 to	 IFN.	Conversely,	 it	 appears	 that	rPIV5mCh-β,	which	contains	a	functional	V	protein,	is	not.			 	
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Figure	6.5:	Comparison	of	mutant	virus	plaque	development	in	A549	naïve	
-/+	Rux	and	Vero	cells.	Each	virus	(rPIV5mCh,	rPIV5mCh-α,	rPIV5mCh-β,	PIV5	W3	and	PIV5	W3-γ)	was	incubated	in	A549	naïve	or	Vero	cells	for	1hour	before	removal	of	the	inoculum,	PBS	wash	and	addition	of	avicell	plaque	assay	overlay	with	4μM	Rux	treatment	or	equivalent	volume	DMSO.	Plaques	were	fixed	at	the	day	 indicated	 and	 immunostained	 using	 antibodies	 against	 PIV5	 NP	 and	 HN.	(Data	representative	of	three	independent	repeats).	
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Figure	6.6:	Quantification	of	virus	plaque	size.	Percentage	(%)	plaque	size	of	mutant	virus	grown	in	A549	naïve	-/+	Rux	and	Vero	cells	is	represented	in	A,	B	and	C,	respectively.	Plaque	size	was	measured	using	Pixelstick	and	normalised	to	rPIV5mCh	in	each	case.	Significance	was	then	analysed	using	an	unpaired	T	test	comparing	each	mutant	to	rPIV5mCh	(For	A549:naïve	(Rux	4µM)	*P=	0.0002,	**	P	<	0.0001,	for	Vero	cells	*P=0.0484).		
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6.1.2.2 Analysis	 of	 PIV5	 mutant	 virus	 growth	 in	 the	 presence	 and	 absence	 of	 an	
active	IFN	response	using	a	multistep	viral	growth	curve		In	addition	to	plaque	analysis,	the	IFN	sensitivity	of	each	mutant	virus	was	also	examined	using	 a	multistep	 viral	 growth	 curve.	 	 Specifically,	we	 compared	 the	growth	of	each	mutant	virus	in	A549	naïve	cells	in	the	presence	and	absence	of	Rux	 (Figure	 6.7).	 The	 results	 demonstrate	 that	 in	 the	 absence	 of	 Rux	 both	rPIV5mCh-α	and	rPIV5mCh-γ	viral	titers	are	approximately	1.5	 logs	 lower	than	their	 respective	 wild-type	 viruses,	 rPIV5mCh	 and	 PIV5	 W3,	 at	 48	 hours	 post	infection.	By	contrast,	in	the	presence	of	Rux	rPIV5mCh-α	and	rPIV5mCh-γ	viral	titers	 increase	 to	 the	 same	 level	 as	 their	 respective	 wild-type	 viruses,	 thus	reiterating	 that	 both	 rPIV5mCh-α	 and	 rPIV5mCh-γ	 are	 sensitive	 to	 IFN.	Conversely,	 in	the	presence	and	absence	of	an	 intact	IFN	response	rPIV5mCh-β	reaches	a	high	titer	similar	to	the	wildtype	virus	thus	reiterating	that	this	virus	is	not	sensitive	to	IFN.	Surprisingly	the	growth	of	the	mutant	viruses	rPIV5mCh-a	and	 rPIV5mCh-b	was	very	 similar	 to	 their	 respective	wildtype	viruses	 in	A549	naïve	cells	in	the	presence	of	Rux.	This	was	in	contrast	to	the	increased	growth	of	rPIV5mCh-a	 and	 rPIV5mCh-b	 seen	 in	 the	 previous	 plaque	 assay	 and	 possible	reasons	for	this	are	discussed	later.				 	
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Figure	 6.7:	 Multistep	 viral	 growth	 curve	 analysis	 of	 PIV5	mutants.	A549:	naïve	cells	were	infected	with	A)	rPIV5mCh	and	rPIV5mCh-α,	B)	rPIV5mCh	and	rPIV5mCh-β	 and	 C)	 PIV5	 W3	 and	 PIV5	 W3-γ	 and	 incubated	 -/+	 4μM	 Rux	 or	equivalent	volume	of	DMSO.	Samples	were	 then	 taken	at	numerous	 timepoints	and	titered	on	Vero	cells.	(Data	representative	of	three	independent	repeats	with	a	lower	limit	of	detection	of	1x	103	PFU/ml).		 	
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In	 conclusion,	 we	 set	 out	 to	 analyse	 the	 IFN	 sensitivity	 of	 each	 mutant.	 The	results	 demonstrate	 that	 the	 mutant	 viruses	 containing	 non-functional	 V	proteins,	rPIV5mCh-α	and	PIV5	W3-γ,	are	sensitive	to	IFN.	This	is	demonstrated	in	 both	 the	 plaque	 assay	 and	 viral	 growth	 curve	 as	 growth	 is	 attenuated	compared	 to	wild-type	virus	growth	 in	 the	presence	of	an	 intact	 IFN	response.	Furthermore,	there	is	a	large	increase	in	growth	in	the	absence	of	an	intact	IFN	response.	 By	 contrast,	 growth	 of	 rPIV5mCh-β,	 which	 contains	 a	 functional	 V	protein,	 is	not	 sensitive	 to	 IFN.	This	 is	demonstrated	by	both	 the	plaque	assay	and	viral	growth	curve,	as	the	virus	is	able	to	grow	in	the	presence	of	an	intact	IFN	 response	 and	 this	 growth	 is	 increased	 in	 the	 absence	 of	 an	 intact	 IFN	response	in	a	similar	manner	to	the	wild-type	virus.	Following	confirmation	that	both	 rPIV5mCh-α	 and	 PIV5	 W3-γ	 cannot	 block	 the	 IFN	 response	 and	 are	therefore	sensitive	to	IFN,	we	focused	our	studies	to	further	examine	these	two	IFN-sensitive	mutants.		 	
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6.1.3 Further	analysis	of	the	IFN-sensitive	mutant	viruses	rPIV5mCh-a	and	PIV5	
W3-g	Following	confirmation	that	 the	both	rPIV5mCh-α	and	PIV5	W3-γ	cannot	block	the	 IFN	 response	 and	 are	 therefore	 sensitive	 to	 IFN,	 we	 set	 out	 to	 further	examine	 these	 two	 IFN-sensitive	mutants.	 Initially	we	 set	 out	 to	 examine	 each	mutant	V	protein	by	examining	if	the	mutations	within	the	V	protein	could	easily	revert	 to	 regain	 the	 ability	 to	 block	 the	 IFN	 response.	 Secondly,	we	wanted	 to	examine	 two	 features	 noted	 during	 previous	 analysis	 of	 the	 viruses	 in	 the	presence	 and	 absence	 of	 an	 intact	 IFN	 response.	 Firstly,	 that	 rPIV5mCh-α	 had	increased	 fusogenicity	 compared	 to	 the	 wild-type	 virus	 in	 the	 absence	 of	 an	intact	IFN	response	and	secondly	that	both	rPIV5mCh-α	and	PIV5	W3-γ	induced	greater	levels	of	apoptosis	compared	to	the	wild-type	virus	in	the	presence	of	an	intact	IFN	response.	
6.1.3.1 Analysis	of	the	ability	of	the	IFN-sensitive	mutant	viruses	to	regain	V	protein	
function	To	assess	the	ability	of	the	IFN-sensitive	mutants	to	regain	V	protein	function,	we	analysed	 rPIV5mCh-α	 and	 PIV5	 W3-γ	 infected	 IFN	 competent	A549/pr(ISRE).GFP	 cells.	 As	 these	 cells	 have	 an	 intact	 IFN	 response	 this	 may	push	the	virus	to	select	mutations	that	regain	the	ability	to	block	IFN	signalling.	Following	IFN	treatment,	each	of	these	samples	was	analysed	by	FACS	and	cells	infected	with	 virus	 that	 could	 potentially	 block	 IFN	 signalling	 (mCherry/Texas	Red	 positive	 and	 GFP	 negative	 cells)	 were	 selected.	 Selected	 single	 cells	 were	then	 sorted	 into	 1x96	 well	 plate	 containing	 A549/pr(ISRE).GFP	 cells	 and	incubated	for	3-4	days	to	allow	virus	amplification	for	 further	analysis.	Each	of	the	 monolayers	 was	 then	 analysed	 by	 fluorescent	 microscopy	 following	 IFN	
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treatment	 to	 assess	 the	 ability	 of	 the	 infecting	 virus	 to	 block	 IFN	 signalling.	Specifically,	 5	 viruses	 displayed	 the	wild-type	 phenotype	 (mCherry/Texas	 Red	positive	 and	 GFP	 negative)	 following	 selection	 from	 PIV5	 W3-γ	 infected	 cells	however	no	viruses	displayed	the	wild-type	phenotype	following	selection	from	rPIV5mCh-α	infected	cells.	The	V/P	gene	of	the	5	PIV5	W3-γ	selected	viruses	was	then	sequenced	to	analyse	for	reversion	to	wild-type	sequence	or	compensatory	mutations	 that	allow	 the	V	protein	 to	 regain	 function.	This	 identified	 that	all	5	selected	 viruses	 had	 reverted	 to	 wild-type	 demonstrating	 that	 the	 single	mutation	L132P	 contained	 in	PIV5	W3-γ	V	protein	 could	 easily	 revert	 to	wild-type	to	regain	the	ability	to	block	IFN	signalling.		In	 addition	 to	FACS	analysis	 and	 selection,	we	 also	passaged	each	virus	 in	 IFN	competent	 A549:pr(ISRE).GFP	 cells	 for	 60	 days	 and	 then	 reassessed	 the	population	for	regain	of	V	protein	function	using	FACS	analysis	(Figure	6.8).	The	results	demonstrated	 that	 following	60	days	 there	were	 few	rPIV5mCh-α	virus	infected	 cells	 and	 those	 infected	 were	 still	 unable	 to	 block	 the	 IFN	 signalling	pathway	suggesting	that	the	virus	had	been	unable	to	regain	V	protein	function.	By	contrast	 there	was	a	 large	population	of	PIV5	W3-γ	 infected	cells	 that	were	unable	 to	 block	 the	 IFN	 signalling	 pathway	 however	 there	 was	 also	 a	 new	population	of	 infected	cells	which	could	block	the	IFN	signalling	pathway.	Cells	from	 this	 population	 were	 sorted	 into	 1x96	 well	 plate	 containing	A549/pr(ISRE).GFP	 cells.	 The	monolayers	were	 then	 incubated	 for	3-4	days	 to	allow	 the	 virus	 to	 propagate	 and	 then	 analysed	 by	 fluorescent	 microscopy	following	IFN	treatment	for	ability	to	block	IFN	signalling.	Ten	viruses	displaying	the	wild-type	phenotype	 (mCherry/Texas	Red	positive	and	GFP	positive)	were	
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then	selected	for	sequencing	of	the	V/P	gene.	As	expected,	the	results	identified	that	 each	 of	 the	 viruses’	 had	 reverted	 to	 the	wild-type	 V	 protein	 sequence.	 In	summary,	the	results	highlight	that	the	numerous	mutations	within	the	V	protein	of	rPIV5mCh-α	are	difficult	to	revert	in	combination	however	the	single	mutation	(L132P)	contained	within	PIV5	W3-γ	is	easily	reverted.		
	
	
Figure	6.8:	rPIV5mCh-α	and	PIV5	W3-γ	serial	passage.	rPIV5mCh-α	(panel	A)	and	PIV5	W3-γ	(panel	B)	infected	cells	were	prepared	as	single	cell	suspensions,	following	 IFN	 treatment,	 at	 Day	 0	 and	 Day	 60	 following	 passage	 in	 IFN	competent	A549:pr(ISRE).GFP,	and	examined	by	FACS	analysis.		 	
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6.1.3.2 Analysis	of	IFN-sensitive	mutant	virus	fusogenicity	in	Vero	cells	Notably,	 the	 wild-type	 viruses	 PIV5	 W3	 and	 rPIV5mCh	 are	 characteristically	non-fusogenic	during	 infection	however	during	previous	 analysis,	 it	was	noted	that	 rPIV5mCh-α	 is	 highly	 fusogenic	 in	 Vero	 cells	 and	 A549	 naïve	 cells	 in	 the	presence	of	Rux	but	not	 in	A549	naïve	cells.	To	analyse	this	further	we	applied	DAPI	 staining	 to	 Vero	 cells	 following	 infection	 with	 each	 of	 the	 IFN-sensitive	mutants	 to	 examine	 the	 fusogenicity	 of	 each	 virus	 (Figure	 6.9).	 The	 results	demonstrate	that	rPIV5mCh-α	was	highly	fusogenic	in	cells	without	an	intact	IFN	response	 compared	 to	 the	 wild-type	 virus.	 Furthermore,	 PIV5	 W3-γ	demonstrated	 small	 patches	 of	 fusion	 but	 it	 could	 not	 be	 stated	 that	 this	 was	significantly	more	fusogenic	than	the	wildtype	virus.	In	summary,	this	indicates	that	 IFN-sensitive	virus,	 rPIV5mCh-α	 is	highly	 fusogenic	compared	 to	 the	wild-type	virus	in	the	absence	of	an	intact	IFN	response.			
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Figure	6.9:	Analysis	of	mutant	fusogenicity.	Vero	cells	seeded	onto	coverslips	were	mock	infected	or	infected	with	rPIV5mCh,	PIV5	W3,	PIV5mCh-α	and	PIV5	W3-γ	at	MOI	10	for	1	hour	before	replacement	of	the	virus	inoculum	with	serum-free	DMEM	and	incubation	for	48hours.	Cells	were	then	stained	using	DAPI	and	mounted	 onto	 glass	 slides	 before	 analysis	 by	 fluorescent	 microscopy	 (10x	Magnification).	(Data	representative	of	two	independent	repeats).	
Uninfected
rPIV5mCh
rPIV5mCh-a
PIV5	W3
PIV5	W3-γ
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6.1.3.3 Analysis	 of	 the	 induction	 of	 apoptosis	 by	 the	 IFN-sensitive	 mutants	
rPIV5mCh-α	and	rPIV5mCh-γ	in	A549	naïve	cells	-/+	Rux	Characteristically	 the	wild-type	 viruses	 PIV5	W3	 and	 rPIV5mCh	do	not	 trigger	apoptosis	 following	 infection.	 However,	 during	 previous	 analysis	 it	 was	 noted	that	both	rPIV5mCh-α	and	rPIV5mCh-γ	induced	an	increased	apoptotic	response	compared	to	the	wild-type	virus	in	A549	naïve	cells	whereas	this	response	was	abrogated	 in	 cells	 without	 an	 intact	 IFN	 response	 (A549	 naïve	 cells	 in	 the	presence	 of	 Rux	 and	 Vero	 cells).	 To	 investigate	 this	 further,	 we	 applied	 DAPI	staining	to	IFN	competent	A549	naïve	cells	-/+	Rux	following	infection	with	each	of	 the	mutant	 viruses	 to	 examine	 for	 apoptotic	 cells	 (Figure	 6.10).	 The	 results	show	 that	 rPIV5mCh-α	 and	 rPIV5mCh-γ	 demonstrate	 an	 increased	 number	 of	apoptotic	nuclei	during	infection	of	A549	naïve	cells	however	this	is	abrogated	in	the	presence	of	the	IFN	inhibitor	Rux.	In	summary,	this	indicates	that	there	is	an	increase	in	induction	of	apoptosis	following	infection	of	IFN	competent	cells	with	the	 IFN-sensitive	 mutants	 rPIV5mCh-α	 and	 rPIV5mCh-γ	 infection,	 which	 is	negated	in	the	absence	of	an	intact	IFN	response.				
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Figure	 6.10:	 Analysis	 of	 apoptosis	 following	mutant	 virus	 infection.	A549	naïve	 cells	 seeded	 onto	 coverslips	 were	 infected	 with	 rPIV5mCh,	 PIV5	 W3,	PIV5mCh-α	and	PIV5	W3-γ	at	MOI	10	for	1	hour	before	replacement	of	the	virus	inoculum	 with	 serum-free	 DMEM	 -/+	 4μM	 Rux	 and	 incubation	 for	 48	 or	 72	hours.	Cells	were	then	stained	using	DAPI	and	mounted	onto	glass	slides	before	analysis	 using	 a	 fluorescence	 microscope	 (10x	 Magnification).	 (Data	representative	of	two	independent	repeats).		
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In	 conclusion,	 we	 set	 out	 to	 further	 characterise	 the	 IFN-sensitive	 mutants	rPIV5mCh-α	 and	 PIV5	W3-γ.	 The	 results	 demonstrate	 that	 the	 combination	 of	mutations	 within	 the	 V	 protein	 of	 the	 IFN-sensitive	 mutant	 rPIV5mCh-α	 are	unable	to	revert	for	up	to	60	days.	In	addition,	this	IFN-sensitive	mutant	exhibits	both	 increased	 fusogenicity	 in	 the	 absence	 of	 an	 intact	 IFN	 response	 and	increased	 induction	of	apoptosis	 in	 the	presence	of	an	 intact	 IFN	response	that	was	 abrogated	 in	 the	 absence	 of	 an	 intact	 IFN	 response.	 By	 contrast,	 the	mutation	 within	 the	 V	 protein	 of	 the	 IFN-sensitive	 virus	 PIV5	 W3-γ	 is	 easily	reverted	as	we	can	select	revertants	to	the	wild-type	V	protein	sequence	directly	from	one	infection	of	the	virus	preparation	and	there	is	an	increase	in	wild-type	virus	following	passage	in	IFN	competent	cells	for	60	days.	In	addition,	this	virus	also	 induced	 apoptosis	 in	 the	 presence	 of	 an	 intact	 IFN	 response	 that	 was	abrogated	in	the	absence	of	an	intact	IFN	response.	Next	we	decided	to	sequence	the	 entire	 mutant	 genome	 to	 determine	 if	 any	 mutations	 found	 within	 genes	other	than	V/P,	could	indicate	an	explanation	for	these	interesting	features.			 	
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6.1.4 Full	genome	sequencing	of	PIV5	mutant	viruses		Following	the	observation	that	the	IFN-sensitive	mutants	rPIV5mCh-α	and	PIV5	W3-γ	exhibited	differences	in	fusogenicity	and	apoptosis,	it	was	decided	to	fully	sequence	 each	 mutant	 using	 directional	 sequencing	 (performed	 by	 Elizabeth	Fleming;	University	of	St	Andrews/University	of	Glasgow).	This	would	enable	us	to	determine	if	any	mutations	found	within	genes	other	than	V/P,	could	indicate	an	explanation	 for	 the	phenotypes	seen	previously.	Notably	we	also	decided	 to	fully	 sequence	 the	 rPIV5mCh-β	virus	 to	 identify	 if	 any	mutations	 could	explain	the	interesting	phenotype	seen	at	low	MOI.			Firstly,	 the	recombinant	PIV5mCh	was	compared	to	the	original	PIV5	W3	wild-type	virus.	This	highlighted	that	there	were	some	differences	between	PIV5	W3	and	the	recombinant	virus	rPIV5mCh	besides	the	mCherry	insertion	(Table	6.1).	Specifically,	two	non-synonymous	mutations	were	found	in	the	F	protein	(T24A	and	S217N),	however,	as	rPIV5mCh	and	PIV5	W3	behave	similarly	with	regards	to	fusion	then	it	seems	likely	that	these	mutations	do	not	affect	protein	function.			
Table	6.1:	Mutations	 found	during	 full	 genome	 sequencing.	The	mutations	found	within	 each	mutant	 are	 depicted	below.	The	position	 of	 each	nucleotide	change	is	numbered	according	to	the	genomic	sequence	of	PIV5	W3.	The	amino	acid	change	is	numbered	according	to	the	individual	proteins	with	ATG	equal	to	number	1	in	each	case.	Non-synonymous	mutations	are	indicated	with	a	‘Y’	and	synonymous	mutations	indicated	with	‘Y*’.		
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Next	 each	 IFN-sensitive	mutant	 virus	was	 compared	 to	 both	 the	 PIV5	W3	 and	rPIV5mCh	 sequences.	 Interestingly,	 the	 only	 non-synonymous	 mutation	identified	in	rPIV5mCh-α	(aside	from	the	numerous	mutations	already	identified	in	the	V/P	gene)	was	found	in	the	fusion	protein	(T24A),	however,	this	mutation	was	 also	 found	 in	 both	 the	 wild-type	 virus	 rPIV5mCh	 and	 the	 mutant	 virus	rPIV5mCh-b.	Furthermore,	 the	only	other	non-synonymous	mutation	 identified	in	PIV5	W3-γ	(aside	from	the	single	mutation	already	identified	in	the	V/P	gene)	was	 found	 in	 the	 L	 protein	 (E35A),	 however,	 no	 differences	 are	 seen	 in	 viral	replication	of	this	mutant	compared	to	the	wild-type	virus.	Hence,	there	are	no	mutations	 that	 would	 immediately	 suggest	 an	 explanation	 for	 increased	fusogenicity	of	rPIV5mCh-α	or	increased	apoptosis	of	both	rPIV5mCh-α	and	PIV5	W3-γ	compared	to	rPIV5mCh	and	PIV5	W3.			Finally,	 rPIV5mCh-β	 was	 also	 compared	 to	 both	 the	 PIV5	 W3	 and	 rPIV5mCh	sequences.	 Interestingly	 only	 one	 other	 non-synonymous	mutation	was	 found,	T24A,	 however,	 this	 mutation	 as	 stated	 previously	 was	 also	 found	 within	 the	wild-type	 virus	 therefore	 this	 could	not	 provide	 an	 explanation	 for	 the	 unique	phenotype	demonstrated	by	this	mutant	when	the	MOI	is	altered.			In	conclusion,	this	suggests	that	the	mutations	seen	within	the	V/P	gene	of	each	virus	are	responsible	for	the	different	phenotypes	demonstrated	by	each	mutant	virus.	
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6.1.5 Overall	conclusions	In	conclusion,	we	have	developed	a	method	that	has	successfully	 isolated	three	mutant	viruses	from	rPIV5mCh	and	PIV5	W3	namely,	rPIV5mCh-α,	rPIV5mCh-β	and	PIV5	W3-γ.	Further	examination	of	these	mutant	viruses	indicates	that	both	rPIV5mCh-α	and	PIV5	W3-γ	contain	non-functional	V	proteins	that	cannot	block	the	 IFN	 signalling	 pathway	 and	 thus	 are	 sensitive	 to	 IFN.	 Surprisingly,	 the	mutant	 rPIV5mCh-β	 was	 unable	 to	 block	 IFN	 signalling	 at	 low	MOI	 but	 could	block	 IFN	 signalling	 at	 high	 MOI.	 Subsequently,	 it	 was	 found	 to	 contain	 a	functional	V	protein	 that	can	block	 the	 IFN	signalling	pathway	and	 is	 therefore	not	sensitive	to	IFN.	Furthermore,	sequencing	of	the	full	genome	did	not	reveal	any	 other	 mutations,	 outwith	 the	 V/P	 gene,	 which	 could	 explain	 this	 unique	phenotype.	Consequently,	 this	 led	us	 to	 focus	our	 further	 investigation	 into	 the	two	 IFN-sensitive	 mutants	 rPIV5mCh-α	 and	 PIV5	 W3-γ.	 This	 further	investigation	found	that	rPIV5mCh-α	demonstrates	an	IFN-sensitive	mutant	that	cannot	 easily	 revert	 to	 regain	 V	 protein	 function.	 Furthermore,	 this	 virus	 also	exhibits	 increased	 fusogenicity	 in	 the	 absence	 of	 an	 intact	 IFN	 response	 and	increased	 induction	of	 apoptosis	 in	 the	presence	 of	 an	 intact	 IFN	 response.	By	contrast,	 the	IFN-sensitive	virus	PIV5	W3-γ	can	easily	revert	to	the	wild-type	V	protein	as	wild-type	V	can	be	selected	directly	from	the	virus	preparation	at	Day	0,	however,	this	virus,	like	rPIV5mCh-α,	also	increased	induction	of	apoptosis	in	the	 presence	 of	 an	 intact	 IFN	 response.	 Intriguingly,	 this	 then	 led	 us	 to	 fully	sequence	the	genome	of	these	IFN-sensitive	mutants	however	this	failed	to	offer	any	other	mutations	outwith	the	V/P	gene	that	could	explain	these	features.	This	therefore	suggests	that	the	mutations	seen	within	the	V/P	gene	of	each	virus	are	responsible	for	the	different	phenotypes	demonstrated	by	each	mutant	virus.	
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7 Discussion			
7.1 Analysis	 of	 the	 IFN	 inhibitor	 Rux	 and	 its	 ability	 to	 enhance	 viral	
replication	in	vitro		
7.1.1 Rux	and	its	array	of	potential	applications	Currently	the	default	option	for	growth	of	IFN-sensitive	viruses	is	 in	Vero	cells,	however	due	 to	host-cell	 constraints	not	all	 viruses	can	be	grown	 in	 such	cells	(Barrett	 et	 al.	 2009).	 Subsequently	 it	 was	 demonstrated	 that	 growth	 of	 IFN-sensitive	 viruses	 can	be	 increased	 in	 cells	 able	 to	produce	 and	 respond	 to	 IFN	using	 stable	 expression	 of	 viral	 IFN	 antagonists	 (Young	 et	 al.	 2003).	 However,	this	method	was	relatively	inflexible	as	new	cell-lines	would	need	to	be	created	depending	on	host	cell	constraints	and	it	creates	regulatory	problems	for	vaccine	manufacturers.	 Our	 study	 has	 shown	 that	 supplementing	 the	 media	 with	 Rux	provides	 a	 more	 efficient	 and	 flexible	 approach	 to	 increase	 growth	 of	 IFN-sensitive	 viruses	 in	 a	 cell-line	 of	 choice	 than	 these	 existing	 methods.	 In	particular,	we	have	shown	that	i)	the	addition	of	Rux	to	A549:	naïve	cells	could	provide	 a	more	 rapid	 and	 hence	more	 efficient	 alternative	 for	 growth	 of	 IFN-sensitive	viruses	than	Vero	cells	and	ii)	that	addition	of	Rux,	can	increase	growth	of	the	IFN-sensitive	virus	BUNΔNSs,	BUN	WT	and	several	other	viruses	from	the	
Bunyaviridae	 family	 in	 a	 number	 of	 cell-lines	 including	 MRC5	 cells	 which	 are	used	 widely	 in	 vaccine	 production	 and	 a	 number	 of	 cell-lines	 derived	 from	different	 mammalian	 species.	 Ultimately,	 this	 supports	 the	 concept	 that	 Rux	could	 aid	 in	many	 practical	 applications	 such	 as	 i)	 vaccine	 production	 and	 ii)	techniques	 to	 isolate	 newly	 emerging	 viruses.	 Notably,	 the	 importance	 of	developing	 such	 techniques	 is	 highlighted	 by	 the	 current	 Zika	 virus	 outbreak	
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(Wahid	 et	 al.	 2016),	 where	 both	 fundamental	 research	 and	 prophylactic	treatment	are	urgently	required.	
7.1.2 Fundamental	studies	initiated	during	this	study	
7.1.2.1 BUN	WT	growth	is	suppressed	in	MDBK	bovine	cells		In	addition	to	practical	applications	we	have	also	demonstrated	the	ability	of	Rux	to	 initiate	 fundamental	 studies	 of	 the	 IFN	 response.	 In	 our	 study	 we	demonstrated	 that	 during	 a	 plaque	 assay	 BUN	WT	 infection	 is	 suppressed	 in	MDBK	cells,	and	blocking	the	IFN	response	using	the	IFN	inhibitor	Rux	negates	this	 effect.	 However,	 further	 examination	 of	 this	 effect	 using	 a	multistep	 viral	growth	 curve	 conflicted	 with	 our	 original	 plaque	 development	 data	 and	indicated	 that	 there	 was	 no	 difference	 in	 viral	 growth	 in	 the	 presence	 and	absence	of	the	inhibitor	(Figure	3.7).	One	potential	explanation	for	this	is	that	a	plaque	assay	is	a	more	sensitive	measure	of	the	IFN	response	than	a	viral	growth	curve.	During	 a	plaque	assay,	 the	 cell	 culture	plates	 are	kept	 stationary	within	the	incubator	meaning	that	the	initial	virus	infected	cell	releases	virus	which	can	only	 infect	neighbouring	 cells	 as	 the	plaque	 assay	 is	 not	moving	 and	 therefore	the	virus	cannot	travel	far.	It	may	therefore	take	multiple	rounds	of	replication	to	develop	 a	 plaque	 giving	 the	 surrounding	 cells	 more	 chance	 to	 mount	 an	 IFN	response.	 Conversely,	 during	 a	 multistep	 viral	 growth	 curve	 the	 flask	 is	constantly	 moving	 following	 the	 initial	 infection	 as	 the	 flask	 is	 placed	 on	 a	rocking	platform.	This	would	allow	the	virus	released	during	the	initial	round	of	infection	to	spread	more	rapidly	throughout	the	monolayer,	potentially	allowing	the	 spread	 of	 infection	 to	 outrun	 the	 IFN	 response	 in	 only	 a	 few	 rounds	 of	replication.		
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A	second	potential	explanation	for	this	conflicting	result	is	offered	in	Barecca	and	Hare	2004.	Previously	they	demonstrated	that	Herpes	Simplex	Virus	1	(HSV-1)	is	suppressed	in	MDBK	cells	following	infection	and	that	this	effect	was	negated	by	the	 blockage	 of	 the	 IFN	 response	 by	 expression	 of	 the	 V	 protein	 from	 PIV5	(Barreca	&	Hare	2004;	Barreca	&	O’Hare	2006).	During	this	study	they	examined	growth	 of	 HSV-1	 in	 MDBK	 cells	 using	 different	 initial	 MOI	 of	 infection	 and	concluded	 that	 if	 enough	 cells	 were	 infected	 initially	 then	 the	 infection	progressed	and	the	cell	monolayer	was	destroyed.	This	indicates	that	within	our	experiment	perhaps	the	initial	infection	during	the	multistep	viral	growth	curve	infected	 enough	 cells	 to	 counteract	 the	 immune	 system	 and	 subsequently	 the	infection	 progressed.	 Further	 multistep	 viral	 growth	 curves	 investigating	different	MOI	of	initial	infection	may	help	to	identify	if	this	is	the	case.			If	the	initial	plaque	development	experiment	is	to	be	accepted	irrespective	of	the	multistep	 viral	 growth	 curve	 two	 potential	 explanations	 for	 this	 unusual	response	are	proposed	 i)	 the	 IFN	antagonist	proteins	of	 these	viruses	are	non-functional	 in	 this	 cell	 line	 or	 ii)	 the	 IFN	 system	 in	 MDBK	 cells	 is	 highly	responsive.	With	regard	to	IFN	antagonist	function,	the	possibility	exists	that	the	IFN	antagonists	of	both	BUN	WT	and	HPV-1	(NSs	and	ICP0)	are	non-functional	in	these	 cells.	 With	 regards	 to	 the	 IFN	 system,	 it	 seems	 possible	 due	 to	 the	differences	 in	 responses	 at	 different	 MOI	 that	 MDBK	 cells	 have	 a	 highly	responsive	IFN	system.	Further	evidence	to	emphasize	this	case	was	provided	by	our	 final	 experiment	 involving	 Rux,	 where	we	 analysed	 a	 number	 of	 different	viruses	from	the	Bunyaviridae	family	(ANAV,	BWAV,	CVV,	KIRV,	MDV	and	SBV)	in	different	 cell-lines	 including	 MDBK	 cells	 in	 the	 absence	 and	 presence	 of	 Rux	
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(Figure	3.9).	In	this	study	we	demonstrated	that	none	of	the	viruses	tested	could	plaque	well	in	the	absence	of	Rux	in	MDBK	cells	but	CVV,	KRIV	and	MDV	plaque	size	was	 increased	 in	 the	 presence	 of	 Rux.	 As	 growth	 of	 each	 of	 these	 viruses	(CVV,	KRIV	and	MDV)	is	increased	in	the	presence	of	Rux	then	this	indicates	that	the	 IFN	 response	 limits	 the	 infection	 of	 each	 of	 these	 viruses	 in	 this	 cell	 line.	Notably	it	also	appeared	that	MDCK	cells	might	also	exhibit	a	similar	response	as	none	 of	 the	 viruses	 were	 able	 to	 plaque	 well	 in	 MDCK	 cells	 and	 each	 was	increased	in	the	presence	of	Rux.	Potentially,	this	provides	further	evidence	that	these	 cells	 have	 a	 particularly	 strong	 IFN	 response.	 Furthermore,	 as	 both	 cell-lines	were	derived	from	renal	tissue	this	could	indicate	that	this	strong	antiviral	response	is	a	common	quality	of	such	cells.	Despite	defining	these	two	potential	explanations	 individually	 it	 is	 also	 possible	 that	 a	 combination	 of	 these	 two	factors	exhibit	this	unusual	response.		
7.1.2.2 Other	host	cell	constraints	aside	from	the	IFN	response	limit	infection	of	the	
Bunyaviridae	virus	family	The	 second	 fundamental	 study	 initiated	 using	 Rux	 set	 out	 to	 analyse	 species-specific	 host	 cell	 constraints	 on	 the	 Bunyaviridae	 virus	 family.	 Other	 than	sequencing	 data	 there	 is	 a	 lack	 of	 information	 regarding	 the	 interactions	 of	ANAV,	BWAV,	CVV,	KIRV,	MDV	with	the	IFN	response.	This	study	was	therefore	the	 first	 to	 analyse	 the	 species-specific	 host	 cell	 constraints	 of	 these	 different	viruses	of	 the	Bunyaviridae	 family	 in	addition	 to	 the	previously	 studied	SBV	 in	different	mammalian	cell-lines	(Figure	3.9).	One	of	the	first	 interesting	features	that	we	wanted	to	examine	was	the	growth	of	ANAV	which	has	been	previously	shown	 to	 lack	 an	NSs	 IFN	 antagonist	 protein	 and	 induce	 IFN	production	 upon	
Discussion:	Chapter	7		
	 172	
infection	 (Mohamed	 et	 al.	 2009).	 Here	 we	 have	 demonstrated	 that	 this	 virus	could	produce	small	plaques	in	A549	naïve	cells	in	the	absence	of	Rux	which	are	greatly	 increased	 in	 the	 presence	 of	 Rux.	 Furthermore,	 ANAV	 did	 not	 grow	 in	MDCK	cells	in	the	absence	of	Rux	but	large	plaques	are	formed	in	the	presence	of	Rux.	 This	 indicates	 that	 the	 presence	 of	 an	 active	 IFN	 response	 restricts	 viral	growth	 in	 A549:	 naïve	 and	MDCK	 cells	 as	 expected	 due	 to	 the	 lack	 of	 an	 IFN	antagonist.	However,	the	IFN	response	is	not	the	only	constraint	on	infection	as	even	when	 the	 IFN	 response	 is	 inhibited	by	 the	addition	of	Rux	 then	 the	virus	still	cannot	grow	in	many	of	the	cell-lines	tested.	Interestingly,	recent	work	has	determined	 that	 many	 Bunyamwera	 viruses	 do	 not	 contain	 NSs	 proteins	 and	contain	 another	 unknown	 mechanism	 by	 which	 they	 achieve	 IFN	 antagonism	(Shchetinin	et	al.	2015).	Further	studies	are	required	to	decipher	the	mechanism	by	which	these	viruses	lacking	an	NSs	protein	achieve	IFN	antagonism	and	aptly	identification	 of	 areas	 that	 permit	 IFN	 antagonism	 could	 be	 investigated	 using	the	method	developed	in	the	second	part	of	this	study.			A	 second	 feature	 we	 wanted	 to	 further	 examine	 in	 this	 study	 was	 if	 the	 IFN	response	 was	 the	 only	 limit	 to	 Bunyaviridae	 infections	 or	 if	 other	 host	 cell	constraints	limit	the	spread	of	infection.	From	this	study	it	was	evident	that	the	IFN	 response	was	not	 the	only	 constriction	 to	 virus	 infection	of	many	of	 these	viruses	in	numerous	cell-lines.	For	example,	ANAV,	BWAV	and	SBV	were	unable	to	grow	in	many	cell-lines	even	in	the	absence	of	the	IFN	response.	One	possible	explanation	for	this	is	that	there	are	differences	in	the	cellular	receptors	used	for	entry	of	the	virus	to	host	cells	and/or	there	is	variation	in	the	virus	glycoproteins	that	 allow	 entry.	 Currently	 the	 cellular	 receptors	 for	 entry	 of	Bunyaviridae	 are	
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unknown	 (Bowden	 et	 al.	 2013),	 and	 until	 the	 cellular	 receptors	 required	 for	entry	 are	 identified	 it	 is	 difficult	 to	 determine	 if	 this	 is	 the	 limitation	 on	 host	range	demonstrated	here.		Other	limitations	to	infection	could	be	limited/lack	of	host	cell	factors	required	for	the	production	of	infectious	virus,	for	example,	it	is	known	that	host	cell	proteases	are	required	to	cleave	the	Glycoprotein	precursor	to	 form	 the	 fusion	 and	 attachment	 proteins	 that	 are	 essential	 for	 formation	 of	infectious	 viral	 particles	 (Shi	 et	 al.	 2016),	 therefore	 if	 these	 cellular	 proteins	were	not	present	then	this	would	also	limit	infection.			In	 general,	 this	 study	 provides	 evidence	 that	 Rux	 can	 be	 used	 as	 a	 broad-spectrum	 aid	 to	 the	 production	 of	 viral	 stocks	 and	 in	 particular	 for	 newly	emerging	viruses	where	there	is	a	lack	of	information	regarding	host	cell	range.	Recently	a	study	described	the	growth	of	SBV	in	numerous	mammalian	cell-lines	including	A549,	MDBK	and	MDCK	cells	and	indicated	that	low	titers	of	virus	were	harvested	 following	 infection	of	 these	 cells	with	a	 low	or	high	MOI.	This	 study	was	used	to	identify	the	most	effective	cell	line	to	plaque	SBV	and	produce	viral	stocks	for	fundamental	study	at	the	time	of	the	SBV	outbreak	2011-13	and	it	was	found	 that	 BHK-21	 (hamster)	 cells,	 which	 are	 IFN	 deficient,	 gave	 the	 most	discernable	plaques	with	a	size	of	3mm	after	3	days	(Elliott	et	al.	2013;	Otsuki	et	al.	 1979;	 Chinsangaram	 et	 al.	 1999).	 Our	 study	 provides	 evidence	 that	 the	addition	 of	 Rux	 can	 enable	 SBV	 to	 produce	 large	 plaques	 and	 hence	 greatly	increase	viral	growth	 in	MDCK	cells	and	RK.13	cells	 thus	 indicating	a	potential	use	 for	Rux	 in	 the	 study	 and	 production	 of	 SBV	 stocks	 for	 use	 in	 fundamental	studies.	However,	a	direct	comparison	between	BHK-21	and	MDCK	cells	would	be	necessary	to	determine	which	cell	line	produces	the	greatest	yield.	Ultimately	
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this	approach	does	not	only	apply	to	SBV	as	this	study	could	be	used	to	identify	and	 expand	 the	 range	of	 host	 cells	 suitable	 for	production	of	 stocks	of	 each	of	these	different	viruses.	As	a	result	of	this	flexibility	Rux	may	also	prove	useful	in	techniques	to	isolate	newly	emerging	viruses	or	viruses	from	clinical	samples	by	expanding	the	range	of	cells	capable	of	supporting	the	growth	of	such	viruses.		
7.1.3 Other	potential	uses	of	Rux	not	explored	in	this	study	
7.1.3.1 The	use	of	Rux	in	the	application	of	oncolytic	viruses	So	 far	 we	 have	 discussed	 that	 Rux	 has	many	 practical	 applications	 as	 well	 as	applications	 in	 fundamental	 research	however	 there	are	other	examples	of	 the	use	of	the	IFN	inhibitor	Rux	that	we	have	not	explored	in	this	study	such	as	its	use	in	the	application	of	oncolytic	viruses.	The	concept	of	oncolytic	viruses	relies	on	the	fact	that	cancer	cells	have	a	dysregulated	tumour	environment	where	the	oncolytic	 virus	 can	 thrive	 causing	 lysis	 of	 tumour	 cells,	whereas	 the	 growth	of	such	 viruses	 is	 prevented	 in	 adjacent	 or	 distant	 normal	 tissue	 (Ferguson	 et	 al.	2012).	 One	 such	 dysregulation	 is	 that	 cancer	 cells	 often	 have	 a	 defective	 IFN	signalling	pathway	and	are	therefore	highly	susceptible	to	infection.	By	contrast,	non-transformed	 cells	 contain	 an	 intact	 IFN	 response	 and	 respond	 to	 infection	with	 production	 of	 IFN	 and	 subsequently	 inhibit	 viral	 replication	 and	 spread.	Previously,	 it	 has	 been	 shown	 that	 certain	 tumours	 are	 highly	 sensitive	 to	oncolysis	 following	 infection	 with	 the	 highly	 lytic	 VSV,	 however,	 others	 are	resistant.	 Subsequently	 it	 has	 been	 shown	 that	 application	 of	 IFN	 inhibitors	including	 the	 JAK1/2	 inhibitor	 Rux	 can	 reverse	 this	 resistance.	 As	 Rux	 has	already	 been	 approved	 for	 clinical	 treatment	 of	 myelofibrosis,	 a	 rare	 blood	cancer	that	causes	overproduction	of	blood	cells	in	the	bone	marrow	(Vaddi	et	al.	
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2012;	Verstovsek	et	al.	2015),	and	has	therefore	been	analysed	in	clinical	trials	and	 declared	 safe	 for	 use	 in	 humans	 then	 this	 may	 accelerate	 the	 use	 of	 this	specific	inhibitor	in	future	virotherapy	trials	(Escobar-Zarate	et	al.	2013).				Notably,	 the	 approval	 of	 Rux	 for	 clinical	 treatment	 may	 also	 open	 up	 many	potential	 uses	 for	Rux	 in	 in	vivo	 studies.	 Currently	many	 in	vivo	 studies	 on	 the	IFN	response	rely	on	the	ability	to	make	IFN	deficient	transgenic	mice.	We	have	demonstrated	 the	 ability	 of	 Rux	 to	 block	 the	 IFN	 response	 in	 numerous	mammalian	tissues	thereby	indicating	a	role	for	Rux	in	the	development	of	other	IFN	 deficient	 animal	 models.	 Furthermore,	 Rux	 may	 also	 have	 applications	 in	multi	 culture	 systems	 used	 to	 analyse	 viral	 infection	 such	 as	 human	 airway	epithelium.	For	example,	 it	could	be	used	to	analyse	whether	 the	 IFN	response	restricts	viral	infection	in	such	cells.	
7.1.4 Potential	Drawbacks		Despite	the	many	benefits	of	the	use	of	the	IFN	inhibitor	Rux	in	many	different	applications	 there	are	 some	potential	drawbacks.	These	 include:	 (i)	 the	 cost	of	the	inhibitor	and	(ii)	the	obtained	stocks	of	virus	would	contain	the	IFN	inhibitor.	With	regard	to	the	cost	of	the	inhibitor,	the	benefits	of	Rux	in	vaccine	production	such	as	reduced	time	to	achieve	higher	titers	may	significantly	outweigh	the	cost	of	 the	 inhibitor	 therefore	 it	 is	 worthwhile	 investigating	 this	 technique.	 With	regard	to	viral	stocks	containing	Rux,	again	it	should	be	noted	that	Rux	has	been	approved	for	the	treatment	of	myelofibrosis	therefore	it	is	declared	safe	for	use	in	humans.	Furthermore,	purification	of	the	virus	stock	would	eliminate	any	IFN	inhibitor	present,	and	this	should	always	be	considered	for	fundamental	studies	
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and	 for	 the	 production	 of	 vaccines	 using	 cell-lines	 as	 a	 variety	 of	 different	cytokines	are	induced	and	secreted	in	response	to	viral	infection	and	would	also	be	present	in	unpurified	stocks.			
7.1.5 Concluding	remarks	In	conclusion,	we	have	demonstrated	that	Rux	could	be	used	in	the	production	of	live	attenuated	vaccines	as	exemplified	by	the	more	efficient	production	of	IFN-sensitive	viruses	in	A549:	naïve	cells	in	the	presence	of	Rux	than	the	default	Vero	cell	 line	 and	 the	 ability	 to	 increase	 viral	 growth	 in	 a	 cell-line	 of	 choice.	Furthermore,	 the	 inhibitor	 may	 also	 prove	 useful	 in	 initiation	 of	 fundamental	studies	 of	 IFN	 antagonists	 and	 the	 IFN	 response	 as	 exemplified	 by	 our	 initial	studies	into	the	IFN	response	of	MDBK	cells	and	the	host	range	of	Bunyaviridae.	Finally,	 the	 inhibitor	 may	 also	 become	 a	 general	 approach	 to	 aid	 growth	 and	isolate	 newly	 emerging	 viruses	 as	 exemplified	 by	 our	 ability	 to	 increase	 viral	growth	of	several	viruses	 from	the	Bunyaviridae	 family	 in	numerous	host	cells.	Consequently,	 our	 further	 investigation	 of	 the	 use	 of	 IFN	 inhibitor	 Rux	 has	established	 that	 supplementing	 the	 media	 with	 this	 inhibitor	 could	 become	 a	valuable	technique	that	could	aid	in	numerous	aspects	of	virological	research.			 	
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7.2 Isolation	of	IFN-sensitive	viruses	using	FACS		
Currently,	methods	 to	 isolate	attenuated	viruses	 include	 i)	 traditional	methods	such	 as	 serial	 passage	 of	 the	wild	 type	 virus	 in	 a	 foreign	 host	 or	 at	 abnormal	temperatures	or	ii)	rational	design.	However,	traditional	methods	can	be	lengthy	and	rational	design	relies	on	the	notion	that	the	IFN	antagonist	is	already	known	and	 is	 complicated	 due	 to	 the	 multifunctional	 nature	 of	 IFN	 antagonists.	Consequently,	 we	 developed	 a	 novel	 method	 to	 rapidly	 isolate	 IFN-sensitive	mutant	viruses	using	FACS.	The	establishment	of	this	technique	aimed	to	speed	traditional	 methods	 of	 obtaining	 attenuating	 IFN-sensitive	 viruses	 and	 select	viable	viruses	that	can	often	be	difficult	to	obtain	because	of	the	multifunctional	nature	of	 IFN	antagonists.	Furthermore,	 it	does	not	rely	on	prior	knowledge	of	the	 IFN	 antagonists.	 Following	 optimisation	 of	 this	 method	 we	 successfully	isolated	three	mutant	viruses	from	rPIV5mCh	and	PIV5	W3.	Upon	examination	of	these	mutants	two,	namely	rPIV5mCh-α	and	PIV5	W3-γ	were	confirmed	as	IFN-sensitive	and	the	other	rPIV5mCh-β	exhibited	an	interesting	phenotype	in	that	it	could	not	block	the	IFN	signalling	pathway	at	low	MOI	but	it	could	at	high	MOI.		
7.2.1 Potential	drawbacks	to	the	method	As	 one	 of	 the	 main	 objectives	 of	 this	 study	 was	 to	 develop	 a	 method	 it	 is	important	 to	discuss	the	 limitations	and	potential	drawbacks	of	 this	method	as	despite	successfully	obtaining	 IFN-sensitive	mutant	viruses,	 it	 is	 likely	 that	 this	method	would	 require	 further	 optimisation	 before	 it	 could	 be	 developed	 as	 a	general	 method	 to	 isolate	 various	 types	 of	 viruses.	 One	 potential	 limitation	includes	 the	 essential	 requirement	 for	 neutralizing	 antibody	 to	 prevent	 the	infection	of	uninfected	cells	by	progeny	viruses	following	initial	infection	(Figure	
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4.5).	This	was	an	important	part	in	the	optimisation	of	the	method	as	the	release	and	infection	of	uninfected	cells	by	progeny	virus	could	 lead	to	the	selection	of	false	positives.	If	this	method	was	to	be	further	developed	as	a	general	method	to	isolate	IFN-sensitive	viruses	then	this	necessity	could	 impede	this	process,	as	a	good	neutralizing	antibody	is	not	available	for	every	virus.	One	potential	method	to	alleviate	this	issue	could	be	to	find	a	more	generalised	method	to	inhibit	virus	entry	following	infection.	For	example,	as	sialic	acid	is	the	receptor	which	allows	entry	 of	 viruses	 such	 as	 Influenza	 and	 certain	 paramyxoviruses	 including	 the	majority	 of	 the	 Respiroviruses,	 Rubulaviruses	 and	 Avulaviruses	 we	 could	investigate	 the	possibility	of	 inhibiting	virus	 entry	 through	 the	use	of	 sialidase	inhibitors	 such	 as	 Tamiflu	 and	 Relenza	 or	 cleaving	 sialic	 acid	 using	neuraminidase	 following	 initial	 infection	 (Villar	&	Barroso	2006;	Magesh	 et	 al.	2009;	 Itzstein	 &	 Thomson	 2009;	 Shtyrya	 et	 al.	 2009).	 This	 would	 therefore	alleviate	 the	 requirement	 for	 neutralising	 antibody	 by	 preventing	 any	 further	infection	 by	 blocking	 or	 cleaving	 sialic	 acid	 on	 host	 cells.	 Initial	 attempts	 to	optimise	this	method	proved	successful	in	that	neuraminidase	treatment	of	cells	prior	 to	 infection	 could	 prevent	 subsequent	 infection	 by	 influenza	 virus	 (Data	not	 shown).	Despite	not	 attaining	 a	 completely	 general	method,	 as	 viruses	use	different	receptors	for	entry,	this	would	broaden	the	range	of	viruses	suitable	for	use	in	this	assay	to	include	clinically	important	viruses	such	as	Influenza.	
7.2.2 Cell-line	development		A	second	step	of	optimisation	that	may	be	required	is	to	further	develop	the	cell	line	used	 for	 the	 isolation	of	 IFN-sensitive	mutants.	 In	our	study	we	developed	the	A549:(ISRE).GFP/ISG56-/Npro	cell	line	which	expressed	shRNA	to	ISG56	and	
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the	BVDV	Npro	protein	to	knockdown	the	expression	of	ISG56	and	to	block	the	IFN	induction	pathway,	respectively	(Figure	4.3).	The	reason	we	developed	this	cell	 line	 is	 that	 ISG56	 has	 been	 shown	 to	 specifically	 prevent	 the	 infection	 of	Rubulaviruses	 such	 as	 PIV5	 and	would	 therefore	 abrogate	 growth	 of	 our	 IFN-sensitive	 viruses	before	 selection	 (Young	et	 al.	 2016).	However,	 this	 ISG	 is	not	important	 for	 abrogation	 of	 other	 viruses.	 Consequently,	 other	 cell-lines	 that	knock	down	ISGs	known	to	prevent	virus	growth	of	the	particular	test	virus	may	be	required	for	the	isolation	of	mutants	from	other	viruses.	
7.2.2.1 Increasing	the	number	of	IFN-sensitive	mutant	viruses	available	for	selection	A	 third	 step	 of	 optimisation	 would	 be	 to	 determine	 methods	 to	 increase	 the	number	of	potential	mutants.	When	adapting	the	method	to	the	non-fluorescent	virus	PIV5	W3,	only	one	potential	mutant	was	isolated	and	analysed	whereas	we	obtained	 two	 mutants	 multiple	 times	 from	 rPIV5mCh.	 Notably	 one	 possible	explanation	 for	 this	 is	 that	 the	 passage	 history	 of	 rPIV5mCh	differs	 from	PIV5	W3,	as	we	do	not	know	the	passage	history	of	these	stocks	prior	to	our	analysis.	In	particular,	 if	 the	rPIV5mCh	mutant	had	been	passaged	multiple	 times	 in	 IFN	incompetent	 cells	 such	 as	 Vero’s	 then	 perhaps	 this	 would	 have	 created	 more	opportunity	 for	 IFN-sensitive	 viruses	 to	 generate.	 As	 we	 wanted	 to	 avoid	 the	lengthy	 process	 of	 serial	 passage	 another	 possible	 method	 to	 increase	 the	number	of	mutant	viruses	would	be	to	mutagenize	the	virus	stock	using	chemical	agents	 such	 as	 5’	 fluorouracil	 or	 sub	 optimal	 levels	 of	 the	 nucleoside	 inhibitor	Ribavirin	 to	 increase	 the	 number	 of	 potential	 mutants	 available	 for	 selection	(Agudo	et	al.	2009;	Marcelin	et	al.	2014).		
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7.2.2.2 Development	of	an	automated	analysis	method	A	final	stage	of	optimisation	suggested	to	develop	this	method	is	to	the	advance	the	analysis	method	following	sorting.	The	process	of	 individually	analysing	96	well	 plates	 is	 time	 consuming,	 however,	 the	 creation	 of	 an	 automated	 system	should	 be	 possible.	 This	 system	 would	 require	 measurement	 of	 GFP	 and	mCherry	 fluorescence	 or	 Texas	 red	 immunostaining.	 Initial	 studies	 identified	that	GFP	and	mCherry	fluorescence	could	be	measured	using	the	IncuCyte	zoom	quantitative	live	cell	analysis	system	and	a	ratio	of	GFP	to	mCherry	fluorescence	calculated.	Any	well	 found	 to	be	exhibiting	a	 ratio	of	1:1	 could	 then	be	 further	analysed	 to	 examine	 if	 it	 exhibited	 dual	 fluorescent	 cells	 (Data	 not	 shown).	However,	 this	 process	 was	 not	 possible	 for	 GFP	 fluorescence	 and	 Texas	 red	immunostaining	 as	 GFP	 expression	 was	 significantly	 brighter	 than	 Texas	 red	immunostaining	 therefore	 a	 more	 sophisticated	 method	 to	 measure	 GFP	 and	Texas	 red	 is	 required	 to	 automate	 this	 system.	Notably	 this	 highlighted	one	of	the	 many	 advantages	 of	 using	 a	 fluorescently	 labelled	 virus	 and	 with	 the	increasing	number	of	 fluorescent	viruses	available	 for	viruses	such	as	RSV	and	PIV3	 then	 it	 is	not	unreasonable	 to	 recommended	 that	 a	 fluorescently	 labelled	virus	be	used	for	this	method	if	available.		
7.2.3 Analysis	of	PIV5	mutants		Using	 our	method	we	 isolated	 three	PIV5	mutant	 viruses	 namely,	 rPIV5mCh-β	which	 was	 unable	 to	 block	 IFN	 signalling	 at	 low	 MOI	 but	 could	 block	 IFN	signalling	at	high	MOI	and	rPIV5mCh-a	and	PIV5	W3-g	which	could	not	block	IFN	signalling	 and	were	 subsequently	 shown	 to	 be	 IFN-sensitive.	 The	 results	 from	analysis	 of	 rPIV5mCh-β	 represent	 an	 interesting	 enigma	 with	 regards	 to	 V	
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protein	function.	Specifically,	this	virus	could	not	block	IFN	signalling	at	low	MOI	but	could	block	IFN	signalling	at	high	MOI.	Deep	sequencing	of	the	rPIV5mCh-β	mutant	 demonstrated	 that	 this	 mutant	 only	 contained	 non-synonymous	mutations	 within	 the	 V/P	 gene	 of	 the	 viral	 genome	 (aside	 from	 the	 T24A	mutation	 found	 in	 F	 protein	 which	 was	 also	 found	 in	 the	 parental	 rPIV5mCh	strain),	leading	us	to	suggest	that	this	unusual	phenotype	is	as	a	result	of	the	two	mutations	found	in	the	V/P	gene	of	the	virus.			During	 further	analysis	of	 the	rPIV5mCh-β	V	protein	we	determined	that	 the	V	protein	was	functional	with	regards	to	blocking	the	IFN	signalling	pathway	as	it	was	 able	 to	 block	 luciferase	 expression	 (a	 reporter	 of	 activation	 of	 IFN	signalling)	 during	 an	 IFN	 signalling	 luciferase	 assay.	 Upon	 reflection,	 one	potential	 problem	with	 this	 experiment	 exists	 in	 that	we	 overexpressed	 the	 V	protein	during	the	luciferase	assay.	As	one	potential	explanation	for	the	ability	of	rPIV5mCh-β	to	block	IFN	signalling	at	high	but	not	low	MOI	is	that	the	V	protein	function	 is	 partially	 functional	 and	 therefore	 concentration	 dependent,	 then	analysis	 of	 the	 V	 protein	 function	 at	 low	 and	 high	 concentrations	 within	 the	luciferase	assay	may	have	provided	a	better	assessment	of	V	protein	function.		A	second	potential	explanation	for	this	unusual	rPIV5mCh-β	V	protein	activity	is	that	 the	 mutations	 permit	 the	 V	 protein	 to	 have	 a	 slightly	 higher	 affinity	 for	another	 cellular	 or	 viral	 protein.	 This	 effect	 would	 be	 evident	 at	 low	concentrations	(low	MOI)	as	some	of	 the	V	protein	would	be	bound	to	another	protein	thereby	impeding	its	interaction	with	DDB1	and	its	subsequent	block	of	the	 IFN	 signalling	 pathway,	 however	 when	 the	 concentration	 of	 V	 protein	 is	
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increased	(high	MOI)	 this	effect	would	be	negated.	To	 test	 this,	again	we	could	complete	an	IFN	signalling	luciferase	assay	using	a	concentration	gradient	of	the	rPIV5mCh-β	V	protein	against	the	wild-type	V	protein	to	identify	if	the	activity	of	the	V	protein	 is	dependent	on	 its	 concentration.	We	 could	 then	also	 assess	 for	new	binding	partners	using	pull	downs.			A	 final	explanation	 is	 that	 the	 single	mutation	 that	affects	 the	P	protein	affects	the	ability	of	the	virus	to	replicate.	For	example,	if	the	virus	is	subtly	slowed	due	to	the	changes	to	RNA	replication	then	at	a	low	MOI	the	virus	may	be	unable	to	block	 IFN	 induction	but	 this	affect	would	be	negated	at	high	MOI.	As	 there	are	two	mutations	within	this	mutant,	one	that	affects	both	V	and	P	and	another	that	affects	 only	 V,	 the	 two	 mutations	 could	 be	 looked	 at	 individually	 by	 reverse	genetics	 to	 narrow	 down	 which	 mutation	 is	 responsible	 for	 this	 interesting	phenotype.		
7.2.4 PIV5	W3-γ		A	 second	mutant	 identified,	 PIV5	W3-γ,	was	 shown	 to	 be	 unable	 to	 block	 IFN	signalling	and	was	consequently	IFN-sensitive,	due	to	a	single	mutation	in	the	N	terminal	V/P	common	domain	(L132P).	Previously	it	has	been	shown	that	the	C	terminal	cysteine	rich	domain	of	 the	V	protein	 is	highly	 important	 for	blocking	the	IFN	response	as	a	recombinant	hPIV2	virus	that	expresses	a	truncated	form	of	V	lacking	the	C-terminal	domain	appeared	to	be	sensitive	to	IFN	(Kawano	et	al.	2001).	 Furthermore,	 a	 PIV5	 virus	 lacking	 the	 cysteine	 rich	 domain	 of	 the	 V	protein	was	shown	to	be	unable	to	block	IFN	induction	or	IFN	Signalling	(He	et	al.	 2002).	 Subsequently,	 the	 IFN-sensitive	 virus	 PIV5	 CPI-	 was	 shown	 to	 be	
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unable	to	block	IFN	signalling	due	to	the	combination	of	Y26H,	L50P	and	L102P	mutations	found	in	the	V/P	common	domain	(Chatziandreou	et	al.	2002),	for	the	first	 time	 implicating	 the	 V/P	 common	 domain	 with	 V	 protein	 function.	Interestingly,	we	have	identified	that	a	single	mutation	(L132P)	found	in	the	N-terminal	 V/P	 common	 domain	 can	 prevent	 the	 V	 proteins	 ability	 to	 block	 IFN	signalling,	 however,	 this	 mutation	 is	 readily	 reverted	 back	 to	 the	 wild-type	sequence.	Interestingly,	the	PIV5	W3-γ	mutant	V	protein	lost	the	ability	to	lead	to	the	degradation	 of	 STAT1	but	 retained	 the	 ability	 to	 interact	with	Mda-5.	 This	taken	together	with	the	fact	that	mutations	from	Leucine	to	Proline	are	likely	to	dramatically	affect	protein	structure	indicates	that	the	structure	in	this	region	of	the	 V	 protein	 is	 essential	 for	 its	 interaction	 with	 DDB1	 and	 the	 resultant	degradation	of	STAT1.	To	examine	this	further	mutagenesis	of	this	amino	acid	to	another	residue	that	is	less	likely	to	affect	V	protein	structure	such	as	an	Alanine	residue	 could	 be	 completed.	 This	would	 determine	 if	 the	 structure,	 the	 amino	acid	itself	or	both	are	essential	to	this	particular	V	protein	function.		
7.2.5 rPIV5mCh-α		The	final	mutant	that	we	isolated,	rPIV5mCh-α,	was	found	to	contain	6	mutations	within	 the	 V/P	 gene	 which	 we	 have	 later	 identified	 to	 disable	 the	 V	 proteins	ability	 to	 block	 IFN	 signalling,	 thus	 rendering	 the	 virus	 IFN-sensitive.	Interestingly	the	mutant	was	found	to	contain	the	L132P	mutation	as	was	found	in	PIV5	W3-g,	however,	unlike	the	PIV5	W3-g	mutant,	rPIV5mCh-a	was	unable	to	revert	 to	 wild-type	 either	 directly	 from	 one	 infection	 with	 the	 viral	 stock	 or	following	 60	 days	 of	 passage	 in	 IFN	 competent	 cells.	 Following	my	 study,	 the	rPIV5mCh-a	 virus	 was	 passaged	 for	 a	 further	 60	 days	 and	 sequenced.	 The	
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results	indicate	that	the	virus	had	still	not	reverted	to	wild-type	or	regained	the	ability	to	block	IFN-signalling	through	compensatory	mutations	(Dan	Young	and	David	Hughes,	University	of	St	Andrews),	thus	indicating	that	this	combination	of	mutations	is	very	difficult	to	revert.			Interestingly,	five	of	the	mutations	found	in	the	V/P	gene	were	found	to	be	in	the	common	 V/P	 region,	 thus	 both	 the	 V	 and	 P	 protein	 would	 be	 affected.	Furthermore,	 four	 of	 these	 changes	 were	 leucine	 to	 proline	 changes	 that	 are	known	 to	 dramatically	 affect	 protein	 structure.	 As	 stated	 previously	 the	 P	protein	 is	 essential	 for	 RNA	 synthesis	 (Fuentes	 et	 al.	 2010),	 therefore	 it	 is	remarkable	 that	 the	 P	 protein	 could	 tolerate	 this	 number	 of	 mutations	 and	particularly	 proline	 changes,	without	 having	 any	 significant	 adverse	 effects	 on	protein	function.	Upon	deep	sequencing	of	the	virus,	no	other	non-synonymous	mutations	were	found	apart	from	the	mutations	previously	identified	in	the	V/P	gene	thus	indicating	that	these	mutations	are	strongly	selected	for.	Furthermore,	this	mutant	was	 isolated	 numerous	 times	 from	 the	 same	 stock	 indicating	 that	this	mutant	 is	 present	 in	 high	 levels	 in	 the	 population.	 A	 potential	 reason	 for	obtaining	so	many	mutations	 in	both	 the	V	and	particularly	 the	P	gene	may	be	that	it	actually	provides	a	selective	advantage	in	IFN	incompetent	conditions.	As	the	 virus	was	 grown	 in	 Vero	 cell’s,	 and	 these	 cells	 are	 IFN	 incompetent	 the	 V	protein	 function	 of	 blocking	 IFN	 signalling	 would	 no	 longer	 be	 required,	therefore	perhaps	 this	would	allow	mutations	 to	build	 that	provide	a	 selective	advantage	based	on	P	protein	function.			
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Previously,	it	has	been	shown	that	phosphorylation	at	T286	within	the	P	protein	increased	RNA	synthesis	(Sun,	Luthra,	et	al.	2011),	whereas	phosphorylation	at	S157	 and	 S308	 can	 inhibit	 RNA	 synthesis	 (Timani	 et	 al.	 2008),	 however	 these	previously	identified	sites	of	phosphorylation	were	not	affected	by	the	mutations	seen	here.	We	have	presented	evidence	whereby	our	mutant	appears	to	have	an	increased	 speed	 of	 replication	 by	 producing	 larger	 plaques	 than	 the	wild-type	virus	during	plaque	analysis	(Figure	6.5).	However,	this	could	not	be	replicated	during	a	multi-step	viral	growth	curve.	As	stated	previously	this	could	be	due	to	differences	in	sensitivity	of	the	plaque	assay	compared	to	the	multistep	growth	curve	 in	assessing	 the	 IFN	response.	 If	 time	had	allowed,	we	could	have	 tested	this	more	accurately	using	qPCR	to	determine	viral	RNA	levels	rather	than	only	determining	 the	 production	 of	 infectious	 viral	 particles.	 What’s	 more,	competition	 assays	 could	be	 completed	 to	determine	 if	 the	mutant	 virus	 could	out-compete	the	wild-type	virus	in	IFN	incompetent	conditions.	Without	further	investigation	it	is	difficult	to	say	whether	these	sites	represented	further	sites	of	interest	 for	 increased	 activity	 of	 the	 P	 protein	 however	 given	 that	 these	mutations	are	being	readily	selected	for	and	that	this	mutant	is	abundant	within	the	 viral	 stock	 then	 it	 seems	 likely	 that	 there	 is	 a	 significant	 advantage	 to	obtaining	these	mutations.	
7.2.5.1 Increased	apoptosis	and	fusogenicity		In	 addition	 to	 inability	 to	 block	 IFN	 signalling,	 we	 have	 also	 shown	 that	rPIV5mCh-α	infection	exhibits	enhanced	apoptosis	in	IFN	competent	cells	(A549:	naïve	cells)	however,	 this	effect	 is	negated	 in	 the	presence	of	 the	 IFN	 inhibitor	Rux.	 As	 apoptosis	 is	 blocked	 in	 the	 presence	 of	 Rux	 then	 is	 likely	 that	 this	
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apoptosis	has	been	induced	in	an	IFN	dependent	manner	as	this	virus	is	unable	to	block	 IFN	signalling.	Notably	 the	same	effect	 is	also	seen	 following	 infection	with	PIV5	W3-g	which	is	also	unable	to	block	IFN	signalling.			A	 second	 interesting	 feature	 of	 rPIV5mCh-α	 is	 that	 in	 IFN	 incompetent	conditions	 (A549:	 naïve	 cells	 in	 the	 presence	 of	 Rux	 and	Vero	 cells)	 this	 virus	exhibits	increased	cell-cell	fusion.	Prior	to	deep	sequencing	it	was	hypothesised	that	 mutations	 elsewhere	 in	 the	 viral	 genome	 would	 explain	 the	 gain	 of	 this	attribute	 however	 surprisingly	 no	 other	 mutations	 were	 found	 outside	 of	 the	V/P	gene.	Consequently,	 this	 leads	us	 to	suggest	 that	either	 the	V	and/or	 the	P	protein	is	responsible	for	preventing	cell-cell	fusion.		
7.2.5.2 The	development	of	rPIV5mCh-α	as	a	viral	vaccine	vector		Excitingly,	the	many	additional	features	outlined	for	rPIV5mCh-a	above,	indicate	that	 rPIV5mCh-a	 may	 have	 a	 potential	 application	 in	 the	 development	 of	vaccines.	Currently	there	is	increasing	interest	in	the	development	of	PIV5	based	vaccine	vectors,	as	PIV5	demonstrates	a	number	of	characteristics	that	are	highly	sought	 after	 in	 such	 vaccines.	 For	 example,	 i)	 PIV5	 is	 avirulent	 in	 humans,	 ii)	PIV5	based	vaccines	have	been	used	safely	for	kennel	cough	in	dogs	for	over	30	years	and	have	not	attributed	to	any	human	illness	despite	the	close	association	of	 humans	 with	 dogs,	 iii)	 PIV5	 can	 be	 readily	 produced	 in	 many	 cell-lines	including	 Vero	 cells	 that	 are	 approved	 for	 vaccine	 manufacture,	 iv)	 PIV5	 can	readily	infect	human	cell-lines	as	well	as	primary	human	cell-lines,	and	finally	v)	it	has	been	shown	that	pre-existing	immunity	to	PIV5	does	not	prevent	immunity	from	 PIV5-based	 vaccines	 and	 that	 vaccination	 can	 rapidly	 induce	 protective	
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immunity	 in	 a	 mouse	 model	 (Li	 et	 al.	 2015).	 In	 light	 of	 this,	 the	 mutant	rPIV5mCh-a	may	be	of	interest	for	the	production	of	such	vaccine	vectors	due	to	the	 additional	 beneficial	 features	 we	 have	 identified.	 In	 particular,	 we	 have	shown	that	 this	virus	has	been	unable	 to	revert	 to	regain	 the	ability	of	 the	 IFN	antagonist	V	protein	to	block	IFN	signalling	following	120	days	of	passage	in	IFN	competent	cells.	This	property	highlights	that	this	IFN-sensitive	attenuated	virus	is	 difficult	 to	 revert	 which	 is	 an	 essential	 basis	 of	 a	 successful	 vaccine.	 In	addition,	we	 have	 shown	 that	 this	 virus	 enhances	 apoptosis	 in	 IFN	 competent	conditions.	Importantly,	this	feature	could	be	preferential	in	the	development	of	vaccines,	as	it	is	thought	that	increased	apoptosis	could	lead	to	increased	antigen	production	 and	 immunogenicity.	 For	 example,	 rBRSVΔSH	 (bovine	 RSV	 with	deleted	 SH	 protein)	 was	 shown	 to	 exhibit	 increased	 apoptosis	 and	 pro-inflammatory	 cytokines	 in	 vitro	 but	 it	 is	 attenuated	 and	 induced	 greater	protective	immunity	to	BRSV	in	calves	than	use	of	the	wild-type	virus	(Taylor	et	al.	2014).	In	addition	to	this,	attenuated	PIV5	viruses	such	as	PIV5ΔSH	shown	to	enhance	 induction	 of	 apoptosis,	 were	 also	 shown	 to	 have	 enhanced	immunogenicity	 and	provided	better	protection	against	 viral	 challenge	 in	mice	compared	 to	 wild	 type	 PIV5	 (Li	 et	 al.	 2013).	 Finally,	 we	 have	 suggested	 that	rPIV5mCh-α	 may	 have	 a	 potential	 growth	 advantage	 in	 IFN	 incompetent	conditions	 which	 may	 be	 useful	 in	 vaccine	 production	 however	 further	investigation	 of	 this	 property	 is	 required.	 Ultimately	 these	 features	 combined	with	the	many	already	identified	advantages	of	PIV5,	may	make	the	rPIV5mCh-α	mutant	of	great	interest	in	the	development	of	PIV5	based	vaccines.		
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7.2.6 Concluding	remarks		In	conclusion,	we	have	successfully	developed	a	method	to	isolate	IFN-sensitive	mutant	 viruses	 from	 Paramyxoviruses.	 Not	 only	 have	 these	 viruses	 instigated	further	fundamental	studies	into	the	function	of	the	V	and	P	proteins	of	PIV5	but	they	may	also	aid	in	the	design	of	live-attenuated	vaccines	and	specifically	PIV5	based	vaccines.	Ultimately,	this	study	is	the	first	step	towards	creating	a	general	method	 to	 isolate	 various	 types	 of	 IFN-sensitive	 viruses	 that	 as	well	 as	 aiding	fundamental	studies,	may	be	further	developed	as	live-attenuated	virus	vaccines	for	clinically	important	viruses	lacking	vaccines.	
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